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ABSTRACT 
Biomaterial-Based Strategies for Craniofacial Tissue Engineering 
by 
James D. Kretlow 
Damage to or loss of craniofacial tissues, often resulting from neoplasm, trauma, 
or congenital defects, can have devastating physical and psychosocial effects. 
The presence of many specialized tissue types integrated within a relatively small 
volume leads to difficulty in achieving complete functional and aesthetic repair. 
Tissue engineering offers a promising alternative to conventional therapies by 
potentially enabling the regeneration of normal native tissues. Initially, a stimulus 
responsive biomaterial designed for injectable cell delivery applications was 
investigated with the goal of providing a substrate for osteogenic differentiation of 
delivered cells. In order to enable faster clinical translation, later efforts focused 
on novel combinations of regulated materials. Most common approaches using 
cell delivery for bone tissue engineering involve the harvest and ex vivo 
expansion of progenitor cell populations over multiple weeks and cell passages. 
The effect of aging and passage on proliferation and differentiation were 
analyzed using murine mesenchymal stem cells as a model. These cells lose 
their ability to proliferate and differentiate with increases in donor age and 
Ill 
passages during cell culture. Delivery of uncultured bone marrow mononuclear 
cells was then investigated, and it was determined that when delivered to porous 
scaffolds these cells, which can be harvested, isolated, and returned to the body 
within the setting of a single operation, significantly increased bone regeneration 
in vivo. Finally, because these techniques of scaffold implantation and cell 
delivery would likely fail if delivered to an exposed or infected wound, a method of 
space maintenance was investigated. Space maintainers made of poly(methyl 
methacrylate) and having tunable porosity and pore interconnectivity were 
evaluated within a clean/contaminated mandibular defect. Low porosity space 
maintainers were found to prevent soft tissue collapse or contracture into the 
bony defect and allowed surrounding soft tissues to penetrate the pores of the 
implant, enabling healing over 12 weeks. The tissue response and wound 
healing characteristics of these implant was favorable when compared to solid or 
high porosity implants. Although optimization and further investigation of these 
techniques is necessary, in combination these approaches demonstrate one 
possible and translatable approach towards craniofacial tissue regeneration. 
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Chapter 1 
Tissue Engineering: A Historical Perspective1 
"Begin at the beginning and go on till you get to the end: then stop." 
-Lewis Carroll, Alice's Adventures in Wonderland 
1.1 Introduction 
Tissue engineering and the synonymous or closely related field of 
regenerative medicine have drawn the widespread attention of clinicians, 
scientists, policy makers, investors, and the general public for over a decade 
dating back to the early to mid 1990s. Earlier, pioneering efforts in and related to 
the field of tissue engineering, including many of the key discoveries that later 
became the foundation for this field, were made long before this more 
generalized recognition and subsequent definition of this field. Because the field 
of tissue engineering, as recognized specifically by term itself, is relatively young 
but draws upon substantial, sometimes centuries old efforts in many related 
fields, adequately providing an overview of the history of tissue engineering is a 
difficult endeavor. 
* Sections of this chapter will be published as the following book chapter: Kretlow JD and 
Mikos AG. Tissue Engineering: A Historical Perspective. Tissue Engineering for the 
Hand: Research Advances and Clinical Applications. Mountain View: World Scientific 
Publishing Co., Inc. (2010). 
2 
Providing a truly complete history of any field so closely tied to the 
understanding of biological processes, human physiology, materials science and 
engineering, and the practice of medicine within the confines of a single chapter 
or thesis would prove to be impractical due to the magnitude of existing and 
relevant knowledge within these fields. Conversely, a historical perspective that 
examines tissue engineering through some rigidly defined criteria such as recent 
definitions of the term tissue engineering, formulated only once the field has 
become well demarcated within related areas of science and engineering, would 
fail to give proper credit to nor engender any appreciation of the substantial 
efforts related to but not wholly within the present day confines of tissue 
engineering. 
Because of this, we will first aim to provide a working definition of tissue 
engineering that somewhat limits our scope but allows for deviations into related 
fields where appropriate. Subsequent sections of this chapter will examine the 
history of the field within this context, organized broadly in chronological order but 
with an attempt to also look at certain key areas of scientific exploration within 
these chronological boundaries. 
1.1.1 Defining tissue engineering 
In the 1993 Science article that is often regarded as having brought tissue 
engineering into focus within the general scientific community, Robert Langer and 
Joseph Vacanti loosely defined the field as one that combines engineering and 
the life sciences towards developing biological tissue substitutes.1 They went on 
3 
to identify cells and cell substitutes, growth factors and delivery vehicles, and 
cell-scaffold constructs as general strategies for tissue engineering. Today, 
researchers often refer to the tissue engineering paradigm when defining the field 
- some combination of bioactive factors, cells, and matrices for the generation or 
regeneration of living tissues. 
Both definitions, while accurate and widely accepted today, prove too 
limiting within a historical context. Many seminal discoveries related to the field 
of tissue engineering were not aimed at conception towards generating tissue 
substitutes. Many of the earliest discoveries or observations also fail to 
appreciate or involve any of the critical aspects that now form the tissue 
engineering paradigm. Nonetheless, these efforts deserve mention. 
For the sake of this chapter, tissue engineering can be defined as an 
attempt, technique, or technology made or at some point applied towards the 
preternatural generation, regeneration, or restoration of native tissue structure 
and/or function using biological components. This definition is purposefully 
broad, allowing for a wide contextual scope highlighting many predecessors to 
today's field of tissue engineering. This definition also includes the field of 
regenerative medicine, which, while often considered identical or overlapping 
with tissue engineering, is more correctly regarded by those in the field as the 
products and techniques developed through tissue engineering processes that 
are directly involved in the support and practice of medicine.2 
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1.1.2 Overview: why tissue engineering? 
What can be gleaned from examining the history of tissue engineering, or 
rather, why should a historical perspective be of interest to those reading this 
thesis? First, even a cursory outline of tissue engineering in the historical sense 
provides strong evidence confirming the interdisciplinary nature of the field. 
Contributions from all areas of the natural sciences, engineering, and medicine 
will be presented both in this chapter and referred to in the rest of this thesis. 
Second, the problems that today's tissue engineers seek to tackle have 
existed for thousands of years, and while etiologies may have changed and 
existing therapies have improved over time, the need for solutions has not. 
Slowly, some of these problems are being incrementally yet effectively addressed 
through tissue engineering approaches. 
Finally, while specific and more recent advances will be covered in this 
chapter and others, historical perspectives are necessary to realize and 
appreciate that what may often be presented as seemingly science fiction is 
actually grounded in years, decades, and in some cases, centuries worth of 
scientific exploration. We do not aim to present tissue engineering as a panacea 
for the destruction or dysfunction of all tissues; it is not. Rather, we aim to 
provide some level of historical context such that, when considered along with 
the other knowledge presented within this thesis, one can examine recent 
advances and potential applications with a hopeful yet critical eye. 
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1.2 Conception to Birth 
Adopting the definition laid out in section 1.1.1, one can loosely trace the 
early history of tissue engineering along a similar path as the history of surgery. 
Areas such as wound healing and organ transplantation are critical in both fields 
and played a large role in forming the foundations of tissue engineering. This 
section will highlight the earliest efforts related to tissue engineering and then 
examine in greater detail the advances of the 20th century and particularly the 
1990s that led to the recognition of tissue engineering as a distinct field. 
1.2.1 Ancient foundations 
Beginning any discussion of tissue engineering with a section describing 
ancient history seems a bit exaggerated. Despite the fact that tissue engineering 
as a formal field is still relatively new, many principles of tissue engineering have 
been applied dating back to ancient times. Some authors have even noted that 
the first verse of Genesis in the Christian Bible mentions tissue engineering in the 
form of extraction and expansion of a man's rib resulting in a complete woman.3 
A brief examination highlighting some ancient predecessors to today's tissue 
engineers proves that while technologies and our understanding of biology and 
engineering have greatly expanded, many of the problems of the ancient time 
have persisted to become modern problems. 
The Edwin Smith papyrus (Figure 1.1), an Egyptian text dating between 
2600 - 2200 B.C., describes sutured closure of wounds allowing for subsequent 
healing by primary intention.4 Although wound healing is of interest in many 
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fields, sutured closure of wound represents one of the earliest examples of tissue 
engineering. Because many of the wounds described would otherwise have 
healed by secondary intention, wound closure and healing represents a 
preternatural regeneration of native tissue structure/function as it minimizes 
scarring and thus improves the strength of the healed wound. Additionally, 
suturing with silk or linen/gum combinations was likely among the first successful 
uses of biomaterials. Despite a greater than four millennia history, wound 
healing remains a heavily investigated topic today as researchers and clinicians 
attempt to both gain improved understanding of its regulation5, 6 and develop 
better therapies to aid in this process.7,8 
Working around 600 B.C., the Indian professor and clinician Sushruta 
provided the first written record of the use of rotational flaps to reconstruct 
amputated noses - the result of corporal punishment meted out in ancient India.9 
These early flaps, taken from the forehead with the angular artery serving as 
blood supply, used autologous tissue to restore the aesthetic function of the 
mutilated nose.10 This technique also represents one of the earliest uses of 
autologous tissue for restorative purposes, and similar techniques remain the 
gold standards of treatment for many cases of tissue loss or dysfunction today. 
A host of other important discoveries upon which today's field of tissue 
engineering lies began during antiquity. While significant efforts towards 
understanding anatomy, physiology, and various disease processes were made 
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during ancient times and are no doubt critical in modern tissue engineering, the 
scope of these subjects makes them best left to other, dedicated texts. 
1.2.2 Renaissance through 19th century 
The Renaissance period was not without contributions in the area of tissue 
engineering. Modified approaches to rhinoplasty, similar to those of Sushruta, 
emerged in Italy at the hands of the 15th century Branca and Viano families,4,11 
followed by the 16th century efforts of Giulio Cesare Arantius (also referred to as 
Aranzio),12 and finally popularized (and often solely attributed to) by the famous 
Renaissance surgeon Gaspare Tagliacozzi (Figure 1.2) in De Curtorum Chirurgia 
per insitionem, a 700-page surgical treatise published in 1597, two years before 
Tagliacozzi's death.13 The technique used in these rhinoplasties, now referred to 
as surgical or vascular delay, at the time involved the elevation of a bipedicled 
flap from the forearm and later the anterior brachium. Medicated linen or cotton 
lint was then placed under the flap to prevent reattachment, and after two weeks 
to one month, the flap was attached to the patient's nose. 
Delay represents a major step forward in the history of tissue engineering. 
Whereas wound edge approximation to allow for closure and healing by primary 
intention seems an obvious (although mechanistically complex) technique, delay 
represents one of the first non-obvious techniques resulting in tissue 
manipulation or truly engineering beyond that visible with the naked eye. 
Although the mechanism involved in delay was almost certainly not understood 
by its earliest practitioners, for one of the first times, autologous tissue was being 
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modified through a complex interplay between sympathetic tone, vascular tone, 
tissue metabolism, and ultimately neovascularization via endothelial progenitor 
cell recruitment.14 It has taken nearly 500 years since Tagliacozzi's publication 
detailing these methods for them to be well understood, and vascular delay 
remains an accepted practice towards conditioning flaps today.15, 16 For tissue 
engineering, vascularization of engineered tissues and angiogenic control remain 
one of the greatest and most unmet challenges facing the field.17 Significant 
research efforts continue towards determining effective material and cellular 
parameters and growth factor regimes to induce neovascularization and 
angiogenesis such that ex vivo or ex situ engineered tissues of a clinically 
relevant size can be constructed.18,19 
Allograft transplantation was the next major historical step towards tissue 
engineering. Although evidence of allografts from earlier points in history are 
apparent, notably including a lower limb allograft transplanted by Saints Cosmas 
and Damian and captured in a famous painting by Fra Angelico (Figure 1.3), 
most early allografts were subject to rejection and disease transmission. The 
British surgeon John Hunter performed some of the first successful 
transplantations in the late 18th century. Hunter focused primarily on 
transplanting teeth, first using a rooster as an animal model but later 
transplanting human teeth between subjects.20 This practice was short lived due 
to the spread of diseases such as syphilis through the practice rather than 
rejection. 
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Skin grafts were likely the first allografts to gain more widespread use. 
Giuseppe Baronio, a contemporary of John Hunter, published extensively on skin 
autografting in animals, likely paving the way for experiments with allografts.4 
Winston Churchill served as a skin graft donor for a fellow soldier in 1898,21 
although it would be nearly 50 years and two world wars before a better 
understanding of immune rejection existed.22 
Corneal transplants were also investigated during the 19th century. Samuel 
Bigger performed a successful allograft cornea transplantation between gazelles 
while a prisoner in Egypt in 1837;23 however, the first successful transplant in 
humans would not occur until the early 20th century. 
Around this time, Nicholas Senn found that decalcified bone induced 
healing within bone cavities;24 demineralized bone matrix is now a widely used 
product for bone healing and regeneration. The mechanism for this effect would 
not be known until the middle of the next century, and Senn's approach was 
impressive because, similar to that of Tagliacozzi's delay, he was modifying a 
human tissue to increase its effectiveness in regenerating an orthotopic defect. 
The next two sections will further discuss the use of the extracellular matrix and 
matrix components as powerful tissue engineering tools. 
1.2.3 20th century advances 
The 20th century saw significant advances in every area of science and 
technology, including tissue engineering. Progress in the first half of the century 
was similar to that of the decades before in that it was rooted deeply but 
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disparately in clinical medicine, biology, and engineering. During the second half 
of the century, however, important advances in a variety of fields began to be 
integrated in what would eventually lead to the birth of tissue engineering as a 
unique discipline. 
Organ transplantation 
In 1905, Austrian physician Eduard Zirm performed the first successful, full 
thickness human corneal allograft transplantation.25 That same year, Alexis 
Carrel and Charles Guthrie reported a method to anastomose vessels,26 a 
discovery that would lead to a Nobel Prize in 1912 for Carrel and that would later 
allow for solid organ transplants. In 1935, Carrel and aviator Charles Lindbergh 
published The Culture of Whole Organs, a book detailing ex vivo culture 
techniques to keep entire solid organs alive, including the use of a perfusion 
pump.27 
Significant other contributions were made towards organ transplantation in 
the early and mid 20th century, including the first successful transplantations of 
many organs and the elucidation of many key aspects of immune tolerance and 
rejection. While undoubtedly these contributions are relevant and important 
within the field of medicine and tissue engineering, we will begin to limit our 
overview at this point to the first attempts towards tissue engineering in the sense 
that the term is used today. Organ transplants are a life saving therapy; 
however, persistent problems with organ shortages and immune rejection can be 
viewed as partially contributing to the development of tissue engineering. 
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In combination with medical advances, political and military events of the 
early 20th century also contributed to the rise of tissue engineering. Antibiotics, 
the use of plasma, and other life-saving medical and surgical techniques 
decreased mortality in the first two world wars relative to previous wars. As a 
result, soldiers were surviving previously fatal injuries but often at the cost of 
disfiguring tissue loss. Other authors have noted the increased importance of 
reconstructive surgeons following WWI due to the incidence of craniofacial 
injuries,28 and this increased morbidity rather than mortality provided a nidus from 
which tissue engineering would later emerge. 
Vascular grafts 
Nearly 50 years after Carrel described vessel anastomosis, Arthur 
Voorhees made the first synthetic vascular graft, replacing aortic segments in 
dogs with a polyvinyl chloride) based fabric.29 Poly(methyl methacrylate) and 
other polymeric materials had been used previously in dental applications such 
as dentures, but Voorhees used a synthetic material to replace a tissue whose 
functionality was dependent on interactions with both adjacent vascular tissue 
and blood. Over the next 30 years, endothelial cell seeding of vascular grafts, 
resorbable graft materials, and finally in vitro graft engineering would be studied. 
Bone and osteoinduction 
Also in the 1950s, Marshall Urist began publishing studies on the 
phenomenon of bone induction using transplanted bone.30 31 Urist published 
groundbreaking papers that described in 1965 the differentiation of 
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osteoprogenitor cells in the presence of decalcified bone matrix32 and later the 
isolation of osteoinductive bone morphogenetic proteins (BMPs),33 confirming a 
preexisting hypothesis regarding the existence of an osteogenic substance within 
bone.34 Sampath and Reddi were later able to isolate this osteogenic substance, 
bone morphogenetic protein 2 (BMP-2),35 and it is now the basis for both 
commercially available products for bone regeneration and the focus of a wide 
variety of experimental applications within bone tissue engineering.36"38 
Stem cells 
Critical advances in cell biology were being made beginning in the 1960s 
that would later be integrated into tissue engineering approaches. Researchers 
were beginning to explore in depth the ability of terminally differentiated tissues to 
renew and regenerate.39,40 Recognition of a population of pluripotent circulating 
progenitor cells gave the first signs of the existence of marrow stromal or 
mesenchymal stem cells, a cell population that is potentially one of the most 
powerful tools at the disposal of today's tissue engineers.41, 42 Following up the 
1964 work of Kleinsmith and Peirce,43 Gail Martin44 and the team of Martin Evans 
and Matthew Kaufman45 described in separate studies published in 1981 the first 
isolation of embryonic stem cells. 
Other cell-based approaches 
Pluripotent cells represent a promising technology for tissue engineering 
due to the ability to potentially harvest cells from the patient, then expand, 
differentiate and possibly form a functional tissue in vitro, followed by implantion 
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of the cellularized construct back into the patient with little risk of immune 
reaction. The use of differentiated cells has the disadvantage of possible lack of 
availability of autologous cells if an organ has been severely damaged or 
uniformly diseased. Nevertheless, tissues engineered using expanded 
allogeneic cells can be used to reduce the shortage of available donor tissue for 
transplantation or reconstruction. 
The birth of tissue engineering 
The field of tissue engineering as we know it today was eventually borne 
from efforts to combine differentiated somatic cells with biomaterials to form new 
living tissues either in vitro or in vivo. One such approach using endothelial cells 
to line synthetic vascular grafts was already, albeit briefly, mentioned. A similar 
approach towards replacing the function of the pancreas was taken by William 
Chick and his colleagues. Their approach involved seeding pancreatic beta cells 
on a semipermeable membrane to create a hybrid pancreas that combined living 
and artificial components.46 This hybrid pancreas was used to successfully treat 
diabetes in rats47 and later dogs48 and in 1985 resulted in the formation of 
BioHybrid Technologies, an early tissue engineering company. 
Following a similar path, W.T. Green investigated cartilage formation in 
vitro and in vivo.49 His approach using cells implanted on a specifically tailored 
scaffold would years later be adopted as the fundamental technique in tissue 
engineering.3 This same principal of using tailored scaffolds to support tissue 
growth was the idea behind the first tissue engineering company (although at the 
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time the founders referred to the idea as tissue gardening), Interpore Cross 
International, Inc., founded in 1975.50 
In 1981, the cell-scaffold approach yielded reports of the first in vitro 
generated, full thickness skin grafts.51, 52 One approach that resulted from 
collaboration between John Burke and loannis Yannas used a collagen and 
silicone based material that served as a dermal template, encouraging the 
ingrowth of native skin and vessels from surrounding skin. The approach taken 
by Eugene Bell and Howard Green used autologous dermal fibroblasts and 
epidermal keratinocytes, expanded in vitro, and a collagen matrix to generate a 
full thickness skin graft or living skin equivalent that can be sutured or stapled in 
place during surgery without the risk of rejection. 
With the ability to grow functional, living tissues in vitro, the birth of tissue 
engineering was well underway. The first use of the term tissue engineering 
appears in a 1984 paper describing the macrophage mediated lining of a corneal 
prosthesis with a membrane.53 One year later, in 1985, Y.C. Fung proposed that 
the NSF establish a new research center to be known as the "Center for the 
Engineering of Living Tissues".50 His proposal was rejected, but tissue 
engineering, both the term and the field, was on the way to becoming established 
within the scientific community. In 1988, Joseph Vacanti and Robert Langer 
published what would be the first of many tissue engineering papers together - a 
study of cell transplantation using bioresorbable scaffold carriers.54 
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1.2.4 The 1990s: research, recognition, and general interest 
Research in the early part of the 1990s continued along a similar path as 
that of the late 1980s. Groups were beginning to focus on biomaterial scaffold 
fabrication and to characterize the interaction between cells and these 
scaffolds,55b8 an area that remains a critical component of tissue engineering 
research to this day. Publication of the article titled "Tissue Engineering" in the 
May 14, 1993 issue of Science is viewed as the introduction of the field to the 
broader scientific community.1 This article helped define tissue engineering, 
describe critical areas for research within the new field, and also provided a 
glimpse into the significant potential held within the field. 
It was also around this time that tissue engineering societies began 
emerging across the U.S. and the rest of the world.59 The Tissue Engineering 
Society was launched in 1994 and later evolved into the Tissue Engineering 
Society International (TESI) and then TERMIS, the Tissue Engineering and 
Regenerative Medicine International Society. Charles A. Vacanti of the 
Massachusetts General Hospital and Harvard Medical School and Antonios G. 
Mikos of Rice University founded the journal Tissue Engineering, published by 
Mary Ann Liebert, Inc. Publishers, in 1994. The first issue was released in early 
1995, and the journal remains the flagship journal dedicated solely to tissue 
engineering research. The journal now publishes in 3 parts, devoted to research, 
reviews, and methods, with Antonios Mikos now joined by co-editors-in-chief 
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Peter C. Johnson, who in the early 1990s had formed the Pittsburgh Tissue 
Engineering Initiative, along with John A. Jansen and John P. Fisher. 
Research in the 1990s continued to expand the knowledge of biomaterial-
cell interactions. Discoveries in other fields that would later become critical to 
tissue engineering applications, such as adult pluripotent stem cell 
characterization,60,61 were also made during this period. 
In 1997, public interest in tissue engineering was sparked by major media outlets' 
coverage of what has become known as the "Vacanti mouse." A 1997 
publication in Plastic and Reconstructive Surgery from the laboratory of Charles 
A. Vacanti described the fabrication of an ear shaped cartilage construct via 
transplantation of chondrocytes onto auricle-shaped poly(glycolic acid)-poly(lactic 
acid) fiber meshes that were implanted subcutaneously onto the backs of athymic 
mice (Figure 1.4).62 Subsequent coverage of the story in the New York Times 
and later on the popular television series Nip/Tuck only increased public attention 
to this result and tissue engineering in general. 
In reality, tissue engineering had been impacting patient care before the 
buzz from advances such as the Vacanti mouse. Charles Vacanti reports using a 
tissue engineering approach to regenerate a patient's sternum as early as 
1991,59 and FDA regulated tissue engineered procedures and products were 
available by the late 1990s as well in the form of Carticel®, a chondrocyte 
expansion procedure offered by Genzyme Biosurgery, and Apligraf®, a collagen 
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based full thickness skin equivalent from Organogenesis used to treat lower 
extremity diabetic and venous stasis ulcers. 
1.3 Growth: The 21st century 
The beginning of the 21st century has seen tremendous advances in tissue 
engineering. The field has established a role within clinical care, and recent 
advances in the laboratory and through in vivo testing using animals models point 
to exciting further developments over the course of the coming years and 
decades. A plethora of undeniably important advances in tissue engineering 
have been made thus far this decade, and for many of these advances, the true 
magnitude of their importance may not be fully realized for many more years. 
Many recent advances and the state of the art in most areas of tissue 
engineering will be discussed in the remaining chapters of this thesis; therefore, 
the next section will highlight a few select examples of clinically used tissue 
engineering strategies. 
1.3.1 Continued advancement 
Earlier this decade, a number of experimental techniques bridged the gap 
from laboratory to clinic. Reports of tissue engineered pulmonary arteries in the 
laboratory63 quickly resulted in major publications reporting clinical use of these 
arteries.64 At the same time, tissue engineering techniques were applied clinically 
to utilize autologous cells to regenerate bone.65 More recently and based on work 
performed in the early 1990s,66 autologous bone flaps have been created in vivo 
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using tissue engineering strategies and then used to engineer a functional 
hemimandible capable of accepting dental implants.67 This technology eliminates 
the need to harvest the patient's fibula or rib to reconstruct the mandible but still 
relies on the use of autologous material, thus eliminating concern of disease 
transmission or rejection. 
The use of biological scaffolds is an exciting technology that deserves 
special note in any discussion of recent tissue engineering trends and advances. 
While not a new idea, as demonstrated by the aforementioned studies by 
Nicholas Senn and Marshall Urist, the processing and use of the extracellular 
matrix has led to a number of exciting advances in tissue engineering this 
decade. Related to the work of Senn and Urist, a large number of decellularized, 
demineralized bone matrix products are commercially available and approved by 
regulatory agencies worldwide. Extracellular matrix based strategies are now 
expanding to include tissue engineering of other organs. 
A group led by Anthony Atala published a landmark study in 2006 
describing the use of tissue engineered autologous bladders to replace 
congenitally defective bladders in 7 patients.68 The engineered bladders 
consisted of scaffolds made from decellularized bladder submucosa or a 
combination of collagen and poly(glycolic acid) seeded with autologous cells 
expanded in vitro from a punch biopsy taken from each patient's bladder (Figure 
1.5). This study marked the first time a whole organ had been engineered for 
clinical use and garnered well-deserved attention and acclaim. 
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A related approach was used in 2008 to replace a patient's left bronchus 
using a tissue-engineered trachea.69 The team of researchers, led by Paolo 
Macchiarini, used a bioreactor to culture autologous bone marrow derived 
mesenchymal stem cells seeded on a decellularized tracheal matrix taken from a 
donor. After 96 hours of culture within the bioreactor, the engineered trachea 
was surgically implanted to replace the patient's stenotic left main bronchus 
(Figure 1.6). 
As a final example of the promising capabilities of the extracellular matrix, 
building on reports that transplanted hearts display donor-recipient chimerism 
indicating autologous seeding of the transplanted organs,70 researchers have 
shown that decellularized cardiac matrices can be recellularized in vitro and can 
regain some of the pumping ability of functional hearts. 
Commercial products that utilize extracellular matrices for tissue 
regeneration are also available. Two such products, Alloderm® and Strattice®, 
both manufactured by LifeCell, Inc., provide decellularized human and porcine 
matrices, respectively, for skin regeneration in vivo. 
1.4 The Future and the Past 
An attempt to predict the future of tissue engineering with any level of 
specificity or temporal conjecture would be foolish; the field continues to advance 
at a rapid but ever changing pace. As with any multidisciplinary field, advances 
will be predicated not only on the efforts of tissue engineers, but also on 
scientists from other fields, including chemists, materials scientists, molecular 
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and cell biologists, pharmaceutical engineers, and clinicians. Discernible trends, 
however, do exist within the field and shed possible light on future directions. 
One such trend is the use of autologous cells to regenerate patient-
specific tissues. While development of embryonic stem cell technology is 
hampered by ethical and political debates in the U.S., the identification and use 
of adult stem cells in tissue engineering research is becoming increasingly 
popular and promising. Stem cell populations in bone marrow, adipose tissue, 
dental tissues, and the skin represent potential targets upon which tissue 
engineering strategies will be based. While harvest and expansion of 
autologous, terminally differentiated cells is possible in many cases, in the future 
tissue engineering strategies may be used to address clinical problems for which 
no such tissue can safely be acquired. Thus tissue engineers have the need for 
a well-characterized, easily accessible stem cell population. Additionally, ideal 
growth factor or conditioning regimes for differentiation and maintenance of 
differentiation are necessary. 
As previously mentioned, organ and tissue transplantation as long-term 
solutions to many clinical problems are limited due to the lack of supply of donor 
organs/tissues and also concern over rejection and long-term 
immunosuppression. Tissue engineering strategies will ideally overcome this 
hurdle. The use of autologous cells for tissue regeneration is one method to 
eliminate the need for immunosuppression. Antigen suppression or elimination is 
another potential solution to this problem. For strategies that rely on allogeneic 
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extracellular matrices, the supply of available materials is certainly greater than 
that of donor organs and tissues but still somewhat limited relative to solutions 
that use synthetic biomaterials. The continued development of methods to create 
functional synthetic extracellular matrices and to generate de novo allogeneic 
extracellular matrices, many of which already exist,71"74 may further alleviate the 
need for donor tissues. 
1.5 Conclusions 
The common opinion of tissue engineering holds that it is a relatively new 
field within science. While this may be true of the name and more precise 
definition of the field, as with any multidisciplinary field, tissue engineering has 
roots that extend far into history. Early attempts at and advances in tissue 
engineering-related sciences were examined to establish the existence of this 
long history and also to exemplify the close relationship of tissue engineering to 
other fields within science and medicine. The defining studies of the 1980s and 
1990s were discussed, as this can be viewed as the time period when the 
modern field of tissue engineering emerged. Highlights of more recent work were 
also provided as a means to justify the importance of tissue engineering within 
the scientific and medical communities and also to give some sense as to the 
possibilities that exist with the continued pursuit of research within the field. 
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1.6 Figures 
Figure 1.1. Plates vi and vii of the Edwin Smith Papyrus. Thought to be written by 
Imhotep, the document is the first known textbook of surgery and describes 
wound closure, one of the earliest forms of tissue engineering. Today the Edwin 
Smith Papyrus can be found at the New York Academy of Medicine. 
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Figure 1.2. A) Posthumously painted (1599) portrait of Gaspare Tagliacozzi from 
the University of Bologna. Gaspare Tagliacozzi, shown in a portrait painted 
posthumously in 1599 from the University of Bologna (A) advanced reconstructive 
surgery through techniques such as delay (B), where a flap is lifted and separated 
from the underlying tissue prior to reconstruction, enabling a complex but 
beneficial series of changes within the flap. (From De Curtorum Chirurgia per 
insitionem. Venice Italy: Bindoni, 1597) 
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Figure 1.3. "The healing of Deacon Justinian" by Fra Angelico (ca. 1440) depicts 
the transplantation of a man's leg, taken from an Ethiopian donor, onto the injured 
deacon. (From Museo di San Marco, Florence, Italy) 
25 
o» 
Figure 1.4. Gross appearance of a chondrocyte seeded-poly(glycolic acid)-
poly(lactic acid) scaffold in the shape of a human ear, implanted subcutaneously 
on the dorsum of an athymic mouse for 12 weeks. Reproduced with permission 
from [62]. 
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Figure 1.5. Generation and implantation of a tissue engineered bladder. A) 
Scaffold seeded with autologous cells. B) Tissue engineered bladder being 
anastomosed to the remaining native bladder for reconstruction. C) Fibrin glue 
and omentum covering the reconstructed bladder. Reproduced with permission 
from [68]. 
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Figure 1.6. Computed tomography volume rendering (A and C) and 
bronchoscopic reconstructions (B and D) of a patient with left main bronchus 
stenosis (arrows) before (A and B) and 1 month after (C and D) resection of the 
bronchus and reconstruction with a tissue engineered trachea made using bone 
marrow mesenchymal stem cells seeded onto a decellularized tracheal matrix. 
Reproduced with permission from [69]. 
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Chapter 2 
Biomaterials for Regenerating Complex Craniofacial Tissues1 
Abstract 
Engineering complex tissues requires a precisely formulated combination 
of cells, spatiotemporally released bioactive factors, and a specialized scaffold 
support system. Injectable materials, particularly those delivered in aqueous 
solution, are considered ideal delivery vehicles for cells and bioactive factors and 
can also be delivered through minimally invasive methods and fill complex 3D 
shapes. In this review, we examine injectable materials that form scaffolds or 
networks capable of both replacing tissue function early after delivery and 
supporting tissue regeneration over a time period of weeks to months. The use 
of these materials for tissue engineering within the craniofacial complex is 
challenging but ideal as many highly specialized and functional tissues reside 
within a small volume in the craniofacial structures and the need for minimally 
invasive interventions is desirable due to aesthetic considerations. Current 
biomaterials and strategies used to treat craniofacial defects are examined, 
followed by a review of craniofacial tissue engineering, and finally an examination 
1
 This chapter was published as: Kretlow JD, Young S, Klouda L, Wong M, Mikos AG. 
Injectable Biomaterials for Regenerating Complex Craniofacial Tissues. Adv Mat 
2009 ;21 (32-33) :3368-93. 
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of current technologies used for injectable scaffold development and drug and 
cell delivery using these materials. 
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(3-TCP: beta-tricalcium phosphate 
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2.1 Introduction 
Reconstruction of the oral and maxillofacial complex following traumatic 
insult, tumor ablation, or congenital deformities remains a formidable challenge 
for clinicians. A myriad of tissue types and morphologically complex structures 
are present in a relatively small area, with the consequence that defects often 
involve multiple tissue types including the facial skeleton, special sense organs, 
soft tissues (i.e. muscle, subcutaneous fat, skin, mucosa), salivary glands, 
cartilage, nerves, vessels, and teeth. Current clinical strategies designed to 
address such composite defects need to restore both the functional and aesthetic 
characteristics of the affected region. Additional considerations include the 
routine presence of bacterial contamination from the oral and sinus cavities, the 
ability to withstand the mechanical stresses imposed by masticatory function, and 
the special aesthetic challenges posed by the restoration of symmetric facial 
structures. 
The morbidity and limitations associated with current surgical techniques 
and materials for oral and maxillofacial reconstruction has spurred the 
development of tissue engineering (TE) strategies to address these 
shortcomings. Injectable TE methods (with the ability to deliver both a therapeutic 
cell population and bioactive factors) are particularly attractive examples of how 
TE can be combined with minimally invasive techniques to reduce morbidity. The 
purpose of this review is to outline contemporary methods and materials in oral 
and maxillofacial reconstruction, describe currently available injectable tissue 
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engineering systems, and discuss the use of such systems for the delivery of 
cells and bioactive factors to regenerate complex tissues within the oral and 
maxillofacial region. 
2.2 Reconstructive materials commonly used in the oral and maxillofacial 
region 
Advances in surgical techniques, biomaterials science, and cell biology 
have established several approaches to the reconstruction of the oral and 
maxillofacial region depending upon certain characteristics of the defect such as 
size, shape, and vascularity. Autologous tissue remains the "gold standard" 
material, although associated harvesting procedures may result in donor site 
morbidity and require additional surgical time. Allograft or xenograft tissues do 
not require additional operative time and expense but may suffer from batch-to-
batch variability and carry the risk of potential viral or bacterial transmission and 
immune-mediated regenerative compromise. Synthetic materials offer the ability 
to precisely control biologically important characteristics such as porosity or 
hydrophilicity/hydrophobicity through the manufacturing process, but they usually 
require the addition of bioactive factors or cells to promote tissue regeneration. 
When complex, composite defects are encountered following treatment for 
neoplastic or cystic pathology and with high-velocity ballistic injuries, autologous 
tissue reconstruction using pre-vascularized hard and soft tissue grafts usually 
represents the technique of choice. However, for single tissue defects (i.e. solely 
bone or soft tissue regeneration), which are much, more common, the surgeon 
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can choose from a wide range of autograft, allograft, xenograft, and synthetic 
materials currently available (Table 2.1). 
2.2.1 Osseous reconstruction 
Autologous tissue 
Many clinicians consider harvested autologous bone (i.e. taken from the 
same individual) as the "gold standard" material for the reconstruction of osseous 
defects. Autologous bone grafts by their very nature are able to deliver a 
physiologically optimized combination of osteogenic cells and growth factors in a 
mineralized scaffold. In 1956, Axhausen75 described two "osteogenetic phases" 
of bone regeneration when using bone grafts. The first phase (i.e. osteogenesis) 
begins several days after the grafting procedure and is attributed to the activities 
of surviving, pre-existing osteogenic cells, which form osteoid within the 
transplanted bone. The second phase (i.e. osteoinduction) occurs several weeks 
later, particularly in response to the resorption and remodeling of the bone graft 
by osteoclasts resulting in exposure of invading host-site stem cells to 
osteoinductive factors such as bone morphogenetic proteins contained within the 
mineralized matrix of the original graft. An autologous graft is also capable of 
initiating bone formation through an osteoconductive mechanism, if it is placed in 
proximity to a well-vascularized bed and bone forming cells. With autologous 
bone grafts, immunologic rejection and disease transmission are absent. 
Depending on the amount of bone graft required, the iliac crest, tibia, skull, 
and mandible76,77 are common areas in which particulate bone or blocks can be 
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harvested. However, the supply of donor tissue is limited and morbidity increases 
as larger amounts of bone are harvested. While the incidence is low, 
complications related to iliac crest bone harvesting such as persistent post-
operative pain, nerve injury, arterial injury, scarring, hemorrhage, hematoma, 
infection, and gait disturbance have been reported.78 
Non-vascularized autogenous bone grafts offer a relatively predictable 
means of filling osseous defects and inducing new bone growth. Following graft 
remodeling, complete integration into the host site occurs. Several parameters 
govern the success of such grafts including prevailing conditions within the host 
site and stability of the graft. Sufficient soft tissue bed vascularity and coverage of 
the non-vascularized bone graft are typically required to prevent healing 
complications such as wound dehiscence or infection79 and allow for survival of 
the transplanted osteogenic cells within the graft. Rigid fixation of the graft allows 
rapid neovascularization of newly formed bone and survival of transplanted cells. 
In some cases, soft tissue bed vascularity may be compromised, as in patients 
who have undergone radiation therapy for malignant disease. A course of 
hyperbaric oxygen treatments can be undertaken to promote soft tissue 
oxygenation and neovascularization, optimizing the quality of the recipient tissue 
bed prior to receiving the non-vascularized bone graft. 
Vascularized bone grafts are less dependent on the presence of an 
optimized soft tissue recipient bed, although their size and shape are largely 
dictated by the morphology of the donor site. Since vascularized bone must be 
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initially transferred with a peri-osseous cuff of soft tissue containing its blood 
supply, a second operation is frequently required to remove the excess soft 
tissue associated with the graft. Additional procedures may also be required to 
augment the volume of grafted bone to allow for dental implant rehabilitation. 
Nonetheless, despite the more technically demanding nature of microvascular 
free tissue transfer, vascularized bone and soft tissue grafts are now commonly 
used by experienced surgeons in the reconstruction of large composite tissue 
defects. 
Allogeneic tissue 
Allograft bone (i.e. harvested from an individual of the same species as 
the recipient) is typically derived from human cadavers and is available from 
bone banks and other commercial vendors. Donor site morbidity and limitations 
as to the quantity of graft are no longer considerations. Both cortical and cortico-
cancellous allograft bone is available in the form of particulate, chips, and blocks. 
Large cortical allografts undergo minimal revascularization and remodeling 
leading to the accumulation of microfractures over time and the persistence of a 
non-vital graft incapable of physiological adaptation to functional loads.80 
There is also a potential risk of bacterial, viral, or prion transmission with 
allograft bone, as well as immunologic rejection depending on the method 
adopted for bone preservation. To address these concerns, donor selection and 
screening (i.e. for human immunodeficiency viruses 1 and 2, and hepatitis B and 
C in the United States) combined with tissue processing (i.e. washing to ensure 
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blood component removal,81 freeze-drying, or gamma irradiation82) are used by 
bone banks and vendors to increase the safety of allograft bone products. As a 
result of these measures, the risk of disease transmission has been calculated to 
be quite small (i.e. the risk of receiving allograft bone from an HIV-infected donor 
is approximately 1 in 1.6 million83). 
Ideally, allograft processing should produce safe yet biologically active 
products for use in osseous reconstruction. However, some processing methods 
have been associated with detrimental effects on the mechanical and biological 
performance of allograft bone. Examples include the promotion of microcracks in 
cortical bone grafts with freeze-drying, increased brittleness of cortical bone with 
gamma irradiation, and a decrease in the osteoinductivity of demineralized bone 
allograft with higher levels of gamma irradiation or ethylene oxide sterilization.84 
As a result, current processing methods render mineralized allograft bone a 
predominantly osteoconductive material with minimal osteoinductivity and no 
osteogenicity. 
The biological activity of allograft bone can be augmented by the addition 
of autogenous bone or platelet rich plasma.85 Alternatively, treatment of 
mineralized allograft bone with hydrochloric acid (0.5 - 0.6 M) or a 1:1 formic 
acid-citric acid mixture yields demineralized bone matrix (DBM) which is less 
immunogenic86 and possesses both osteoconductive and osteoinductive 
properties (through the exposure of bone morphogenetic proteins previously 
contained within the mineral component of the allograft).84 The biological activity 
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of DBM is not consistent. Variations in growth factor content from lot-to-lot and 
between different commercial formulations of DBM have been reported87 and 
confirmed by variations in osteoinductive potential between various products 
seen in animal studies.88 To enhance intra-operative handling properties, DBM 
has been combined with carriers such as hyaluronate (i.e. DBX® from Synthes, 
USA), glycerol (Grafton® from Osteotech, USA), gelatin (Regenafil® from 
Regeneration Technologies, USA), poloxamer (Dynagraft® from GenSci 
Regeneration Sciences, Canada) and calcium sulfate (Allomatrix® from Wright 
Medical Technology, USA) by various commercial vendors.89 
Xenogeneic tissue 
Xenogeneic bone grafts (i.e. harvested from a different species) have the 
same potential advantages as allograft bone, in that virtually unlimited amounts 
can be procured without donor-site morbidity. As with the use of allografts, there 
is a small risk of pathogen transmission, although the risk of bovine spongiform 
encephalopathy (BSE) or the transmission of porcine endogenous retroviruses 
(PERVs) from xenogeneic products is low,90 because unlike central nervous 
system tissues (i.e. brain and spinal cord), bone, skin, or skeletal muscle are not 
believed to contain infectious levels of transmissible spongiform encephalopathy 
agents.91 The chemical and heat treatment of bovine bone to denature and 
remove proteins has also proven to be effective in the inactivation of prions.92 
Although immunologic rejection of transplanted xenogeneic tissues is a 
possibility considering the large histocompatibility mismatch between animal and 
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human tissues, processed xenograft bone has been used (either alone or in 
combination with autograft bone) in numerous dental applications such as 
implantology,93 maxillary sinus floor augmentation,94 alveolar ridge 
preservation,95 and periodontal regeneration without significant reaction.96 
Several commercial products available for dental and orthopedic bone 
regenerative applications include cross-linked bovine collagen I fibers coated in 
hydroxy apatite (Healos® Bone Graft replacement from DePuy Spine, USA), 
deproteinized bovine bone (Bio-Oss® from Osteohealth, USA), porcine collagen I 
and III resorbable membrane (Bio-Gide® from Osteohealth, USA), and a 
composite of 60% hydroxyapatite + 40% tricalcium phosphate ceramics in a 
bovine fibrillar collagen carrier (Collagraft® from Angiotech Pharmaceuticals, 
USA).90 
Synthetic biomaterials 
Ceramics 
The extracellular matrix of bone has been described as a composite 
material composed of collagen type I fibrils mineralized with nanocrystals of 
hydroxyapatite.97 Approximately 70% of bone by weight is composed of calcium 
salts, with hydroxyapatite (Caio(P04)6(OH)2) as the primary mineral constituent. 
Strictly speaking, bone mineral is not purely hydroxyapatite, and the presence of 
ion impurities has actually led to the consensus that a more accurate term for the 
inorganic component is carbonatehydroxyapatite with the formula 
(Ca,Mg,Na)io(P04HP04C03)6(OH)2.98 Devoid of an organic component, calcium 
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salts such as hydroxyapatite are biocompatible, non-immunogenic components 
of bone and are considered to be osteoconductive. Consequently, there has 
been much interest in designing synthetic osteoconductive grafting materials 
based on these naturally occurring calcium salts. 
LeGeros98 has characterized commercially available calcium phosphate 
(CaP) biomaterials as either hydroxyapatite of natural origin or synthetically 
produced CaP. The hydroxyapatite of natural origin is either obtained from bovine 
bone (as discussed above) or from certain species of coral. These naturally 
derived sources of hydroxyapatite are processed so that their macroporous, 
interconnected structure is maintained, allowing for in-growth of host tissue upon 
implantation, as well as the diffusion of nutrients throughout the graft material. 
Coralline-derived ceramics are typically prepared in two ways. The first 
method involves a solid-state hydrothermal exchange reaction called the 
Replamineform process, in which the calcium carbonate-based coral skeleton is 
converted to a calcium phosphate-based material (while still maintaining its 
architecture), which is predominantly in the form of hydroxyapatite." This 
material is marketed under the name Pro Osteon® (Interpore Cross International, 
USA). Since Replamineform grafting materials are nearly non-resorbable,100 
newer coralline ceramics that have undergone a partial Replamineform process 
have been developed, resulting in a material which is composed mainly of 
calcium carbonate with calcium phosphate present only on the internal and 
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external surfaces. This material is marketed as Biocoral® (Biocoral, USA) and 
has been shown to be resorbed and replaced by bone over time.100 
Numerous synthetic CaP biomaterials are commercially available and 
have been classified according to their composition by LeGeros98 as 
hydroxy apatite, unsintered calcium deficient apatite, beta-tricalcium phosphate, 
or biphasic calcium phosphate. Hydroxyapatite can be produced with either a 
dense or macroporous morphology, and is typically sintered at temperatures 
above 1000 °C in granular or block forms. The high heat of sintering produces a 
material that cannot be reshaped to fit into a bone defect (i.e. if in block form) and 
is non-resorbable.101 Beta-tricalcium phosphate (|3-TCP) has the formula 
Ca3(P04)2 and like hydroxyapatite is a brittle material with low fracture resistance. 
Both hydroxyapatite and |3-TCP are biocompatible, osteoconductive, and 
bioactive (i.e. they develop a direct, adherent bond with bone).98 
Under physiological conditions, hydroxyapatite is essentially a non-
resorbable material, while on the other hand p-TCP has been shown to degrade 
within 6 weeks after implantation.102 The dissolution of CaP biomaterials is 
dependent on composition (hydroxyapatite vs. (3-TCP ratio), surface area of the 
implant (particulate vs. block form), porosity, and crystallinity (sintering creates 
larger, slower dissolving crystals).98 Biphasic CaP products which contain 
hydroxyapatite and (3-TCP in various ratios (the higher the p-TCP content, the 
greater the resorbability103) are aimed at the provision of a bone grafting material 
which is able to degrade within a physiologically optimized time frame, while 
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providing some measure of mechanical stability until sufficient bone in-growth 
has occurred.102 
CaP cements are also available, and these combine a dry powder (CaP) 
and a liquid component (i.e. an inorganic or organic acid, or sodium phosphate 
solutions) in a setting reaction that occurs under physiologic pH and 
temperatures.98 Examples include Norian® (Synthes Craniomaxillofacial, USA), 
BoneSource® (Stryker Leibinger, Germany), and Mimix® (Walter Lorenz Surgical, 
USA). A variety of CaP compounds have been used for the solid phase such as 
dicalcium phosphate, dicalcium phosphate dihydrate, calcium-deficient 
hydroxyapatite, and amorphous calcium phosphate.101 These cements are 
injectable and able to be molded for variable periods before hardening. They are 
also described as resorbable, though clinical experience has demonstrated 
retention of the material over extended periods. While CaP cements have been 
successfully used for clinical applications such as vertebroplasty104 and cranial 
defect repair,105 they are brittle and contraindicated for use in areas of mobility, 
active infection, or in situations where they directly contact the sinuses or dura.101 
Synthetic polymers 
The long and successful history of synthetic polymers in medicine 
combined with the ability to control their material properties has generated much 
interest in their use for bone regeneration strategies. Polymers currently used for 
oral and maxillofacial osseous reconstruction/augmentation include silicones, 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) 
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(PLGA), poly(ethylene), poly(caprolactone) (PCL) and poly(methy! methacrylate) 
(PMMA). These materials are biologically inert and do not possess osteogenic, 
osteoconductive, or osteoinductive properties. Hence, none of these materials 
have been incorporated into commercial bone grafting products as of yet. 
However, the biocompatibility of many synthetic polymers, combined with the 
ability to reproducibly control their composition, rate of degradation, pore size, 
porosity, interconnectivity, hydrophobicity/hydrophilicity, ability for cell 
attachment, morphology, and handling properties has made them attractive 
materials for investigation as scaffolds and delivery vehicles of cells, drugs, and 
growth factors in tissue engineering. 
Currently, the most common synthetic absorbable polymers available for 
oral and maxillofacial applications include the poly(alpha-hydroxy esters) PGA, 
PLA, and their copolymer, PLGA. Once implanted, these materials slowly 
degrade through hydrolysis and the by-products (lactic acid from PLA and 
glycolic acid from PGA) are incorporated into the Krebs cycle and eventually 
eliminated as carbon dioxide and water.106 They have been used as resorbable 
sutures for the past 40 years, and recently as degradable plates and screws for 
bone fixation following craniofacial surgery,107 orthognathic surgery,108 and 
trauma.109, 11° Advantages of these devices over traditional titanium plates and 
screws include elimination of long-term palpable devices and continued skull 
growth in the pediatric population once they have degraded.107 Resorbable 
membranes made of PLA and PLGA have also been successfully used as 
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barriers for use in guided tissue regeneration procedures to treat periodontal 
defects.111 
The biocompatibility of non-degradable synthetic polymers has led to their 
commercialization as permanent implants for craniofacial augmentation or 
reconstruction. Solid facial implants made from silicone elastomer have been 
used for almost 50 years, and are available for skeletal augmentation of the 
malar eminence, zygomatic arch, and chin.112 These implants are available in 
various pre-contoured forms and can be carved intra-operatively to customize the 
shape for implantation in a particular area. Once implanted, the smooth-surfaced 
silicone implants are encapsulated by an avascular fibrous capsule, although 
initial fixation of the implant is important to prevent displacement or subsequent 
mobility which can lead to complications.112 Porous high-density polyethylene 
(HDPE) (MedPor®, from Porex Industries, USA) is also available as a 
customizable pre-fabricated porous implant and has found applications as a 
skeletal augmentation material, a space maintainer following globe exenteration, 
and as a structural support for orbital reconstruction following trauma and tumor 
resection.113 
Another non-degradable polymer commonly used in craniofacial osseous 
reconstruction is PMMA. The biocompatibility of PMMA, established over a 50 
year history of clinical use, has led to it being the most frequently used synthetic 
material for skull reconstruction in the world.114 In situ curing PMMA cement is 
available as a two-phase system, in which a powder (consisting of PMMA 
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polymer particles and a polymerization catalyst) is mixed with a liquid (consisting 
of MMA monomer). The combination produces a moldable, putty-like material 
that polymerizes into a rigid, high strength solid within 10-15 minutes. The 
exothermic nature of the setting reaction and the leaching of unreacted monomer 
from the implanted PMMA has been shown to cause bone necrosis and 
inflammation.115 Consequently, PMMA cement is usually polymerized extra-
corporeal^ before insertion into the defect. PMMA can also be obtained as a pre-
formed implant, whose shape is customized to fit a patient's bone defect through 
the use of computed tomography stereolithographic models.116 
Since PMMA does not bond directly to the surrounding hard and soft 
tissues, techniques have been developed to allow better fixation of the material, 
such as the incorporation of titanium mesh scaffolding in cranioplasty117 or by 
combining PMMA with carboxymethylcellulose gel to generate surface 
porosity.118 PMMA is considered to be the alloplastic material of choice for 
cranioplasty in adults with good soft tissue quality and no frontal sinus exposure 
or previous history of infection. It should be used with caution in children since 
this essentially "permanent" and rigid material cannot adapt to a growing 
craniofacial skeleton.114 
Recombinant growth factors 
In view of the biological limitations associated individually with autograft, 
allograft, and synthetic materials, surgeons have attempted to augment the 
activity and physical properties with composite grafts combining several different 
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materials. For example, particulate allograft bone can be used as an "expander" 
for autograft bone, resulting in less bone having to be harvested from a donor 
site, but still allowing for a grafting material which is osteoinductive, 
osteoconductive, and osteogenic. Recently, the commercial availability of 
recombinant growth factor products has given oral and maxillofacial surgeons an 
additional option for the reconstruction of bony defects. In the United States, 
recombinant human bone morphogenetic protein-2 (BMP-2) in an absorbable 
collagen sponge carrier (Infuse® from Medtronic, USA) has been approved for 
maxillary sinus augmentation and localized alveolar ridge augmentation in the 
oral and maxillofacial region. Orthopedic procedures approved by the United 
States Food and Drug Administration (FDA) for the use of Infuse® bone graft 
include spinal fusion and open tibia fractures. Platelet-derived growth factor 
(PDGF) in a |3-TCP carrier (GEM 21S® from Osteohealth, USA) has been 
approved in the United States as well for the treatment of bone defects and 
gingival tissue recession associated with advanced periodontal disease. 
The use of recombinant growth factor products for bone regeneration is 
appealing since they reduce the need for bone harvesting, are readily available, 
and contain high concentrations of a purified biological agent involved in the bone 
healing process. The implantation of such factors into a bone defect and the 
controlled release of the factor over time should promote the proliferation and 
differentiation of osteogenic stem cells within the wound, accelerating the healing 
process. Thus, products such as Infuse® contain the osteoinductivity of autograft 
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bone, combined with the convenience of "off the shelf" demineralized bone 
matrix, without the concerns of pathogen transmission or batch-to-batch 
variations in potency. These advantages have already spurred surgeons to find 
"off-label" uses of BMP-2 such as the reconstruction of mandibular continuity 
defects following tumor resection, the grafting of maxillary clefts, and the 
reconstruction of hard tissue avulsion defects following trauma.119 
Since our clinical experience with such technology is relatively new, issues 
such as: 1) the long-term effects of implanting materials containing supra-
physiologic doses of growth factors and, 2) the use of growth factors for the 
reconstruction of defects associated with neoplasms, remain unresolved. In 
addition, the potential efficacy of these materials and their ability to reduce 
operating time and donor site morbidity will have to be weighed against their 
relatively high cost. 
2.2.2 Soft tissue reconstruction 
Autologous tissue 
Similar to osseous reconstruction, autologous tissue is the standard for 
reconstruction of oral and maxillofacial soft tissue defects. Small to medium-sized 
superficial defects can be repaired with skin grafts, which can be harvested as 
either "full-thickness" or "partial-thickness". Both types of skin graft contain the 
entire epidermis, but full-thickness grafts incorporate the entire dermal 
component (including dermal appendages such as hair follicles or sweat glands if 
present), while partial-thickness grafts are harvested at the level of the more 
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superficial papillary dermis, leaving the deeper reticular dermis in place. 
Autologous grafts can also be harvested from various regions of the oral cavity, 
including the free gingiva, buccal mucosa, and palate. During the first 2-3 days of 
transplantation, nutrient exchange to the graft occurs through serum imbibition, 
after which the graft becomes revascularized through anastomoses between the 
host and donor vessels. Thus, the survival of both types of skin grafts relies on a 
recipient site that is well vascularized and immobility of the graft against its 
nutrient bed. 
Unlike free grafts, soft tissue flaps are prepared in such a way that their 
blood supply is maintained following transfer to the recipient site. The donor 
tissue for local flaps is located close to the recipient site so that the tissue can be 
advanced or rotated into position while retaining a nerve and blood supply 
through its pedicle. A number of local flaps have been used for reconstruction of 
oral and facial defects including those involving the lip (i.e. Abbe flap)120 and oral 
cavity (i.e. palatal flaps and tongue flaps).121 Larger oral and maxillofacial soft 
tissue defects require more tissue and can be reconstructed with regional flaps. 
Like local flaps, regional flaps rely on an intact vascular pedicle for their blood 
supply, although the donor site is more distant. Examples of regional flaps 
include the pectoralis major, deltopectoral, and temporalis flaps. The pectoralis 
major flap can be used to transfer both muscle and skin (hence its classification 
as a "myocutaneous" flap) to large oral and maxillofacial defects.122 The 
temporalis muscle flap is another regional flap which can be used for soft tissue 
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reconstruction of oral defects. It is elevated from the temple and rotated into the 
orbit or oral cavity. Regional flaps for closure of palatal defects are reliable and 
versatile, but create cosmetic defects at the donor site and often require 
secondary procedures to remove excess tissue.123 Such flaps are also unable to 
transfer bone along with the soft tissue and cannot address the comprehensive 
needs of a composite defect. 
The advent of microvascular surgical techniques in the 1980s allowed the 
development of a new way to transfer soft and hard tissue together in the form of 
vascularized free flaps. These flaps are harvested from distant sites along a 
dominant arterial supply and venous system and re-anastomosed to vessels at 
the recipient site, providing an instantaneous vascular system. A variety of free 
flaps have been described for oral and maxillofacial reconstruction, and they can 
be harvested with soft tissue alone (i.e. fascio-cutaneous or fascial flaps) or with 
a combination of hard and soft tissue (i.e. osseo-fascio-cutaneous flaps). A 
review by Gonzalez-Garcia et al.A2A lists numerous vascularized free flaps 
available for such purposes, with donor sites such as the radius, fibula, iliac 
crest, deltoid, anterolateral thigh (ALT), and scapula. The authors also describe 
the versatility of the radial forearm free flap (RFFF) in particular, which can be 
used to cover defects involving any location within the oral cavity including the 
floor of the mouth, tongue, gingiva, buccal mucosa, soft palate, and retromolar 
area. In skilled hands, the overall failure rates of vascularized free flaps for soft 
tissue reconstruction in the head and neck region are relatively low, ranging from 
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5.5-8.8%,124 indicating that this versatile technique is predictable and an 
important technique for the reconstruction of composite defects or those where 
vascular compromise of the recipient bed is an issue. 
Aside from the reconstruction of soft tissue defects, autologous soft tissue 
has also been used for cosmetic facial augmentation. Composite grafts such as 
dermofat or adipofascial grafts from the ALT region have been used for this 
purpose,125 as well as local flaps such as the buccal fat pad flap.126 "Microfat" 
grafting has also been described,127 in which adipose tissue is harvested 
atraumatically by suctioning or direct excision and then injected into the 
subcutaneous or intramuscular layers of the deficient site. While the supply of 
donor site adipose tissue is generally abundant, substantial over-filling of a defect 
is required due to the unpredictable stability and longevity of the injected fat over 
time. 
The ex vivo expansion of harvested autologous cells for dermal 
augmentation has also been attempted commercially. Isolagen® (from Isolagen 
Technologies, USA) is a product currently in Phase 3 clinical trials within the 
United States where it is being investigated for the treatment of wrinkles.128 The 
process involves harvesting skin from the post-auricular region using a 3 mm 
biopsy punch, and sending the specimen to the manufacturer to isolate and 
culture dermal fibroblasts. 4-6 weeks later, an autologous expanded explant is 
ready for use as an injectable dermal filler. Two to four treatments are typically 
required to obscure a wrinkle. As growth factors are used during the culturing 
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process, this product is considered a "medical device" and requires additional 
safety testing prior to approval by the United States FDA. 
Allogeneic tissue 
Autologous skin grafts are the preferred method for the treatment of burns. 
Patients with extensive burns, however, often lack sufficient donor tissue. The 
temporary use of allograft skin for third-degree facial burn coverage has been 
reported,129 where it was used to promote initial vascularization of the wound bed 
following debridement, then removed 6 days later prior to the placement of a 
split-thickness skin autograft. Allograft skin usually undergoes rejection within 2 
weeks, although there are reports of skin allografts persisting in non-
immunosuppressed burn patients for up to 7 weeks, possibly due to the 
repopulation of the allograft by host cells.130 Skin grafting involving the entire face 
is associated with poor aesthetic and functional results, since multiple grafts are 
required, producing a patchwork appearance.131 
One of the most spectacular and controversial solutions to the problem of 
total facial reconstruction is the use of allograft transplantation of a composite 
flap containing all the soft tissue structures: skin, fat, muscle, and nerves. The 
first human partial face transplant was completed in 2005.132 Apart from difficult 
ethical and psychological issues involved with such a procedure, patients must 
be placed on immunosuppressive drugs for life.133 The initial outcome of such 
work appears promising, and satisfactory functional and aesthetic results have 
been observed 18 months post-transplantation.134 
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A more biocompatible allogeneic grafting material for soft tissue 
reconstruction is freeze-dried, de-epithelialized, acellular dermal graft (Alloderm® 
from LifeCell, USA). The removal of all cellular components from the graft 
reduces the potential for pathogen transmission while also decreasing the 
immunogenicity of the material. The resulting product is an acellular dermal 
matrix which can be used as sheets or as an injectable particulate. Both 
formulations undergo rapid vascularization and repopulation of the graft material 
with host cells derived from the wound site.135, 136 Alloderm® sheets have been 
used for the treatment of acute burns137 and the reconstruction of eyelids138 and 
buccal mucosa! defects,139 while the injectable material Cymetra® has been 
described for use in lip augmentation procedures.140 
Xenogeneic tissue 
One of the most commonly used dermal fillers is bovine collagen. 
Commercial preparations such as Zyderm® (from Allergan, USA) are composed 
of purified, fibrillar collagen type I and III and are approved for cosmetic 
procedures for the treatment of wrinkles, frown lines, crow's feet, and acne scars. 
A related product called Zyplast® (from Allergan, USA) is composed of cross-
linked bovine collagen which is less prone to enzymatic degradation after 
injection, but is recommended for injection into deeper defects because it may 
result in a beaded appearance.141 While these materials have variable rates of 
degradation depending on the area of injection, collagen fillers typically last 2-4 
months in duration. One of the main drawbacks to the use of bovine collagen is 
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the risk of a severe allergic reaction, thus a skin test should be performed on all 
patients prior to treatment. Approximately 3-10% of patients will display a positive 
response such as redness, itching, tenderness, or firmness at the test site, and 
should not undergo grafting with this material.141 
Hyaluronic acid is a glycosaminoglycan that forms a major non-structural 
component of the connective tissue extracellular matrix and aids the skin in 
maintaining its turgor through its hydrophilicity. Since the hyaluronic acid moiety 
is identical across all species, xenogeneic hyaluronic acid is not immunogenic in 
humans.142 Cross-linked hyaluronic acid derivatives are commercially available 
as soft tissue fillers, including Hylaform® (from Biomatrix, USA) which is derived 
from rooster combs, and Restylane® (from Medicis Aesthetics, USA) or 
Juvederm® (from Allergan, USA) which are produced through bacterial 
fermentation. Like the bovine collagen fillers, these hyaluronic acid-derived 
products are approved by the FDA as injectable materials for soft tissue 
augmentation. While allergic skin testing is not necessary prior to treatment, rare 
allergic reactions have been known to occur to the residual avian/bacterial 
proteins in these materials.142 The dermal augmentation achieved with hyaluronic 
acid-derived products has been reported to persist for longer periods compared 
with bovine collagen (up to 6 months) and longevity can be extended up to 9 
months with the concomitant use of botulinum toxin to reduce recipient site 
mobility around the filler material.143 
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Synthetic biomaterials 
Up to this point, the injectable materials discussed for soft tissue 
augmentation have all been "temporary" in nature, with the results generally 
lasting less than one year. Although some permanent injectable dermal fillers are 
available, Homicz and Watson144 caution that changes in facial form or adverse 
reactions to injected materials may actually warrant the use of temporary fillers. 
One of the most controversial permanent soft tissue fillers is liquid silicone, 
which has been used by physicians for more than 50 years. Currently the FDA 
approves medical-grade liquid silicone injections solely for ophthalmologic use to 
tamponade retinal detachments. However, some physicians have also used it off-
label for soft tissue augmentation using a "microdroplet" technique, in which the 
silicone is injected in 0.01 ml increments, 1 mm apart in the sub-dermal layer.145 
Over several weeks, the injected silicone droplets produce a granulomatous 
reaction in the host tissues, and are encapsulated as foreign bodies within fibrous 
tissue. While some clinicians prefer the more natural feeling augmentation which 
can be achieved with silicone, the injection of large volumes has sometimes led 
to severe local and system reactions.144 
Another permanent injectable dermal filler material is ArteFill® (from Arte 
Medical, USA) which is a FDA-approved combination of PMMA microspheres 
suspended in a solution of 3.5% ultrapurified bovine collagen and 0.3% 
lidocaine.146 The manufacturer recommends the injection of small quantities of 
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ArteFill® every 1-3 months to minimize the chances of severe inflammatory 
reactions. Following injection, the bovine collagen is degraded and each 
microsphere is encapsulated in a fibrous sheath with minimal foreign body 
reaction, although some authors have reported the induction of foreign body 
granulomas following ArteFill® injections for lip augmentation.147 
In an effort to address the need for a temporary material with longer 
lasting results, a new product called Sculptra® (from Dermik Laboratories, USA) 
has recently been approved by the FDA for the treatment of HIV-associated facial 
lipatrophy. Sculptra® is an injectable filler composed of freeze-dried, crystalline, 
irregularly sized microparticles of poly-L-lactic acid (PLLA) combined with sodium 
carboxymethylcellulose as a delivery vehicle.148 PLLA is a well-known 
biocompatible and biodegradable polymer which has been used in numerous 
medical technologies ranging from resorbable sutures and plates and screws to 
drug delivery vehicles. To minimize the risk of complications from aggressive use 
of Sculptra® injections (such as the formation of nodules and granulomas), 
recommendations include limiting the volume of each injection, placing the 
material subcutaneously and not intradermal^, post-injection massage of the 
area, and a delay of 6 weeks between treatment sessions.148 Some authors have 
reported results lasting up to 18-24 months, fulfilling its promise as a longer-
lasting yet non-permanent dermal filler material. 
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2.2.3 Composite tissue reconstruction 
Severe traumatic insults and the surgical treatment of extensive oral and 
maxillofacial pathology can involve a considerable loss of facial tissues. Local 
control of disease requires complete removal without regard for aesthetically 
sensitive areas and may produce defects which are disfiguring and impose 
significant emotional stress on the patient. While tissue engineering holds 
promise for the future, the current mainstay of reconstruction and rehabilitation in 
patients with large composite tissue deformities remains with a combination of 
microvascular free tissue transfers and maxillofacial prosthetics. 
Since vascularized free flaps have already been discussed, this section 
will focus on the use of maxillofacial prosthetics for the restoration of complex 
defects involving the loss of multiple tissues. 
Commonly used polymeric materials for maxillofacial prostheses 
Acrylic resins 
Polymethylmethacrylate is the most widely used acrylic polymer in health 
care. Variations in the molecular structure produces hard polymethacrylates used 
for dentures and orthopedic bone cement while various soft polyacrylates (i.e. 
ethyl or butyl acrylates) are used in contact lenses.149 
Methyl methacrylate resins are readily available and the durability and 
color stability of PMMA make it an excellent material for facial prostheses. The 
strength of PMMA enables the clinician to thin the exposed margins of the 
58 
prosthesis, improving the aesthetic result. In addition, benefits to the patient 
include compatibility with most adhesive systems and easily cleaning.150 
Acrylic resins are most successfully employed in specific types of facial 
defects, namely those in which minimal movement of the underlying tissue bed 
occurs during function (i.e. prosthetic eyes). If placed in an inappropriate location, 
rigid PMMA facial prostheses can be uncomfortable and erosion may occur 
through the soft tissue. 
Polyetherurethane elastomers 
Polyetherurethanes have a variety of commercial uses and have also 
become popular for biomedical applications. In general, polyetherurethanes 
possess a number of favorable characteristics making them suitable for restoring 
defects with mobile tissue beds.151 Polyurethanes can be made flexible without 
compromising edge strength, allowing the clinician to thin the margins giving the 
prosthesis a lifelike appearance and feel. In addition, when processed properly 
these elastomers are chemically inert, abrasion-resistant, and do not require the 
use of plasticizers to attain their flexibility. 
A serious drawback to the use of polyurethanes in maxillofacial prosthetics 
is the difficulty in processing these materials consistently. A precise, 
stoichiometric admixing of all the components is necessary, with little margin for 
error. Furthermore, the toxic and hazardous diisocyanate component is moisture 
sensitive, as water contamination will cause gas bubble formation resulting in 
poor curing of the material with defects. As a consequence, either specially 
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prefabricated metal molds must be utilized for the polymerization reaction or if 
stone molds are employed, they must be thoroughly dehydrated prior to use. In 
addition, facial prostheses fabricated from polyurethane are not color-stable, 
possibly due to the effects of ultraviolet light and surface oxidation.150 From the 
patient perspective, additional problems with polyurethane prostheses are their 
poor compatibility with adhesive systems and difficulty to clean.152 
Silicone elastomers 
Technically called polydimethylsiloxane (PDMS), the silicones are 
probably the most widely used materials in maxillofacial prostheses.150 Silicone 
elastomers are formed by cross-linking the PDMS chains into a network, a 
process which is also referred to as vulcanization. Compounding the material 
with silica fillers typically provides additional strength. 
The numerous silicone elastomers used for maxillofacial prostheses have 
been classified into two general categories based on the type of cross-linking 
reaction used to form the final shape of the device: room-temperature vulcanizing 
(RTV) and heat-vulcanizing (HTV). Thus, vulcanization can occur both with and 
without the application of heat, and depends on the specific catalysts and cross-
linking agents utilized by the two general types of silicone elastomers. 
Although HTV silicone elastomers have been shown to have excellent 
thermal stability, color stability upon ultraviolet light exposure, and biologic 
inertness, they do not possess sufficient flexibility to function well on moveable 
tissue beds. Clinically, the aesthetics of this material have been criticized for their 
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opacity and lifeless appearance.150 Nonetheless, when compared to their RTV 
silicone counterparts, HTV silicone elastomers exhibit better physical and 
mechanical properties, partly by overcoming the problem of hand-mixing 
pigments as typically used for fabricating prostheses from viscous RTV silicones. 
149 
Designed for cross-linking at room temperature, RTV silicone elastomers 
are composed of relatively short-chain silicone polymers which are partially end-
blocked with hydroxyl groups.151 In general, some limiting aspects of RTV 
silicone elastomers include air entrapment from mixing the various components 
prior to cross-linking.149 These voids persist in the finished prosthesis, which may 
lower tear resistance and help accumulate skin exudates. Silica fillers are used to 
enhance tensile strength as well as mask discoloration of the material, although a 
considerable amount of translucency is lost, thus compromising the ability to 
achieve optimal intrinsic coloration of the material through the incorporation of 
pigments. 
An improved alternative is MDX 4-4210® (from Dow Corning, USA), a 
Medical Grade RTV silicone elastomer which is the most commonly used 
material in clinical practice for the fabrication of maxillofacial prostheses.153 This 
material has a chloroplatinic acid catalyst and a hydro-methylsiloxane cross-
linking agent, allowing for curing to take place through an addition-type reaction, 
and hence a lack of reaction by-products.150 MDX 4-4210® has been reported to 
address the general limitations of RTV silicone elastomers with superior 
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coloration qualities and edge strength,154 reducing the need for tear repair which 
typically requires the skilled application of additional PDMS or reinforcement of 
the edge with fabric. Although MDX 4-4210® does not possess all the 
characteristics of an ideal maxillofacial polymer, it has many desirable properties 
as discussed. Nonetheless, efforts continue to improve the material properties of 
this popular maxillofacial prosthetic material by increasing tear strength155 and 
surface wettability.156 
2.2.4 Tissue engineering approaches for composite tissue regeneration 
Up until 2004, autologous tissue remained the only source for transferring 
viable hard and soft tissue simultaneously. From vascularized osseo-fascio-
cutaneous free flaps for craniofacial reconstruction, to simple, non-vascularized 
costo-chondral grafts used for the reconstruction of the mandibular condyle, an 
allogeneic, xenogeneic, or alloplastic material does not exist which can match the 
characteristics of composite tissue grafts/flaps. 
Recently however, a tissue engineering approach for mandibular 
regeneration in a patient was reported by Warnke et a/.,157 in which a custom, 
vascularized bone graft was used to restore masticatory function and aesthetic 
form to a patient who had undergone subtotal mandibulectomy 8 years prior. The 
patient had received post-surgical radiation treatment, decreasing the probability 
for a successful non-vascularized bone graft. He was also on anti-coagulation 
therapy for an aortic valve replacement which increased his risk of severe post-
operative bleeding following a large bone harvest. 
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Thus, a tissue engineering strategy was selected, in which a titanium 
mesh tray was custom designed for the mandibular defect and then filled with 
blocks of Bio-Oss® (deproteinized bovine bone) coated with recombinant BMP-7 
in a bovine collagen type 1 carrier. In addition, 20 mL of bone marrow was 
aspirated from the patient's right iliac crest and mixed with Bio-Oss® particulate 
as a "grout" between the Bio-Oss® blocks of the construct. This approach utilized 
all the components of a tissue engineering strategy: cells (from the bone 
marrow), growth factors (the recombinant BMP-7 and endogenous growth factors 
in the marrow aspirate), and a scaffold (both the titanium mesh for the overall 
morphology of the implant and Bio-Oss® blocks providing an osteoconductive 
material). 
To overcome the problem of transplanting this construct into the poorly 
vascularized tissue bed of the residual mandible, it was instead placed within the 
latissmus dorsi muscle of the patient fpr 7 weeks to allow for revascluarization of 
the construct. In this way, a vascularized free flap transfer of the TE construct 
and its accompanying soft tissue envelope was possible, whereby the 
thoracodorsal artery and vein of the latissmus dorsi were anastomosed to 
vessels of the neck. Warnke et al. were able to follow the patient for 15 months 
until he passed away from cardiac arrest, but during that time the patient's quality 
of life improved dramatically as his ability to eat and speak had improved.158 
This brief overview of conventional treatments for disfiguring and large 
composite tissue defects using vascularized free flaps and prostheses illustrates 
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the fact that all of the materials and methods currently in clinical use fall short of 
providing complete aesthetic and functional regeneration of lost tissues. The 
following sections will provide an overview of current research in craniofacial 
tissue engineering which has the potential to revolutionize the clinical methods of 
reconstruction we know today. 
2.3 Engineering multiple craniofacial tissues 
Tissue engineering strategies rely on the use of cells, bioactive factors, 
and scaffolds or combinations thereof. The scaffold serves the purpose of a 
delivery vehicle, a space-filling and structurally supportive agent, and can be 
designed to be biointeractive, i.e. to guide tissue regeneration. The field of tissue 
engineering has made significant advances over the past 15 years. 
Interdisciplinary research spanning basic cell biology to nanotechnology has 
deepened our understanding of nature and enabled methods of biomimicry to 
augment or replace tissue or even organ function. Research on the regeneration 
of virtually all types of tissues is being conducted, and products for cartilage, 
bone, and skin regeneration are already approved for commercial use by the 
United States FDA. The engineering of more complex tissues remains a 
challenge, but encouraging advances in the form of a tissue engineered bladder68 
and an increased focus on issues specific to engineering complex tissues159 have 
recently appeared in the literature. 
The coordinated regeneration of multiple tissues in the complex 
craniofacial environment requires a deep understanding of their physiology and 
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remodeling characteristics. Complex tissues must be engineered with the 
structural and functional characteristics of native tissue in a process that is not 
only biocompatible but also interactive and integrative with neighboring tissues 
simultaneously. Another challenge lies in that one type of tissue can be found in 
various structures that serve different functions and have therefore different 
properties. For example, the cartilaginous structures found in the craniofacial 
region have very distinct characteristics. A specifically tailored approach may be 
required to regenerate the weight-bearing, dense, and bilaminar cartilage found 
in the temporomandibular joint (TMJ) and a quite different approach required to 
create the delicate elastic cartilage found in the ears or nose.160 
Tissues of the craniofacial region include skin, bone, muscle, cartilage, 
adipose tissue, tendons, ligaments, salivary glands, blood vessels, nerves, and 
teeth (Figure 2.1). Extensive research is conducted on each of these tissues and 
the need for them well established,161 but few studies focus on regenerating 
multiple tissues in tandem. Recent advances in craniofacial tissue engineering, 
as summarized by Mao et a/.,162 include integrated bone and cartilage layers for 
the TMJ condyle, various elements of the periodontium, craniofacial bone, cranial 
suture-like structures as well as adipose tissue. Tissue engineering of skin is not 
always reported in articles reviewing craniofacial tissue regeneration; however, 
skin regeneration is an important aspect to consider, as trauma is one of the 
major causes of tissue loss. Trauma affects both hard and soft tissues, damaging 
the skin and severely compromising its protective barrier function. 
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The next sections will focus on briefly reviewing the distinct anatomical 
and physiological properties of craniofacial and oral components, as well as 
progress towards engineering these tissues. Finally, the parameters that will 
allow for tissue engineering of complex structures will be discussed. 
2.3.1 Bone 
Tissue engineering of the cranial and facial bones holds great potential 
towards the functional and aesthetic restoration of this tissue. Craniofacial bone 
serves as a protective barrier to the intracranial structures and maintains the 
shape of the head and face. Bone loss results in severe functional and aesthetic 
consequences such as problems in mastication and compromised head and 
facial contour with collapse of the surrounding soft tissues. Bone is a highly 
vascularized and cellular tissue. The inorganic mineral component of bone 
extracellular matrix (ECM) provides the mechanical strength of the matrix.163 
Approaches towards bone tissue engineering are numerous, and much progress 
has been reported towards that goal. Desirable bone tissue engineering 
constructs are osteoconductive and osteoinductive. Review articles on bone 
tissue engineering considerations have been extensively published.164"169 Our 
group and other researchers have been using synthetic biomaterials in 
conjunction with growth factors and/or cellular delivery to regenerate bone. 
Synthetic polymers, ceramics, or composites thereof are biomaterials commonly 
investigated for bone tissue engineering; many of these systems are injectable as 
well and will be discussed in subsequent sections. 
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Osteogenesis is likely very strongly dependent on angiogenesis.159 
Besides the facilitated transport of nutrients, oxygen, and minerals, blood vessels 
stimulate bone morphogenesis due to the osteogenic effects of vascular cells.170 
This association has led many researchers to investigate the incorporation of 
angiogenic growth factors into bone tissue engineering models.19,171,172 Potent 
osteogenic factors such as BMP-2 have been shown to induce ectopic bone 
formation, i.e. in sites where bone would not normally grow.173, 174 As our 
understanding of bone biology and development deepens, potential frontiers 
open within tissue engineering. One such breakthrough was the isolation and 
identification of mesenchymal stem cells (MSCs), a class of bone tissue 
progenitor cells. Biomechanical and biochemical factors that enhance the bone-
forming capacity of these cells are currently heavily examined.175"178 
2.3.2 Skin 
The skin is the largest organ in the body. Its barrier function protects the 
internal organs from the external environment, maintains water and temperature 
homeostasis and provides communication with the immune system. Skin consists 
of two main layers, the epidermis and the dermis, the latter being vascularized. 
Bell et a/.51 and Burke et aC19 reported some of the first attempts to create a full 
thickness, tissue engineered skin graft. Natural polymers such as collagen gels 
have been widely used as matrices for skin tissue engineering.51, 179, 18° 
Vascularization is critical for success of engineered skin, and room for 
improvement in this area exists for current tissue engineered skin181. This has 
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been addressed by various techniques such as seeding skin cells together on a 
scaffold with endothelial cells that can then form new vessels.180,182 The potential 
role of growth factors in skin tissue engineering is reviewed elsewhere.181 Skin 
tissue engineering has been largely successful relative to other tissues and must 
now be performed in combination with tissue engineering of other less superficial 
tissues such as bone and muscle for the treatment of deep wounds or for 
regeneration following aggressive tumor resections. 
2.3.3 Cartilaginous structures 
Cartilage regeneration in vivo seldom occurs due to the avascular nature 
and relatively sparse cellularity of native cartilage. Therefore, tissue engineering 
strategies employing scaffolds, cells and bioactive factors represent one of the 
only methods to regenerate or repair cartilage following injury. In craniofacial 
structures, cartilage is mainly found in the ear, the nasal tip, and the TMJ. As 
mentioned before, the cartilage in these structures has distinct characteristics 
and serves different functions that are reflected by differences in the composition 
and architecture of the various cartilage types. In the first two organs, cartilage 
provides shape and flexibility but has no load-bearing properties. In order to 
increase ECM production and considering the relatively low number of 
chondrocytes in cartilage, cell transplantation is one of the most common 
approaches in cartilage regeneration. Much research has been devoted in 
identifying the right cell source and culture conditions for cartilage tissue 
engineering and for auricular and nasal tissues in particular.183,184 Kamil et a/.185 
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were able to engineer full-sized human cartilaginous skeletons for the external 
ear and the nasal tip in vitro by seeding chondrocytes on prefabricated, 
biodegradable scaffolds. Even though injectable hydrogels that mimic the 
cartilaginous matrix have been used extensively as models for articular cartilage 
regeneration, there has been limited use of these systems in nasal and auricular 
cartilage tissue engineering. The TMJ is another distinct, cartilaginous structure 
within the joint connecting the mandible to the temporal bone; TMJ cartilage can 
be found on the surface of the mandibular condyle, as a layer lining the temporal 
bone, and as the TMJ disc positioned between the two bone surfaces.186, 187 
These load-bearing structures lubricate the surface between the bones and may 
have shock-absorbing and load-distributing properties.186 The TMJ disc is 
composed of fibrocartilage, a type of cartilage characterized by high collagen 
fiber content in its matrix. 
Review articles summarizing TMJ properties and design parameters using 
the tissue engineering paradigm of cells, scaffolds and stimuli, are available.186" 
188
 Tissue engineering of the mandibular condyle needs to account for its distinct 
architecture, consisting of a cartilage layer and the underlying subchondral bone. 
Successful attempts towards regeneration of that complex structure have been 
performed using pre-differentiated, osteogenic and chondrogenic, cell 
populations,189 although no consistently successful tissue engineering solution is 
clinically available. 
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2.3.4 Oral and dental tissues: periodontium and teeth 
The oral cavity represents a unique environment for tissue regeneration as there 
is widespread need to develop functional tooth replacements with proper 
attachment, and healing within the oral cavity must occur in the presence of the 
oral flora, which creates a "contaminated" environment.159 Engineering a whole 
tooth is a difficult task due to the complexity of the teeth, which are mineralized, 
multi-layered matrices. Enamel, dentin, and cementum layers form the hard 
tissue part of teeth, whereas dental pulp forms the soft tissue in the central core. 
An additional hurdle in tooth tissue engineering is the creation of appropriate 
innervation and vasculature.190 Other common dental conditions include diseases 
of the periodontium, which can lead to tooth loss. The periodontium is comprised 
of cementum, the periodontal ligament, which is the fibrous connective tissue 
surrounding the root of a tooth, and the attached alveolar bone. Approaches 
towards the regeneration of the periodontal ligament and surrounding osseous 
defects with growth factors, gene and cellular delivery have been reviewed 
elsewhere.162 
2.3.5 Muscle and adipose tissue 
The treatment of craniofacial injuries or anomalies often requires the 
regeneration of soft tissues such as skeletal muscle and adipose tissue. Skeletal 
muscle directly attaches to bone and, in the craniofacial region, allows for 
mastication, respiration, eye movement, and facial expression.191 Skeletal muscle 
tissue engineering is still at an early stage. Results from in vitro studies have 
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shed light on the extracellular matrix remodeling of muscle192"194 and identified 
conditions for increased skeletal muscle differentiation and growth.195,196 Shah et 
a/.191 have investigated the potential of a three-dimensional phosphate glass fiber 
scaffold for craniofacial muscle engineering. Human muscle-derived cells seeded 
on these scaffolds and cultured in vitro with insulin-like growth factor 1 (IGF-1) 
were able to proliferate and produce prototypical muscle fibers. 
Adipose tissue regeneration is needed for the reconstruction of 
craniofacial structures such as the cheek, chin and jaw.197,198 There have been 
several studies that demonstrated the potential for in vivo adipose tissue 
regeneration. MSCs isolated from the bone marrow199"201 or adipose tissue200 
have been shown to be promising candidates for adipose tissue engineering. 
Conditions that promote differentiation of these uncommitted progenitor cells to 
adipose cells, such as adipogenic culture media199, 200, 202 and growth factor 
regimes,201 have been reported. An interesting approach towards the creation of 
vascularized adipose tissue was recently suggested by Marra et al.203 Particles of 
the small intestinal submucosa were used as a carrier for the delivery of 
progenitor fat cells. The cells attached and proliferated on these particles, and 
cell survival in vivo was noted for a period of 14 days. This injectable vehicle 
allowed also for the incorporation of PLGA microspheres loaded with fibroblast 
growth factor 2 (FGF-2), which enhanced vascularization. 
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2.3.6 Future directions and considerations 
Tissue engineering of complex tissues such as these found in the 
craniofacial region is a demanding task. One needs to account for multiple 
cellular phenotypes and find ways to enhance cellular interactions towards tissue 
repair, possibly stimulating their behavior by supplying bioactive factors. 
Furthermore, the problem of insufficient vascularization must be overcome since 
most tissues are strongly dependent on blood supply for growth. Creating 
stratified tissue architectures and recreating the physiological structure-function 
properties of the native tissues is the ultimate goal. The choice of a tissue 
engineering scaffold can significantly aid in this process, not only by serving as a 
delivery vehicle for cells and bioactive factors but also by providing the ability to 
interact with and guide tissue growth. Cell-material interactions and mass 
transport are only some of the important parameters that need to be incorporated 
into the design. Additionally, one needs to consider that the location and form of 
craniofacial tissues requires special treatment. For this delicate region, aesthetic 
considerations are important and there should ideally be minimal scar formation. 
All these parameters will be further examined in the next sections where the use 
of injectable systems for multiple tissue regeneration is discussed. 
2.4 Injectable systems in tissue engineering 
As highlighted in the previous sections, technologies and strategies in 
tissue engineering, and in particular those designed for engineering multiple 
functional tissues, utilize the delivery of cells and bioactive factors in combination 
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with the placement of a support structure or scaffold. Injectable systems, 
particularly aqueous systems, hold great promise in tissue engineering 
applications as they can potentially deliver water soluble drugs and growth 
factors in combination with cells to a tissue defect in a manner that provides an 
adequate environment for long term cell survival, proliferation, and differentiation. 
In the clinical setting, particularly when considering surgical repair, 
revisions, and/or subsequent reconstruction/regeneration of tissue defects, 
injectable materials at present hold the most immediate promise in treating 
defects for which minimally invasive strategies already exist. The delivery of cells, 
bioactive factors, and support materials via an injectable system within the 
context of an endoscopic, arthroscopic, laparoscopic, or radiologically guided 
procedure is feasible given the current state of the art. Within the craniofacial 
complex (CFC), however, most current surgical techniques towards the treatment 
of traumatic injury, tumor resection, or congenital deformity are somewhat more 
invasive than those previously mentioned. Injectable systems are attractive in 
this setting due to the ability of these systems to conform to complex craniofacial 
shapes, contours, and defects without the need for extensive presurgical 
modeling. Additionally, due to the close proximity of multiple tissue types within 
the CFC, injectable systems containing multi- or totipotent cell populations and 
growth factors will potentially allow for more natural remodeling and regeneration 
of damaged, diseased, and excised tissues. In the case of a staged surgical 
intervention, the use of injectable systems to aid tissue regeneration may avoid 
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the need for multiple invasive operations, thus reducing the morbidity and 
negative aesthetic effects associated with these repeated procedures. Finally, 
and as mentioned previously, there are many aesthetic cases where the use of 
injectable materials is already widespread due to the requirement in these cases 
for no incision as to minimize potential scarring. As described before, these 
materials are however not used for tissue engineering purposes but are rather 
volume fillers with biological activity that is often limited to being encapsulated as 
part of the foreign body response. 
While the ability to deliver cells and bioactive factors make injectable 
systems attractive alternatives to the preformed implant materials currently used, 
the success of any injectable system will largely be determined by the support 
system or framework the system provides. This scaffold must provide early 
mechanical support commensurate to that of the tissue it replaces, allow cells to 
survive, proliferate, and differentiate, and it must provide for the controlled 
release of any drugs or growth factors delivered simultaneously. Above all, this 
matrix must be biocompatible and ideally will be biodegradable such that with 
time regenerated tissue will replace the biomaterial component of the system, 
resulting in functional, healthy tissues approximating those of the premorbid 
individual and avoiding long term implant failure requiring subsequent retrieval 
(Figure 2.2).204 A large number of materials have been developed and applied in 
vitro and in animal models towards this end; we will highlight a number of those 
materials in the next section to introduce promising materials and 
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fabrication/synthetic strategies for creating injectable tissue engineering 
scaffolds. 
2.5 Injectable scaffolds 
2.5.1 Requirements 
In addition to the basic requirements for any biomaterial to be considered 
in clinical applications (biocompatibility of the material and subsequent 
degradation products, handling characteristics allowing achievement of any 
necessary processing and end functions, etc.), a number of unique requirements 
exist for complex tissue engineering within the CFC. Three fundamental 
requirements for biomaterial scaffolds used in the CFC include the ability to fit 
complex anatomical defects, provide mechanical support for regenerating and 
surrounding tissues, and deliver bioactive factors to aid tissue regeneration.205 
The following sections of this chapter will demonstrate the ability of 
injectable biomaterial scaffolds to fit complex defects, given that the defects have 
well defined borders or given the incorporation of a rigid template to define the 
shape as well as the well documented delivery of bioactive factors and cells with 
injectable material scaffolds. Mechanical requirements for biomaterials in the 
CFC vary widely based on tissue type and location. Within a human mandible, for 
example, significant regional variation has been found for cortical bone thickness 
and the direction of maximum stiffness, with maximum elastic moduli exceeding 
30 GPa.206, 207 Similarly, the cranial vault and zygoma exhibit high levels of 
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anisotropy and elastic properties based on regional and functional character.208 
Facial muscles have wide variations in tensile properties as well,209 thus making 
it apparent that a single material without variable properties will not likely be 
successful for applications in which multiple tissues or large portions of one 
structure are to be regenerated. For such applications, combinations of materials 
or materials with varying mechanical and biological properties must be 
investigated. Therefore, in addition to those requirements laid out previously, any 
injectable biomaterial to be used for complex tissue engineering in the CFC must 
either have tunable mechanical properties or be able to be integrated into a 
delivery system or scheme that involves the use of other biomaterials. An ideal 
system will also degrade in a manner so that the degradation rate is proportional 
to the rate with which tissue ingrowth or differentiation occurs into or within the 
scaffold and the extent of mechanical support needed by that specific tissue. 
The following section provides examples of injectable materials. These 
materials, selected from amongst a multitude of injectable materials currently 
being studied as biomaterials for tissue engineering and other applications, have 
been chosen to highlight different classes of materials and different methods that 
are commonly used or promising in their potential for future use and development 
in making the transition from an injectable material to a tissue engineering 
scaffold. 
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2.5.2 Injectable scaffold materials 
Calcium phosphate cements 
As described earlier, there are a number of CaP cement-based injectable 
biomaterials that are currently used and regulated in clinical applications. While 
these materials have achieved widespread success for bone defect repair and 
regeneration, concerns about degradation and the brittle mechanical profile of 
these materials limits their successful usage in many applications.210 Most 
commonly used for bone related applications, CaP composites have also been 
used as soft tissue fillers, demonstrating the potential versatility of these 
materials.211 
CaP composites have been studied to alleviate some of the negative 
properties of materials based solely on CaP cement. Macroporous CaP materials 
are more favorable for tissue engineering applications than nonporous 
implants.212 PLGA microparticles incorporated within an injectable CaP 
formulation can, upon degradation of the PLGA, yield macroporosity for tissue 
ingrowth and, possibly through a lowered local pH upon degradation of the 
PLGA, can accelerate degradation of the CaP phase.213"216 The incorporation of 
other degradable particles such as poly(trimethyl carbonate) and gelatin 
microparticles has yielded similar favorable results within injectable 
formulations,217,218 and the potential for drug or growth factor release from these 
systems has been well demonstrated.38, 213, 219221 including a water soluble 
porogen such as mannitol can both improve the injectability of CaP cement while 
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also improving the flexural strength and toughness of the resulting scaffold.222 
Although not part of an injectable system, the incorporation of an absorbable 
polymer mesh within a CaP cement can also significantly increase the flexural 
strength and toughness of the material while resulting in macroporosity upon 
degradation of the network.223, 224 CaP composite systems that utilize an 
injectable CaP cement with a porogen have distinct advantages over CaP 
cements alone and will likely, once gaining final regulatory approval, be counted 
among the preferred choices of clinicians for bone regeneration and tissue 
engineering applications. 
A second class of composite scaffolds uses CaP granules within water 
soluble carriers. These materials, which among others can use modified225,226 or 
unmodified227"229 hydroxy-propyl-methyl-cellulose as the polymer carrier, have 
resulted in faster initial osteoconduction in vivo when compared to other 
macroporous CaP cements. If achieved rapidly enough, this early bony 
apposition could potentially ameliorate any mechanical deficiencies in the 
material, facilitating its use in load bearing tissue applications. Smaller, 
nanosized CaP crystals have been incorporated into other injectable 
biomaterials,230 and coating of mesenchymal stem cells with CaP nanorods 
enhances osteoblastic differentiation and extracellular matrix production of the 
cells,231 indicating that CaP materials, at least in some forms or as composites, 
may be suitable carriers for the injection and induction of stem cells. 
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In situ polymerizable and crosslinkable materials 
Polymeric biomaterials are the most widely studied class of biomaterials 
investigated for use as injectable scaffolds. In situ solidification of polymeric 
systems is typically achieved either through phase separation or via 
polymerization or crosslinking of reactive monomers and macromer chains. 
Systems that utilize phase separation to solidify or harden in situ will be 
considered along with other self-assembling systems in a subsequent section. 
Both in situ polymerization and crosslinking often use a radical initiator 
that, through interactions with reactive functional groups such as the double bond 
within a vinyl or acrylic moiety, results in enhanced mechanical properties and 
shape definition of the scaffold. Photopolymerization using ultraviolet light-
activated initiators is one method by which biomaterials can be crosslinked in 
situ. One such radical initiator is bis(2,4,6-trimethylbenzoyl) phenylphosphine 
oxide (BAPO), a molecule that is activated by long wavelength ultraviolet light 
and has been successfully used to crosslink networks of polypropylene 
fumarate) (PPF).232 233 Photopolymerizable interpenetrating networks of 
poly(ethylene glycol) (PEG) and poly(ethylene glycol) diacrylate (PEGDA) have 
been used to encapsulate human MSCs, and the network mechanical properties 
can influence extracellular matrix (ECM) deposition and cellular differentiation.234 
A similar PEG network used photoinitiation to pattern the hydrogel surface.235 
Successful encapsulation of and differentiation of MSCs into osteoblast-like cells 
79 
on poly(D,L lactide-cos caprolactone) photocrosslinked injectable scaffolds has 
also been demonstrated.236,237 
Transdermal photopolymerization has been successfully performed using 
ultraviolet light;238, 239 however, most clinical applications using ultraviolet-
activated photocrosslinkable or photopolymerizable systems will require an open 
defect to allow for penetration of light to the material, a potential drawback in the 
clinical setting. Using a near IR light source would however allow deeper tissue 
and material penetration such that larger material volumes could be 
polymerized/crosslinked, and the use of such a light source also allows for three-
dimensional patterning of the material.240 Similar to three-dimensional patterning, 
Sun et al. demonstrated microstructural control of polymer nanocomposites with 
tunable physical characteristics based on crosslinking density as influenced 
through crosslinker and photoinitiator concentrations.241 Similarly, Burdick et al. 
utilized a microfluidic approach to create surface peptide gradient hydrogels via 
photopolymerization.242 
Thermal initiators are perhaps more amenable to minimally invasive 
delivery and in situ formation of an injectable scaffold. Systems that are activated 
near or at body temperature (37 °C) are ideal as they utilize normal in vivo 
conditions to initiate scaffold or network formation. Ammonium 
persulfate/N,N,N',N'-tetramethylethyldiamine (APS/TEMED) is a water soluble 
thermal initiator system with demonstrated cytocompatibility that has been 
studied as part of an in situ crosslinkable oligo(poly(ethylene glycol) fumarate) 
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(OPF) hydrogei.243 One of the main problems with radically initiated systems is 
that, although tolerated at low concentrations, high initiator concentrations can be 
cytotoxic to encapsulated cells,244 thus limiting the amount of initiator that can be 
included for in situ forming systems and subsequently limiting the range of control 
over important parameters such as formation kinetics and material mechanical 
properties. 
In addition to free radical initiation, a variety of chemical crosslinking or 
polymerization strategies for the in situ formation of biomaterial scaffolds exist. In 
situ crosslinkable PEGDA gels were fabricated using a reverse emulsion and 
Michael-type addition, resulting in materials with an ultimate compressive 
strength of nearly 7 MPa and making them potential scaffolds for load bearing 
soft tissue regeneration.245 Nano- and microscale control of scaffold architecture 
has been demonstrated for in situ prepared nanocomposites and microspheres 
using a condensation reaction and interfacial polymerization, respectively.246,247 
More biologically motivated systems for in situ scaffold formation also 
exist. Enzymatic methods for chemically crosslinking polymer chains in situ have 
been used to fabricate matrices composed of peptide modified synthetic 
polymers248,249 and natural polymers.250"252 Transglutaminases, which naturally 
crosslink blood clots and other biological structures, are commonly used to 
crosslink protein scaffolds or peptide modified scaffolds as the enzyme facilitates 
an acyl transfer reaction between a free amine group and a y-carboxyamide.253, 
254 
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Stimulus responsive systems 
Materials that undergo physical gelation rather than chemical crosslinking 
are also being explored for use as injectable scaffold materials for tissue 
engineering. These materials can undergo physical gelation in response to one 
or multiple changes in their surrounding environment including changes in 
temperature, pH, ions, and pressure or the presence of electrical and/or magnetic 
fields.255"257 
Thermogelling materials, which undergo entropically driven phase 
separation above their lower critical solution temperature (LCST), are widely 
investigated for use in drug delivery and tissue engineering applications.258 For in 
situ gel formation following injection, water-soluble materials with LCSTs at or 
below normal body temperature are desirable as they rapidly gel following 
injection and can then encapsulate cells and bioactive factors within a well-
hydrated network. Poly(N-isopropylacrylamide) (PNIPAAm) has a LCST of 32 
°C; however, when copolymerized with hydrophilic molecules, PNIPAAm 
containing materials with LCSTs closer to physiological temperature and thus 
undergoing less syneresis at 37 °C have been synthesized.259"262 Other synthetic 
thermogelling polymers that have been studied as tissue engineering scaffolds 
and cell delivery vehicles include block copolymers of poly(ethylene oxide) and 
polypropylene oxide)263"265 as well as copolymers of PEG with PPF,266 
poly(organophosphazenes),267 and PLA.268 Natural polymers and associated 
composites also demonstrate thermogelling character and have been explored 
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as injectable tissue engineering matrices.269"271 The use of tandem gelation 
combining physical and chemical gelation techniques has led to materials that 
undergo rapid thermogelation and subsequent chemical crosslinking, yielding 
injectable materials that combine the favorable kinetics associated with physical 
gelation with the mechanical characteristics and stability of covalently crosslinked 
materials.272"275 
Self assembling materials 
Similar to stimulus responsive materials, injectable self-assembling 
materials undergo gelation or precipitation, often with the ability to form precise 
nano- or microscale structures without the need for chemical crosslinking or 
initiating agents. Many such systems use hydrophobicity, either of the bulk 
material for phase segregation or of certain molecular domains for amphiphiles, 
as the key means by which self-assembly occurs. 
Injectable materials that self assemble in situ via phase segregation are 
often delivered in the form of a water insoluble polymer injected in solution with a 
water miscible solvent. Following injection, the solvent diffuses into the tissue 
space, allowing the polymer component to precipitate within the aqueous 
environment of the injection site. The solvent must thus be biocompatible to 
surrounding tissues and cytocompatible if cellular delivery is to be achieved; 
dimethyl sulfoxide (DMSO) and N-methyl-2-pyrrolidone (NMP) are two such 
solvents. Phase separating systems based on PLGA have been studied for 
nearly 20 years,276 and continuing recent research has been directed at 
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optimizing PLGA and other polymeric systems by better controlling the solvent 
removal rate and drug release kinetics in vivo277,278 
Tisseel® (Baxter Biosciences, USA), one of the earliest developed and 
clinically most successful of these phase separation systems uses a dual 
injection of fibrinogen and thrombin to form a fibrin clot or scaffold. Thrombin 
cleaves soluble fibrinogen into insoluble fibrin that then self assembles into fibrils 
resulting in, in combination with platelets, a clot. These fibrin clots, formed from 
the same biomolecules as used for natural clotting in vivo but at higher relative 
concentrations, are widely used as an adhesive sealant to achieve hemostasis 
during surgical procedures. Although Tisseel® as packaged for current clinical 
applications is not an ideal scaffold material because the high crosslinking 
density of the fibrin network prevents cell migration into and throughout the 
clot,279 more dilute fibrinogen and thrombin solutions can support stem cell 
proliferation280,281 and with appropriate mechanical properties can also induce 
stem cell differentiation.282 Fibrin-based systems have also been modified, 
resulting in promising materals for engineering specific tissue types. Research 
has yielded engineered BMP-2 fusion proteins that incorporate into fibrin 
matrices and enhance bone regeneration283 and fibrin gels with incorporated 
ECM peptides that enhance key aspects of nerve regeneration (Figure 2.3).284 
Although not truly self assembling systems, as mentioned previously biomaterials 
such as PEG can also be modified with peptides so that they can be crosslinked 
using similar thrombin/clotting factor systems, eliminating the need for soluble 
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synthetic initiators that may be cytotoxic to encapsulated cells or surrounding 
host tissue.249 
Self-assembling amphiphiles are another promising class of injectable 
materials for tissue engineering. A recently developed self-assembling peptide 
hydrogel undergoes shear thinning, such that when an appropriate shear stress 
is applied, the material thins into a low viscosity gel allowing for injection.295 After 
injection, the gel recovers its initial mechanical rigidity, making it a promising 
candidate for injectable applications. Peptide amphiphiles that self assemble with 
nanostructural organization in aqueous solution can be modified with peptide 
sequences to influence cell behavior, leading to increased cellular adhesion 
(Figure 2.4)286,287 or guided axonal regeneration within an injured spinal cord.288 
Kirkham et al. have investigated similarly functional self assembling peptide 
amphiphiles that nucleate mineralization in physiological conditions, an effect that 
has applications in dental and other hard tissue engineering applications.289,290 
Self-assembling peptide amphiphiles modified with heparin have been used to 
stimulate angiogenesis291 and, within a titanium scaffold, to aid in bone 
regeneration;292 these applications demonstrate the ability of modified peptide 
amphiphiles to aid in regeneration of multiple tissue types, making them ideal 
candidates for complex tissue engineering. 
Other promising self-assembly strategies for injectable scaffold fabrication 
exist. Micro- and nanosphere injection for use as drug delivery vehicles and 
scaffolds is possible;293, 294 however, simple injection of the uncrosslinked 
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particles offers little control over bulk mechanical properties or material behavior 
in vivo as the individual particles are bound only by space limitations and may 
migrate. Self-assembly techniques that result in crosslinking of the particles allow 
for augmented mechanical characteristics and control over scaffold architecture 
even as tissue remodeling commences, lonically crosslinked networks of 
positively and negatively charged nano-295 and microspheres296 exhibit tunable 
mechanical properties and hold potential as both drug and cell delivery vehicles. 
Salem et al. crosslinked biotinylated PLA-PEG microparticles using avidin in the 
presence of cells to create injectable cell-containing matrices with mechanical 
strength suitable to support bone regeneration in vivo (Figure 2.5).297 
2.6 Drug delivery via injectable scaffolds 
Most of the materials and techniques used in the development of 
injectable scaffolds for tissue engineering were first or have concurrently been 
investigated as injectable drug delivery systems. Many of the requirements for 
injectable drug delivery systems and injectable scaffolds are the same as any 
injectable biomaterial in that they must be biocompatible, and precise control of 
drug release kinetics will be of great benefit in both areas. In tissue engineering, 
there are, particularly for applications such as bone and dental regeneration, 
more demands upon a material and scaffold to be mechanically similar to the 
tissue being replaced since at the time of delivery the material must not only 
support regeneration but also largely perform the structural function of the native 
tissue. Because of this, not all materials developed for drug delivery are suitable 
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for tissue engineering purposes. Detailed reviews of injectable materials for drug 
delivery298 and drug delivery from injectable tissue engineering matrices167 are 
available; the following sections will briefly examine delivery of antibiotics and 
growth factors, two agents critical to successful tissue regeneration within the 
CFC, within injectable tissue engineering scaffolds. 
2.6.1 Antibiotic delivery 
The presence of infection is an important parameter that must be 
considered for nearly any reconstructive technique, be it the currently used 
surgical techniques utilizing implants and flaps or proposed tissue engineering 
solutions. Infections following traumatic craniofacial injuries are a common 
occurrence, particularly when the injury involves wound contamination through 
either penetration of a foreign object or loss of skin.299 Additonally, open 
communication with the oral cavity can lead to infection from oral flora, and in 
many cases latent infection that may not lead to clinical signs of infection but may 
hinder wound healing and tissue regeneration is present.300"302 Antibiotic delivery 
may thus be an important aspect of tissue engineering strategies in the CFC, 
both for curing and preventing latent or active posttraumatic and postsurgical 
infections. 
Although antibiotics can and have been incorporated into many 
commercially available bone cements, poor release kinetics and the sensitivity of 
many antibiotics to the high curing temperatures associated with cements such 
as PMMA make incorporation into the bulk material an inefficient and in some 
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cases ineffective strategy.303"305 Many drug delivery systems for antibiotic and 
other bioactive factors utilize drug-loaded microspheres or microparticles. At 
small particle or sphere sizes, these systems are easily injectable, have well 
characterized and tunable release kinetics, and can be fabricated from 
biocompatible, biodegradable materials such as PLGA306,307 or gelatin.308 
Tobramycin loaded PLGA-PEG blend microparticles have been shown to 
have well-controlled release profiles and can maintain tissue tobramycin 
concentrations over the minimum inhibitory concentration of Staphyloccous 
aureus for over one month,309 resulting in more effective treatment of 
osteomyelitis when compared to tobramycin released from a bulk bone 
cement.310 PLGA microspheres injected with chemically crosslinkable PPF 
exhibited continuous drug release over one month, and the degradation of the 
microspheres yielded scaffold porosity to facilitate tissue ingrowth without 
compromising the compressive strength of the scaffold.311 In the absence of 
microspheres, greater control of release kinetics can be achieved by including a 
hydrogel component or coating along with a bulk CaP cement.312,313 Osteoblasts 
cultured in the presence of antibiotic-loaded microspheres made of 
nanohydroxyapatite attached to and proliferated well in the material;314 however, 
there is some concern regarding stem cell proliferation and differentiation 
capacity in the presence of antibiotics,315 meaning combined delivery of stem 
cells with antibiotics must be carefully considered and studied prior to 
implementation. 
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2.6.2 Growth factor delivery via injection for engineering multiple tissues 
Growth factors are extracellular signal proteins that mediate the growth, 
proliferation and differentiation of cells. All these processes are crucial for tissue 
growth and repair in vivo, often determining the success of an engineered tissue. 
Growth factors act by binding to specific receptors on the same cell that has 
secreted the factors (autocrine signaling), neighboring cells (paracrine signaling), 
or distant cells (endocrine signaling). Upon binding, a cascade of cellular events 
is initiated, leading to cell proliferation, differentiation and maturation, as well as 
to the production of extracellular matrix and other growth factors.316 Growth 
factors can act on multiple cell types and are generally not specific for one type of 
tissue, making them especially useful for complex tissue engineering. The 
following paragraphs aim to categorize the use of growth factors towards 
regeneration of certain tissues, and review the injectable carriers available for 
their delivery. 
Angiogenic growth factors 
The formation of blood vessels has been identified as a key factor towards 
tissue regeneration and growth. Angiogenesis is the formation of new blood 
vessels from existing ones and is driven by endothelial cell proliferation and 
migration. This is opposed to vasculogenesis which is the formation of blood 
vessels de novo.317 The two main growth factor families that have been shown to 
directly stimulate angiogenesis are vascular endothelial growth factor (VEGF) 
and FGF. Moreover, the well-characterized transforming growth factor-B (TGF-8) 
89 
superfamily has an indirect effect on angiogenesis in vivo, as does the PDGF 
family18. Growth factors inducing angiogenesis contribute largely to the wound 
healing process, as for example the TGF-p superfamily.318 
Osteogenic growth factors 
Growth factors that encourage the formation of new bone have been 
identified and applied to heal bone defects around medical and dental implants 
and without implant placement.319 Review articles on the properties and delivery 
of osteogenic growth factors are available.320, 321 BMPs, which are part of the 
TGF-|3 superfamily, have osteo- and chondroinductive properties.322 The BMP 
family consists of at least 20 different proteins, among which two (BMP-2 and 
BMP-7) are commercially available for clinical applications.323 Other factors 
include the insulin-like growth factors (IGF), which have been shown to have an 
effect on tissue formation, especially bone, FGF, which are synthesized by 
skeletal cells,310 and PDGF, which is known for enhancing protein synthesis in 
bone.324 
Chondrogenic growth factors 
Members of the growth factor families listed above have been also shown 
to stimulate the formation of new cartilage, including TGF-p, BMP and IGF 
proteins.325"327 The regulatory effects of growth factors on articular 
chondrogenesis are summarized elsewhere.328,329 
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2.6.3 Injectable growth factor delivery 
Tissue engineering of complex craniofacial tissues, as has been stressed 
in previous sections, requires thorough understanding of these tissues' biology as 
well as their environment. In order to mimic physiological processes and 
regenerate tissue in vivo, growth factor delivery will be an important aspect to 
consider. The expression of different growth factors during the healing cascade 
within complex tissue defects has been the object of much research, and the 
challenge facing tissue engineers is to direct the release of multiple growth 
factors at various time intervals from a scaffold as to simulate and enhance the 
actual healing process.159 Many studies so far have used growth factors at 
concentrations much higher than physiological concentration in order to increase 
their bioavailability, although improving efficiency in growth factor loading and 
delivery is the focus of some new delivery vehicles.330 Delivery of higher 
concentrations of growth factor than physiologically encountered may not, 
however, have the desired effects and also increases costs tremendously. 
Controlled release of growth factors is therefore a crucial variable in achieving a 
safe and effective dosage, and the scaffold can play a role in achieving 
appropriate temporal and spatial delivery. The next paragraphs will review the 
recent advancements in growth factor delivery from injectable tissue engineering 
carriers. 
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Polymeric carrier materials for multiple tissue regeneration 
Polymers are probably the most widely used class of injectable materials 
for achieving controlled growth factor release. The importance of controlled 
release kinetics was highlighted in a study conducted by Woo et a/.331 Using a 
carboxymethylcellulose hydrogel with PLGA microparticles loaded with 
recombinant human BMP-2, they showed that sustained release of the growth 
factor promoted bone healing significantly better than a burst release system. 
Similar to antibiotic delivery, many other systems incorporating microparticles for 
growth factor delivery have been developed. The encapsulation of growth-factor 
loaded gelatin microparticles in OPF hydrogels minimizes the burst release often 
associated with this type of material.326 Growth factor loading on gelatin 
microparticles is achieved by polyionic complexation, and the in vivo release is 
governed by the enzymatic degradation of gelatin.332 A design for multiple tissue 
regeneration was suggested with such a composite. A bilayered OPF hydrogel 
system with incorporated TGF-01-loaded gelatin microparticles, consisting of a 
bone forming and a cartilage forming layer, was used with promising results for 
osteochondral repair (Figure 2.6).333 The same scaffold was later used for dual 
delivery of TGF-(31 and IGF-1. It was designed to release TGF-(31, a 
chemoattractant and morphogen, rapidly, followed by release of IGF-1, a 
stimulator of extracellular matrix formation, in a more sustained manner.334 The in 
vivo findings, however, did not suggest a synergy between these factors as 
expected from in vitro observations and did not result in significant improvement 
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of new tissue quality. Dual growth factor delivery has been also proposed for 
bone repair. Patel et a/.19 have investigated the effect of dual delivery of an 
angiogenic (VEGF) and an osteogenic (BMP-2) growth factor in a rat critical size 
cranial defect. The growth factors were incorporated in gelatin microparticles and 
were injected into porous PPF scaffolds. After four weeks, the dual release 
system resulted in much higher bone formation than either growth factor alone, 
indicating a synergistic effect in this time interval. At twelve weeks, BMP-2 and 
dual release groups showed increased bone formation over VEGF alone and 
control groups but were not significantly different from each other (Figure 2.7). In 
addition to growth factors released from polymer matrices to induce cellular 
differentiation, an alternate strategy utilizes growth factors to encourage cell 
migration into or throughout a hydrogel in a similar manner to the previously 
mentioned adhesion molecule-modified peptide amphiphiles and fibrin gels.335 
Thermoresponsive hydrogels have been also used for growth factor 
delivery. These hydrogels are typically liquid at ambient temperature and solidify 
at close to physiological temperatures. A poly(NIPAAm-coacrylic acid) hydrogel 
was blended with hyaluronic acid and used for TGF-(33, dexamethasone, and cell 
delivery.336 Gao et a/.337 were able to conjugate rhBMP-2 to thermoreversible 
polymers while maintaining the osteoinductive properties of the growth factor. 
Thermoresponsive Tetronic® was copolymerized with e-caprolactone and 
subsequently conjugated with heparin, resulting in polymeric micelles. Basic 
FGF, a heparin-binding growth factor, could be released from these micelles in a 
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controlled manner over two months.338 Moreover, the amphiphilic nature of the 
micelles allows for the dual delivery of a hydrophilic molecule such as a growth 
factor together with a more hydrophobic compound.339 
Heparin has been also used in combination with a modified chitosan 
hydrogel for sustained release of FGF-2. Significant angiogenesis and fibrous 
tissue formation was observed in animals following injection of the loaded 
hydrogel.340 The angiogenic effects of VEGF alone341 or in sequential release 
with PDGF-BB342 were investigated using different molecular weight alginate 
polymers. Good spatiotemporal control of the release kinetics was achieved with 
these hydrogels, resulting in a promising vehicle for stimulating angiogenesis. 
Hosseinkhani et al. developed another interesting carrier applied towards the 
same goal. They synthesized an injectable, self-assembling peptide-amphiphile 
that allows for simple mixing of an aqueous solution with basic FGF suspension 
and can be injected and self-assemble in vivo. This system proved advantageous 
for angiogenesis as compared to basic FGF or amphiphile injection alone and 
holds promise as a carrier for therapeutic proteins.343 Hiemstra et al. have also 
investigated a dextran-based system for FGF delivery that forms in situ via a 
Michael-type addition.344 
2.6.4 Injectable ceramic materials and their composites for bone tissue 
regeneration 
Calcium phosphate (CaP) cements have been used with good results in 
bone tissue engineering. Their advantages include easy handling and injectability 
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as well as osteoconductivity.345 In order to further improve their potential for bone 
regeneration, these carriers have been delivered together with growth factors, 
such as recombinant human TGF-(31.346 Using calcium phosphate cement as a 
delivery vehicle for recombinant human BMP-2, Kroese-Deutman et al. observed 
bone growth in an ectopic, subcutaneous, animal model after ten weeks of 
implantation.174 This and other studies have revealed the potency of rhBMP-2 as 
an osteoinductive factor, and further attempts have been made towards 
achieving a more controlled release profile. The use of CaP with embedded 
PLGA microspheres resulted in an injectable delivery system that exhibited linear 
release profiles without an initial burst in vivo347 and showed that the controlled 
release of a low BMP-2 dose was able to induce bone growth in an experimental 
animal model.220 
2.7 Ceil delivery for engineering complex tissues 
The delivery of cells to a defect is a means to accelerate the healing 
process as the body would not have to rely on host cells being recruited to that 
site. Cellular delivery vehicles may also allow for regeneration of native tissues 
before fibrosis and scarring occur. The cell source and type is a topic of much 
discussion and research over the past decades, and approaches using 
xenogeneic, allogeneic, or autologous cells have been studied. There are 
advantages and disadvantages involved in all of these approaches, and the 
decision has to be made with careful consideration of the application and the 
necessary steps to translate from research to a final tissue engineered product. 
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The other big question facing researchers is the choice between differentiated 
cells and either embryonic or adult stem cells. Stem cells have the ability to 
proliferate in an undifferentiated state or, with the application of certain stimuli, to 
differentiate into one or more cell lineages. Investigators have recognized the 
tremendous potential of stem cells in regenerative medicine, and given their 
versatility, they can offer a valuable solution for engineering complex tissues. 
Embryonic stem cells are isolated from embryonic or fetal tissues, and are 
capable of giving rise to all types of tissues.348 Adult stem cells can be mainly 
categorized into hematopoietic and mesenchymal stem cells. Hematopoietic 
stem cells (HSCs) are derived from the bone marrow and are blood cell 
progenitors. MSCs can be found in a variety of tissues, including bone marrow, 
periosteum, adipose, and possibly the umbilical cord matrix and can differentiate 
into bone, cartilage, muscle, fat, and other tissues.349"352 Most craniofacial tissues 
derive from MSCs, and there is evidence that for some craniofacial structures 
such as the TMJ, MSCs are better suited for tissue regeneration than 
differentiated cells (Figure 2.8).353 A recent review article by Mao et al.A62 outlines 
advances in the field of craniofacial tissue engineering using stem cells. 
Once in the body, stem cells receive signals that govern their fate. These 
signals can be chemical or mechanical in nature, and are provided either by the 
physiologic environment or can be incorporated in the cell delivery vehicle. The 
mechanisms by which these signals affect stem cells are not yet fully understood. 
The field of tissue engineering is greatly advanced by stem cell biology findings, 
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and tissue engineering scaffolds have been used with promising results for stem 
cell delivery for various tissues. The nature of injectable materials, which allows 
for simultaneous cell and bioactive agent encapsulation, makes them particularly 
attractive for this application, as does the ability to control scaffold mechanical 
properties, which can provide the appropriate mechanobiological environment for 
cell proliferation and differentiation. 
2.7.1 Cell delivery systems 
Hydrogels, due to their high water content, are excellent ECM analogues, 
and are used extensively for cell delivery. Injectable hydrogel systems such as 
OPF, with or without the addition of growth factors, were shown to promote 
mesenchymal stem cell differentiation, with possible applications in bone and 
cartilage regeneration (Figure 2.9).354,355 By controlling the scaffold swelling and 
mechanical characteristics, appropriate signals were transduced to the cells. Also 
the addition of a functional group to the polymer, for example a group that will 
enhance biomineralization, has been shown to induce cell differentiation, helping 
MSCs turn into osteoblast-like cells.356 The importance of growth factors in 
enhancing cell function for tissue engineering applications has been outlined in 
the previous section. Yamada et al. utilized the abundance of growth factors 
released by platelets by delivering MSCs in a platelet-rich plasma gel, observing 
bone formation and neovascularization in vivo.357 Morphogenic factors are often 
co-injected with cells but can also be applied to the cells to pre-differentiate them 
in vitro prior to administration. An example for engineering complex tissues using 
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the latter strategy is the work of Alhadlaq et a/.358 Rat MSCs were treated for 
three to four days with either chondrogenic or osteogenic supplements and 
loaded in two hydrogel layers formed by photopolymerization. After four weeks in 
vivo, stratified layers of chondrogenesis and osteogenesis were observed. The 
authors concluded that this approach could offer a solution for tissue engineering 
complex tissues using a single adult mesenchymal stem cell population. 
2.7.2 Co-culture models and future considerations 
Another exciting option for stimulating cell differentiation and proliferation 
is the co-culture of multiple cell types. The signals exchanged between cells help 
augment tissue regeneration by guiding differentiation and matrix production 
down the desired pathway. Co-cultures essentially mimic the physiological 
environment, where different cells act cooperatively and bioactive factors 
secreted by one cell type provide cues for the action of another cell type. It is 
known, for example, that in endochondral bone formation, cartilage precedes 
bone development. Alsberg et a/.359 co-transplanted chondrocytes and 
osteoblasts embedded in hydrogels and observed formation of distinct tissue 
types. Gerstenfeld et a/.360 investigated the effect of chondrocytes on 
mesenchymal stem cell osteogenesis. They found that MSCs co-cultured with 
chondrocytes underwent osteogenic differentiation, but did not observe this when 
MSCs were cultured with fibroblasts or osteoblasts. In a parallel study, treatment 
of MSCs with BMP-7 induced both chondrogenesis and osteogenesis. 
Osteogenic differentiation alone was observed in the MSCs co-cultured with 
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chondrocytes.360 Interestingly, co-culture of MSCs with cartilage, separated by a 
membrane and without any external growth factors, was found to increase 
markers of chondrogenic differentiation. Therefore, it seems that the secretion of 
soluble factors from the whole cartilaginous matrix controls chondrogenesis of 
mesenchymal stem cells, and that the MSCs in turn influence the already formed 
cartilage, possibly preventing its hypertrophy or ossification.361 
One of the important hurdles to overcome in tissue engineering is the 
blood supply to the growing tissue. Cell co-cultures could potentially play a role in 
this area by delivering cell populations that would form new blood vessels and 
also initiate tissue development. Early studies by Sun et al. showed promise in 
bone regeneration and angiogenesis using a vascular endothelial cell / bone 
marrow MSC co-culture model.362 Using a different approach, the formation of 
microvascular networks in vivo was demonstrated with neural progenitor and 
endothelial cells embedded in a macroporous hydrogel.363 
Research in the area of co-culture systems is crucial to our understanding 
of cell communication with soluble signaling molecules. Models for establishing 
these relations exist; however, it must be noted that precautions should be taken 
until there is a clear understanding of the mechanisms that govern cellular 
interactions, especially involving stem cells. In a direct co-culture setup, there 
may be danger of cell fusion and endocytosis.364 Therefore, many researchers 
use membrane-separated cell culture chambers where cells are not in direct 
contact, but soluble factors secreted by one population can freely float in the 
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culture medium and act on the other cell type. Once it is determined whether 
direct cell contact is necessary or paracrine mechanisms are involved, new 
directions for cell co-culture and possibly the delivery of multiple cell types 
together with stem cells will be developed. Facing the problem of complex tissue 
regeneration, the option of cell therapy with multiple populations seems 
appealing, particularly considering the multipotency of stem cells. We can 
anticipate great progress towards that goal in the years to come. 
2.8 Injectable materials for engineering complex tissues 
The last 15 years has seen a remarkable influx of ideas and technologies 
to the areas of biomaterials and tissue engineering. While this research has 
resulted in an expansion of knowledge and in select cases an impact on clinical 
medicine, regenerating complex tissues remains a largely unaddressed 
challenge. Advances specifically in injectable biomaterials are frequently 
presented; however, tissue regeneration in humans using injectable materials 
remains an unmet goal. As has been shown, regenerating complex tissues is a 
complicated endeavor that, particularly in the CFC where a number of structures 
reside in limited space, will require a synergistic approach drawing on knowledge 
from many areas of science and engineering. 
2.8.1 Goals and future directions 
Continued advances in biomaterials and tissue engineering will be 
required to realize the goal of regenerating complex craniofacial tissues using 
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injectable biomaterials. First, a more complete understanding of the function and 
utility of stem cells within the context of tissue engineering will be necessary for 
regenerating any complex tissue. Adult and embryonic stem cells are a powerful 
tool for regenerative medicine applications, but to tailor complex tissues, precise 
control over differentiation and subsequently morphogenesis must be achieved. 
Advances in these areas may result from better understanding of development 
and natural tissue regeneration, such as more precise knowledge of growth 
factor and cell signaling cascades. 
At the materials level, new materials are continually introduced, and much 
current work focuses on promising materials tailored for engineering specific 
tissues. The integration of these materials with one another or the development 
of materials with multiple patterned, micro- and nanoscale domains for specific 
tissue and organ patterning will be critical to complex tissue engineering.365, 366 
The interaction of these domains with stem cells and the effect of bioactive factor 
release kinetics must be well characterized and utilized. The creation of 
surface367, 368and 3D369 patterning or pore gradients and orientation,370, 371 for 
example, and in particular mechanical gradients via any of the methods for 
solidification discussed can be of great benefit to tissue engineers, as such 
patterning can influence cell behavior including differentiation.372 For complex 
tissue engineering, an injectable material that can encapsulate cells and 
bioactive factors and deliver them to a multi-tissue defect so that different regions 
of the defect regenerate into anatomically oriented and functionally capable 
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tissues is the end goal; however, many hurdles must be overcome in the path to 
developing such a system. 
2.9 Conclusions 
This chapter aims to examine recent advances in injectable biomaterials 
for tissue engineering within the challenging but illustrative context of complex 
tissue engineering within the craniofacial complex. A region with great need for 
better biomaterials and tissue engineering strategies, currently used techniques 
and biomaterials for craniofacial augmentation and repair were described to 
establish the current end-stage state of the art. The challenge of engineering 
complex tissues and advances in tissue engineering the broad scope of 
craniofacial tissues were described followed by an overview of injectable material 
technologies and drug and cellular delivery via injectable materials. Finally, the 
notable challenges and perceived future needs and directions in addressing the 
challenges described were mentioned. Many promising injectable biomaterials 
exist, and forays into in vivo testing using animal models have been largely 
successful. The goal, however, of regenerating complex tissues remains unmet 
in the clinic and will require continued commitment and advancement within the 
field. 
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2.10 Figures 
Table 2.1. Materials and methods currently used for craniofacial reconstruction. 
Tissue Type 
Hard tissue 
Source 
Autologous 
Allogeneic 
Xenogeneic 
Synthetic 
Clinically Available Methods & Materials 
Non-vascularized bone grafts from iliac crest, tibia, skull, and 
mandible. 
Mineralized allogeneic bone available from tissue banks. 
Demineralized bone matrix combined with various carriers: 
w/ hyaluronic acid (i.e. DBX®) 
w/glycerol (i.e. Grafton®) 
w/gelatin (i.e. Regenafil®) 
w/ poloxamer (i.e. Dynagraft®) 
w/ calcium sulfate (i.e. Allomatrix®) 
Crosslinked bovine collagen I coated in hydroxyapatite (i.e. 
Healos®). 
Deproteinized bovine bone (i.e. Bio-Oss®). 
Porcine collagen I and III resorbable membrane (i.e. Bio-Gide®). 
60% hydroxyapatite + 40% tricalcium phosphate ceramics in 
bovine fibrillar collagen carrier (i.e. Collagraft®). 
Ceramics 
Hydroxyapatite of natural origin 
Coral sources (i.e. Pro Osteon® and Biocoral®). 
Bovine bone (i.e. Bio-Oss®). 
Synthetic hydroxyapatite. 
Synthetic unsintered calcium deficient apatite. 
Synthetic p-tricalcium phosphate. 
Synthetic biphasic calcium phosphate. 
Calcium phosphate cements (i.e. Norian®, BoneSource®, 
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Soft Tissue Autologous 
Allogeneic 
Xenogeneic 
Synthetic 
Mimix®). 
Polymers 
Poly(a-hydroxy esters) such as poly(lactic acid), 
poly(glycolic acid), and poly(lactic-co-glycolic acid). 
Applications include resorbable fixation plates and 
screws, and resorbable membranes. 
Porous high density polyethylene implants (i.e. MedPor®). 
Poly(methyl methacrylate) implants. 
Recombinant growth factors 
Bone morphogenetic protein-2 in an absorbable collagen 
sponge (i.e. Infuse®). 
Platelet-derived growth factor in a p-tricalcium phosphate 
carrier (i.e. GEM 21S®). 
Soft tissue grafts 
Full-thickness and partial-thickness skin grafts. 
Oral mucosa grafts (i.e from the free gingiva, buccal 
mucosa, palate, etc.). 
Microfat grafting. 
Dermal fibroblast harvest, ex vivo culture and re-
implantation (i.e. Isolagen®). 
Soft tissue flaps 
Local flaps (i.e. buccal fat pad). 
Regional flaps (i.e. from pectoralis major, deltopectoral, 
temporalis). 
Vascularized free flaps (i.e. from the radial forearm, 
anterolateral thigh, etc.). 
Short-term skin allografts. 
Long-term face transplants. 
Freeze-dried de-epithelialized acellular dermal graft (i.e. 
Alloderm®). 
Dermal fillers 
Fibrillar bovine collagen I and III (i.e. Zyderm®). 
Crosslinked fibrillar bovine collagen I and III (i.e. 
Zyplast®). 
Crosslinked hyaluronic acid derivatives (i.e. Hylaform®, 
Restylane®, Captique®). 
Dermal fillers 
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Composite 
tissue 
Synthetic 
Autologous 
Synthetic 
Dermal fillers 
Liquid silicone. 
Poly(methyl methacrylate) microspheres in collagen 
solution (i.e. ArteFill®). 
Poly(L-lactic acid) microparticles in 
carboxymethylcellulose gel (i.e. Sculptra®). 
Vascularized osseo-fascio-cutaneous free flaps (i.e. from the 
radial forearm, fibula, iliac crest, deltoid, and scapula). 
Non-vascularized osteochondral grafts (i.e. from the ribs). 
Polymeric prosthesis materials 
Poly(methyl methacrylate) 
Polyurethane elastomers 
Silicone elastomers (i.e. MDX 4-4210®) 
Tissue engineering approaches 
Titanium mesh scaffold filled with bone marrow and Bio-
Oss* blocks coated with recombinant BMP-7. Construct 
placed in muscle for 7 weeks, then transplanted to 
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Figure 2.1. Craniofacial tissues needed for reconstruction. Reproduced from 
[161]. Copyright 2007 Springer. 
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Figure 2.2. Silastic implant fragments surgically retrieved from patients. The 
primary reason for retrieval was patient pain, likely secondary to implant failure. 
A and B show fracture lines within the implant, while C shows fraying and 
exposure of Dacron fibers that are intended to reinforce the implant. Reproduced 
from [204]. Copyright 2008 Elsevier, Inc. 
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Figure 2.3. Cross sectional images of nerves regenerated in self assembling fibrin 
tubes. A 4 mm segmental defect was created in the dorsal root nerve of a rat and 
then bridged with a polymer tube implant. The gap was either left empty (A, B), 
filled with unmodified fibrin (C, D), or filled with fibrin modified with four peptides 
from the laminin family of adhesion molecules (E, F). The homogeneity of the 
nerve and alignment of the neuritis can be appreciated in the samples receiving 
peptide-modified fibrin bridges (A, C, E bar= 50 j/m, B, D, F bar = 25 /jm). 
Reproduced from [284]. Copyright 2000 Nature Publishing Group. 
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Figure 2.4. Focal adhesion formation of cells expressing green fluorescent 
protein labeled integrin (A-F) or yellow fluorescent protein labeled signal 
transduction protein (paxiilin, G-L) in response to peptide amphiphiles expressing 
RGDS sequence(s). (A, G) branched peptide amphiphile with one cyclic RGDS, 
(B, H) branched peptide amphiphile with two RGDS, (C, I) branched peptide 
amphiphile with one RGDS, (D, J) branched peptide amphiphile with one d-RGDS, 
(E, K) linear peptide amphiphile with one RGDS, and (F, L) show cells on linear 
peptide amphiphile with one RGDS. Focal adhesions are seen as brightly 
fluorescent spots and demonstrate the presence of cellular organization during 
adhesion and migration in response to the presence of RGDS. This represents an 
example of how at the cellular level behavior can be regulated via substrate 
modification, a potentially powerful tool for regenerating of complex tissues. 
Reproduced from [287]. Copyright 2007 Elsevier B.V 
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Figure 2.5. Schematic representation of avidin induced self assembly of 
biotinylated PEG-PLA microparticles. Reproduced from [297]. Copyright Wiley 
2003 VCH. 
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Figure 2.6. Osteochondral tissue repair in rabbit knees 14 weeks after 
implantation with a bilayered scaffold (A, D, G - TGF-pi releasing porous 
chondral and porous subchondral layers; B, E, H - TGF-f51 releasing porous 
chondral and nonporous subchondral layers; C, F, I porous chondral layer and 
nonporous subchondral layer). The boxed regions in (A-C) (2.5x magnification) 
are shown at higher magnifications in (D-F) (10x), and (G-l) (20x). Arrows point 
towards the joint surface, while columnar arrangements of chondrocytes, cell 
clusters, and cartilage fissures are respectively indicated by CO, CL, and FI. The 
image demonstrate the ability of a bilayered scaffold along with regionally 
specific growth factor release to regenerate multiple tissues within the same 
construct. Reproduced from [333]. Copyright 2005 Wiley Interscience. 
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Figure 2.7. Microcomputed tomography images of rat cranial bone defects treated 
with angiogenic, osteogenic or both growth factors. Figures A-D represent an 
untreated control group, angiogenic VEGF-treated group, osteogenic BMP-2-
treated group, and a dual delivery group at 4 weeks. Blood vessels and bone are 
visible. Figures E-H represent control, VEGF, BMP-2 and dual groups at 12 weeks. 
Blood vessel formation was not evaluated at this time point. Bar represents 200 
urn. Reproduced from [19]. Copyright 2005 Elsevier B.V. 
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Figure 2.8. Safranin O/fast green stained (left) and chondroitin-4-sulfate 
immunohistochemically stained cultures of human umbilical cord matrix (HUCM) 
derived stem cells and TMJ cartilage cells. HUCM were cultured in control (top 
left) and chondrogenically supplemented (top right) media for 4 weeks following 
initial culture in chondrogenic media. HUMCs produced more 
glycosaminoglycans as shown by both staining modalities than already 
differentiated TMJ chondrocytes, indicating the utility of stem cells in craniofacial 
tissue engineering compared to differentiated cells. Reproduced from [353]. 
Copyright Mary Ann Liebert 2007. 
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Figure 2.9. Cumulative secretion of osteopontin, a marker of osteogenic 
differentiation, from OPF hydrogel matrices with encapsulated MSCs. (A) MSCs 
encapsulated in OPF formulated from PEG with MW 10,000 Da and 3,000 Da were 
cultured in dexamethasone containing (+) and non-supplemented (-)culture media 
for 28 days. (B) Two types of OPF/MSC formulations maintained for 28 days in 
culture media without dexamethasone. The samples with higher molecular 
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weight PEG (10K) underwent greater swelling than the less hydrophilic samples 
(PEG MW 3K), which led to enhanced osteogenic differentiation of encapsulated 
MSCs. Reproduced from [355]. Copyright 2004 Wiley Interscience. 
115 
Chapter 3 
Objectives 
There are many promising techniques for bone tissue engineering in 
isolaton; that is, without regard to factors such as cost, translational potential, 
concomitant morbidities, or other factors that would affect the adoption of the 
technique for clinical use. Increasing consideration of these factors shaped the 
work presented here. 
The original goal of this work was to develop a hydrogel cell carrier for 
bone tissue engineering applications. Such a cell carrier would need to not only 
support cell viability and ideally initiate osteodifferentiation of delivered progenitor 
cells, but would perhaps most importantly need the mechanical strength 
necessary to provide support within a bony defect. 
As this project progressed, the focus shifted towards more translational 
approaches for cell delivery and tissue engineering. The effect of donor age and 
extended cell culture in the form of passages was investigated to determine 
whether ex vivo handling of cells had any deleterious effects and to investigate 
whether such effects were dependent on donor age. After determining that there 
were potentially negative effects associated with culture, delivery of uncultured 
bone marrow mononuclear cells to scaffolds using an existing FDA-approved 
fibrin glue was explored to determine if freshly harvested cells without ex vivo 
culture or expansion could regenerate bone within a critical size defect. 
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Finally, considerations of the types of injuries being treated led to the final 
objective of the project. Traumatic craniofacial injuries, particularly those 
resulting from military combat, often result in soft tissue loss and subsequent 
infection. Such comorbidities would likely render a tissue engineering approach, 
such as those explored in the first two objectives of this thesis, ineffective at 
worst. Delayed definitive treatment would thus be necessary, but without a 
bridge to prevent scarring and tissue contraction, delays in treatment might 
negatively effect long term results. Thus a space maintainer technology was 
investigated for use in these situations. 
The specific objectives of the work presented within this thesis are: 
1. Synthesize and characterize stimulus responsive polymers and 
hydrogels for cell delivery applications in bone tissue 
engineering, focusing on cytocompatible methods for gel 
formation and reinforcement. 
2. Investigate the effect of cell culture on the differentiation capacity 
of mesenchymal stem cells from donors of different ages. 
3. Investigate the use of gel-encapsulated, uncultured bone marrow 
mononuclear cells for bone tissue regeneration within a critical 
size defect. 
4. Investigate methods to facilitate soft tissue healing and bony 
space maintenance within a critical size bone defect using an 
117 
animal model that more realistically simulates that encountered 
following traumatic craniofacial injury. 
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Chapter 4 
Synthesis and characterization of dual stimuli responsive macromers 
based on poly(N-isopropylacrylamide) and poly(vinylphosphonic acid)+ 
Abstract 
Stimulus responsive materials hold great promise in biological applications 
as they can react to changes in physiological stimuli to produce a desired effect. 
Stimulus responsive macromers designed to respond to temperature changes at 
or around 37 °C and the presence of divalent cations were synthesized from N-
isopropylacrylamide, pentaerythritol diacrylate monostearate, 2-hydroxyethyl 
acrylate, and vinylphosphonic acid by free radical polymerization. Monomers 
were incorporated into the macromers in ratios approximating the molar feed 
ratios, and macromers underwent thermogelation around normal body 
temperature (36.2 - 40.5 °C) as determined by rheology and differential scanning 
calorimetry. Macromers containing vinylphosphonic acid interacted with calcium 
ions in solution, displaying decreased sol-gel transition temperatures (27.6 - 34.4 
°C in 100 mM CaCI2), with decreases of greater magnitude observed for 
macromers with higher relative vinylphosphonic acid content. Critical micellar 
f
 This chapter will be published as the following: Kretlow JD, Hacker MC, Klouda L, Ma 
BB, Mikos AG. Synthesis and characterization of dual stimuli responsive macromers 
based on poly(N-isopropylacrylamide) and poly(vinylphosphonic acid). 
Biomacromolecules 2009: in press. 
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concentrations also decreased in a dose-dependent manner with increased 
vinylphosphonic acid incorporation in solutions with CaC^ but not in solutions 
with NaCI. These dually responsive macromers allow examination of the effect of 
increasing vinylphosphonic acid content in a macromer which holds promise in 
biological applications such as drug and cell delivery or tissue engineering due to 
the macromer responsiveness at physiological temperatures and concentrations 
of calcium. 
Abbreviations 
AAm 
AIBN 
CMC 
DLS 
DSC 
HEA 
LCST 
NIPAAm 
pNIPAAm 
TGA 
THF 
acrylamide 
2,2'-azobis(2-methylpropionitriIe) 
critical micellar concentration 
dynamic light scattering 
differential scanning calorimetry 
2-hydroxyethyl acrylate 
lower critical solution temperature 
N-isopropylacrylamide 
poly(N-isopropylacrylamide) 
thermogravimetric analysis 
tetrahydrofuran 
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4.1 Introduction 
The development of injectable biomaterials and similarly the identification 
of methods through which materials may form in situ are popular topics in 
materials science, particularly in the area of biomaterials. Injectable materials 
are attractive for biological applications as they can potentially be delivered using 
minimally invasive techniques, precisely fill complex three-dimensional voids in 
regenerative medicine applications without the need for extensive imaging and 
custom fabrication, and controllably deliver bioactive molecules and/or cells for 
therapeutic purposes. 
Most research and development in the area of injectable biomaterials 
focuses on in situ formation via self-assembly297,373, phase separation374, or in 
situ polymerization and cross linking.238, 375378 Materials that undergo phase 
separation or self assemble in response to environmental cues or stimuli are 
promising for biological applications as the stimulus triggering the phase 
separation or assembly can be one normally encountered upon injection into 
living tissues, such as a temperature increase or pH change. Such methods for 
in situ formation may reduce or eliminate the need for radical initiators or 
crosslinking agents that may be cytotoxic at high concentrations,243,244 potentially 
making these materials ideal for cellular encapsulation and delivery as well as 
alleviating potential damage to existing host tissues. 
Biomaterials have recently been developed that respond to a large 
number of internal or externally applied environmental stimuli, including 
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temperature,379"381 pH,382 ionic strength,383 the presence of specific biological 
molecules,384"386 and magnetic field presence.387 Recent reviews are available 
describing the roles of these materials in scaffold fabrication,388 drug delivery,389 
and as tunable bio-interfaces.390 
In order to impart greater versatility or allow better control over the 
behavior of these "smart" biomaterials, materials have been developed that 
respond to multiple stimuli, such as both pH and temperature.391"395 The 
response to each stimuli may be different396 or additive.397 
Materials that undergo tandem gelation via a stimulus responsive, physical 
mechanism, typically thermogelation, and an additional mechanism such as 
chemical crosslinking offer comparable versatility to dual stimuli responsive 
materials. Tandem gelling materials can offer the favorable, nearly 
instantaneous gelation kinetics of physical gelation coupled with the stability and 
irreversibility of chemical crosslinking.272, 398 These materials may be particularly 
attractive alternatives for applications where the environmental stimuli that 
triggers physical gelation is subject to variability, such as pH within a healing 
wound or fracture, which can be both variable and unpredictable.399 
We have previously synthesized and characterized a series of thermally 
and chemically gelable macromers based on poly(N-isopropylacrylamide) 
(pNIPAAm).262 By copolymerizing N-isopropylacrylamide (NIPAAm) with other 
monomers to vary the amphiphilic structure of the resulting macromers, we were 
able to synthesize macromers with variable rheological properties and lower 
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critical solution temperatures (LCSTs) around 37 °C. These macromers 
displayed less syneresis at body temperature than macromers that thermogelled 
at lower temperatures; however, chemical modification and subsequent chemical 
crosslinking was still necessary to produce stable gels. 
The goal of the present study is to examine the effect of ionic interactions 
on the rheological and micellar behavior of pNIPAAm-based macromers similar 
to those previously synthesized and characterized in our laboratory by 
incorporating phosphonic acid moieties through copolymerization of NIPAAm, 
vinylphosphonic acid (VPA), and other monomers to modulate the amphiphilic 
structure of the macromers. A hydrophobic chain was incorporated through 
copolymerization with pentaerythritol diacrylate monostearate (PEDAS), a 
bifunctional monomer incorporating a stearic acid chain and two acrylic acids 
esterified to the biocompatible alcohol pentaerythritol. Hydroxyethylacrylate 
(HEA) was incorporated to allow for possible chemical modifications of the 
accessible hydroxyl groups and also to further balance the hydrophobicity of the 
macromers. The synthesis and characterization of macromers that thermogel 
near normal physiological temperature, as well as the interactions of these 
macromers with divalent ions in solution towards gel and micelle formation, is 
described. 
4.2 Materials and Methods 
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4.2.1 Materials 
Pentaerythritol diacrylate monostearate (PEDAS), N-isopropylacrylamide 
(NIPAAm), acrylamide (AAm), 2-hydroxyethyl acrylate (HEA), vinylphosphonic 
acid (VPA), and 2,2'-azobis(2-methylpropionitrile) (azobisisobutyronitrile, AIBN) 
were purchased from Sigma-Aldrich (Sigma, St. Louis, MO) and used as 
received. Analytical grade tetrahydrofuran (THF), diethyl ether, isopropyl alcohol, 
and acetone were purchased from Fisher Scientific (Pittsburgh, PA) and used as 
received. 
4.2.2 Methods 
Macromer synthesis 
Macromers were synthesized using free radical polymerization (Scheme 
4.1) as previously described.262 Briefly, 3 g of PEDAS and amounts 
corresponding to the desired molar ratios of comonomers (NIPAAm, VPA, HEA, 
AAm) were dissolved in 250 mL THF at 60 °C under nitrogen and initiated with 
1.5 mol % AIBN. Reactions proceeded under nitrogen for 18 h at 60 °C followed 
by an additional 1 h of reflux. Products were isolated by rotoevaporation, 
precipitation in ice-cold diethyl ether followed by drying and a second dissolution 
in THF and precipitation in ice-cold diethyl ether. Products were then vacuum 
dried at ambient temperature for 7 days before being dissolved in 200 mL 
isopropanol and dialyzed against isopropanol for 4 days in a 1,000 MWCO 
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membrane (Spectra-Pore, Spectrum Laboratories, Rancho Dominguez, CA). 
Following dialysis, purified products were isolated through azeotropic distillation 
with acetone followed by precipitation in ice-cold diethyl ether and finally followed 
by filtration and vacuum drying at ambient temperature for 7 days. A summary of 
the synthesized macromers is provided in Table 4.1. 
Nuclear magnetic resonance 
1H and 31P NMR spectra were obtained using a 500 MHz spectrometer 
(Inova, Varian, Inc., Palo Alto, CA). Samples were dissolved at a concentration 
of 20 mg/mL in equal parts CDCI3 and deuterated DMSO. Post-acquisition data 
analysis was performed using MestRe Nova software (Mestrelab Research S.L., 
Spain). 
Osmometry 
Freezing point osmometry was used to determine the number average 
molecular weight of the synthesized macromers. Macromers were dissolved at 
varying concentrations (0.5%-15% w/v) in ultrapure (Type I) water (Super Q, 
Millipore Corporation, Billerica, MA) and left overnight on an orbitally rotating 
platform. Samples were tested to determine which samples fell within the 
calibrated detection range of the osmometer (Osmette A, Precision Systems, 
Inc., Natick, MA), and osmometry measurements were performed on 1% w/v 
samples in triplicate. 
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Thermogravimetric analysis (TGA) 
Thermal stability of the synthesized macromers was analyzed under a 
nitrogen atmosphere (80 mL/min) using a TA Instruments TGA Q50. 
Approximately 5 mg of vacuum dried sample was ground into a fine powder and 
evenly distributed over the surface of a platinum sampling pan (TA Instruments). 
Samples were heated to 100 °C and held at that temperature for 5 minutes to 
remove residual moisture, after which the samples were heated from 100 °C -
800 °C at a rate of 10 °C/min. 
Rheology 
For Theological characterization of the macromers, samples were 
dissolved in ultrapure water, and pH was adjusted to 7.4 using 0.5 N NaOH. 
CaCb, NaCI, MgCb, were added to samples at varying (CaCl2 and MgCI2: 2.5 
mM, 100 mM, NaCI: 5 mM, 200 mM) concentrations. Sample concentration was 
finally adjusted to 7.5% w/v. All samples were left overnight on an orbitally 
rotating platform to ensure complete dissolution. 
Measurements were performed using a thermostatted, oscillating 
rheometer (Rheolyst AR1000, TA Instruments, New Castle, DE) equipped with a 
6 cm steel cone geometry (1°). Gelation properties and transition temperatures 
were determined as previously described.262 Briefly, samples were loaded onto 
the rheometer and cooled to 5 °C, presheared for 1 min (rate 1 s~1), and 
equilibrated for 15 minutes before a temperature sweep was performed from 5-60 
°C at a rate of 1 °C/minute and a displacement of 1 X10~ 4 rad. All formulations 
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were tested in triplicate, and analysis was performed using the manufacturer's 
supplied software (TA Data Analysis, TA Instruments). 
Differential scanning calorimetry (DSC) 
Transition temperatures were also determined by DSC. Samples were 
prepared in the same manner as performed for rheological characterization 
(7.5% w/v, pH 7.4), and 20 /JL of each sample were pipetted into an aluminum 
sample pan (TA Instruments, Newcastle, DE) that was then hermetically sealed. 
Experiments were performed in triplicate on a TA Instruments DSC 2920 with a 
refrigerated cooling system. Samples were equilibrated at 5 °C for 10 minutes 
and then heated to 60 °C at a rate of 5 °C/minute. 
Calcium-binding assay 
Samples were prepared in triplicate in ultrapure water (7.5% w/v, pH 7.4) 
augmented with CaCI2 at concentrations of 0.01 mM, 0.1 mM, 1 mM, 2.5 mM, 4.0 
mM, 10 mM, 25 mM, 100 mM, and 1000 mM and stored for 24h at 37 °C on a 
shaker table. After 24 h, the supernatant was removed, cooled to room 
temperature, and analyzed for residual calcium ions using a colorimetric calcium 
assay (Arsenazo III, Genzyme Diagnostics, Framingham, MA). Samples were 
diluted to within the assay's linear range {<. 5.0 mM), and sample concentration 
was determined by comparison to a standard curve using an absorbance 
microplate reader (650 nm, FLx800, Bio-Tek Instruments, Winooski, VT). 
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Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) characterization of macromers in aqueous 
solution was performed using a 90PLUS particle size analyzer (Brookhaven 
Instruments Corp, Holtsville, NY)) operating at 659 nm wavelength. Dilute 
macromer samples (0.01%, 0.10%, 0.25%, 0.5%, 1.0%, 2.5% w/v) were 
prepared in freshly filtered (0.22 jL/m, Millipore Corporation) ultrapure water with 0, 
100 fjM, 500 juM, 2.5 mM, 4.0 mM, 10 mM, or 100 mM of CaCI2 or control 
solutions with double the CaCI2 concentration of NaCI (200 /vM, 1 mM, 5 mM, 
etc.) to better elucidate effects due to calcium ions rather than chloride ions in 
solution. Prepared samples were left on an orbitally rotating platform overnight 
before sampling. DLS was performed on samples at 25 °C and 37 °C in 
triplicate; each sample was allowed to temperature equilibrate for 15 min prior to 
measurement. Intensity weighted size (Rh) distributions were determined from 
the autocorrelation function through the inverse Laplace transform non-negatively 
constrained least squares (CONTIN, regularized) algorithm.400 
Statistical analyses 
Statistical analysis was performed between groups for rheological and 
DSC characterization of transition temperature, TGA of residual sample weight 
percentages, and calcium binding assays. Analyses of variance were performed 
using Minitab® statistical software (Minitab, Inc., State College, PA) and an a 
priori significance level of 0.05. Pairwise comparisons were performed using 
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Tukey's HSD test. Where applicable, data are presented as mean ± standard 
deviation. 
4.3 Results and Discussion 
4.3.1 Macromer synthesis and structural characterization 
Macromers were synthesized as shown in Table 4.1. Relative molar 
contents of the macromers were calculated from 1H NMR spectra (Figure 4.1) 
and correlated well to the theoretical and actual comonomer feed ratios. The 
peak at 0.85 ppm was assigned to the methyl protons of PEDAS, peaks at 1.1 
and 1.2 ppm were assigned to the methyl protons contributed by NIPAAm and 28 
of the 32 methylene protons of the stearate chain of PEDAS, respectively, and 
the peak at 3.7 ppm was assigned to the backbone methine proton of VPA. A 
solvent (CD3(SO)) peak is visible at 2.5 ppm in all spectra. 31P NMR (Figure 4.1) 
also confirms the presence of the phosphorous in polymerized VPA at 30 ppm, 
close to previously reported values.401 VPA monomer impurities, previously 
reported to appear between 16.0-18.6 ppm on 31P NMR,401,402 were not observed 
after dialysis. 
Number average molecular weights as determined by freezing point 
depression osmometry are reported in Table 4.1. Consistent decreases in Mn 
were observed with increasing VPA in the monomer feed and subsequently in the 
synthesized macromers; however, the comonomer ratios of the synthesized 
macromers approximated the feed ratios well despite the slight variability in Mn. 
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These values are within the range of molecular weights for similarly synthesized 
macromers containing PEDAS and NIPAAm as reported by Hacker etal.262 
TGA curves (Figure 4.2) show 60-80% thermal decomposition of all 
macromers by 500 °C. Differential TGA curves (Figure 4.2) show a left shoulder 
followed by a peak at around 430 °C for the low and medium VPA containing 
macromers while the high VPA containing macromer shows two distinct peaks at 
310 °C and 380 °C along with a broad right shoulder extending from 410 °C to 
500 °C. Pure pNIPAAm has previously been shown to thermally decompose at 
422 °C; however, when copolymerized at high molar ratios with other monomers, 
the decomposition temperature of pNIPAAm falls.403 The TGA curve for the 
control macromer demonstrate this effect. The different character of the 
differential TGA curve for the high VPA containing macromer is likely due to a 
similar decrease in the decomposition temperature of pNIPAAm due to the 
relatively high NIPAAm composition of this formulation combined with cleavage 
of the more abundant carbon-phosphorus bond of polymerized VPA.404 
Figure 4.3 shows the average residual weight percentages at 800 °C for 
all VPA-containing macromers and the control macromer. Poly(VPA) or 
copolymers containing VPA or other pendant phosphorous moieties typically 
leave a nonvolatile residue of approaching 40 wt% when degraded in nitrogen.405, 
406
 The residual weight percentages for each synthesized macromer was 
significantly different from that of all the other synthesized macromers (p < 0.05) 
and the relative differences between the groups correlated well to the relative 
131 
differences in VPA molar ratios between the macromers, further verifying the 
incorporation of the VPA and its effect on macromer functional character despite 
the relatively low amounts of VPA present. 
4.3.2 Functional characterization 
Thermogelation by rheology and DSC 
Rheology and DSC were used to characterize the transition temperatures 
of the synthesized macromers. For rheological characterization, the gelation 
temperature, denoted Z, was considered to be the inflection point of the phase 
angle {6) curve. In general, below this inflection point the storage (G') and loss 
(G") moduli for each macromer remained below 1 Pa and then increased rapidly 
by at least 4 orders of magnitude at temperatures above T4. Figure 4.4 shows 
representative rheological traces of a 7.5% w/v aqueous macromer solution of 
VPA_H, as well as the effect of the presence of both divalent (Ca++) and 
monovalent (Na+) ions on the complex viscosity and phase angle during 
temperature sweeps. 
Using DSC, the transition temperature (TDsc) of the macromers was 
defined as the onset at inflection of the endothermic peak in the DSC 
thermogram. Transition temperatures for the synthesized macromers from both 
DSC (in water only) and rheological experiments are shown in Figure 4.5. 
Statistically significant differences (p < 0.05) were found for the T„ of all three 
VPA-containing macromers in water. Furthermore, for the VPA_H macromer, 
increasing concentrations of CaCl2 led to significant decreases in Tf when 
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compared to the same macromer in water alone and also when compared to 
similar solutions of VPA_M. TDsc values for the VPAJH macromer were 
significantly different from the low and medium VPA-containing macromers in 
water, and all three VPA-containing macromers had significantly lower Toscthan 
the control macromer, which was synthesized using AAm instead of VPA. 
Significant differences for Ta, of the Control_AAm macromer were also found in 
the presence of CaCI2 when compared to all of the VPA-containing macromers. 
At high concentrations (100 mM) of CaCI2, there were significant differences in 
the Ts, of the ControLAAm compared to the same macromer at lower (2.5 mM) 
salt concentrations. There were significant differences in the T„ of all VPA-
containing macromers in 100 mM CaCI2 when compared to the Ta, of the same 
macromers in 200 mM NaCI. There was, however, no significant difference 
between T„ in the presence of 100 mM CaCI2 or 200 mM NaCI for the control 
macromer. Changes due to the presence of MgCI2 compared to equimolar 
concentrations to CaCI2 were not significant (not shown). Additionally, no 
differences in TDsc were found in the presence of any salt solutions when 
compared to the macromer Tosc in water alone (not shown). It is important to 
note that due to the design of these macromers for biological and specifically cell 
delivery applications, all macromer solutions were characterized at pH 7.4. 
Adjustment of the pH with NaOH thus added slight variability in solution 
osmolarity between the VPA-containing macromers; however, the amount of salt 
contained in the tested solutions was greater than that used for pH adjustment. 
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Previous studies have shown that salts tend to decrease the LCST of 
pNIPAAm-based materials based on the concentration of the salt and following 
the trend of the Hofmeister series.407, 408 While these and other studies have 
shown that the DSC-determined transition temperature of the materials does 
change due to a salting out phenomenon, the concentrations of salt used to elicit 
these changes are far higher than those used in the current study.409 
Furthermore, the changes in transition temperature observed with DSC often 
differ with those reported using other methods.410, 411 In the present study, 
decreases in TDsc were not found in the presence of relatively low concentrations 
of salt; however, similar concentrations of salts containing divalent cations 
resulted in changes in sol-gel transition temperature (Ts) when detected using 
rheology. Considered along with the lack of change in TDSC, this more functional 
measurement of material gelation and the fact that equivalent salt concentrations 
with monovalent cations did not change the gelation temperature indicates that 
ionic crosslinking of macromer strands is likely responsible for this behavior 
rather than a salting out phenomenon. The transition is still primarily due to the 
hydrophobic collapse of the NIPAAm moieties, but ionic crosslinking likely gives 
the material the stability to meet the criteria for rheological gelation at a lower 
temperature than that which is detected calorimetrically. Fine-tuning of the LCST 
via the addition of salts or through the fabrication of materials that will interact 
with salts in situ could prove to be a useful technique for biomaterial applications. 
Gan et al. recently characterized microgel system of copolymerized NIPAAm and 
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2-hydroxyethyl methacrylate in a 7:3 ratio that required the presence of CaCb or 
sufficiently high concentrations of NaCI for the formation of a gel with increasing 
temperatures.412 This is likely due to the purely hydrophilic nature of the 2-
hydroxyethyl methacrylate comonomer, which allows rearrangement of the 
colloidal dispersion at high temperatures such that the collapsed NIPAAm 
domains arrange in the core of microgel particles, minimizing cohesive 
interactions between particles that would lead to gel formation. 
Previous work investigating the sol-gel transition of thermogelling 
copolymers of VPA and NIPAAm focused on copolymers synthesized from 
monomer feeds with a NIPAAm:VPA ratio of at least 9:1.413, 414 Comparing the 
sol-gel transition temperatures reported in the present study to those previously 
reported, much greater amounts of calcium ions were needed to elicit similar 
changes in the sol-gel transition temperature than those found using the current 
formulations, which have a much lower ratio of NIPAAm to other monomers. 
Although the magnitude of the sol-gel transition, with respect to viscosity 
increase, may be diminished due to the lower relative amount of NIPAAm, the 
proportionally higher amount of VPA enables larger changes in the LCST to 
occur at physiologically relevant calcium concentrations that should not be toxic 
to encapsulated cells or cells present at a delivery site. 
The pendant stearic acid chain of PEDAS likely contributes to this effect 
as well. Previous work has shown that for hydrogels with long pendant 
hydrophobic chains (R > Cs) binding and mixed micelle formation occurs with 
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surfactant molecules in a relatively concentration independent manner.415 
Additionally, cohesive associations between hydrophobic pendant groups has 
been shown to increase the mechanical toughness of hydrogels.416 From a 
design standpoint, PEDAS was included in the macromers for this reason, as for 
potentially mineralizable hydrogels to have a role in hard tissue applications such 
as bone tissue engineering, they will need to have a greater mechanical 
toughness and compressive properties than typically achieved with hydrogels. 
Thus a combination of the presence of the stearic acid chain of PEDAS and the 
relatively high VPA content of the macromers may explain the observed 
rheological changes at low salt concentrations relative to previous studies. 
Furthermore, the presence of additional functional moieties such as the hydroxyl 
group of HEA potentially allow for these macromers to be acrylated or 
methacrylated and then chemically crosslinked with increasing temperature. 
Such reactions have been carried out on similar macromers while not 
compromising the cytocompatibility of the macromers.417 Such covalent 
crosslinking could strengthen the gels at temperatures above the sol-gel 
transition temperature beyond what might be achieved by increasing the relative 
content of NIPAAm. 
Calcium-binding assay 
Macromer binding or complexation of free calcium ions in solution was 
measured by determining the concentration of free calcium ions in the 
supernatant of 7.5% w/v samples of each macromer after 24 h incubation. Data 
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are presented (Figure 4.6) as the absolute miliimoles of calcium ion bound per 1 
gram of macromer in solution. Statistically significant differences in calcium 
binding were present for all VPA-containing macromers at and above 
concentrations of 10 mM CaC^. Calcium binding for the ControLAAm macromer 
was significantly different from all macromers at concentrations of CaCl2 greater 
than and equal to 1 mM, except for formulations in 100 mM CaC^ solutions, 
where the binding was not significantly different from the VPA_M group. 
Increases in the bound Ca++ were observed for the ControLAAm macromers with 
increasing CaCI2 concentrations; however, given the rheological behavior of 
these macromers, these are thought to be nonspecific interactions such as 
entrapment in micelles or other salted out colloids. 
The ability of these materials to bind or complex calcium as described in 
this assay could potentially prove useful in a number of biological applications. 
Surface induced mineralization of a number of substrates has been 
demonstrated previously through surface modification with nucleating proteins or 
moieties that mimic such proteins has been demonstrated as a way to potentially 
increase orthopaedic implant adhesion to bone or to create a synthetic bone 
analogue.418"420 Many of these natural nucleators contain phosphoserines, and, 
when dephosphorylated or degraded lose their ability to interact with apatite 
mineral, leading to decreased calcification of the organic matrices to which they 
are associated and indicating the key role of these moieties in mineralization.421 
A number of strategies can be used to mineralize a synthetic matrix,169 including 
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modification with phosphoserine itself.422 Schneiders et al. modified 
hydroxyapatite/collagen composite bone cements with phosphoserine and after 
implanting the composites into a bone defect within a rat tibia found that new 
bone formation, particularly in the early phases of healing, was significantly 
greater in defects implanted with the phosphoserine modified composites 
compared to unmodified composites.423 
Phosphonic acid, the structure of which is similar to that of the 
phosphoserines found in many nucleators, has previously been used in 
biomaterials applications to improve the adhesion of dental cements to the 
mineralized components of teeth.401,424,425 Copolymers of VPA have been shown 
to mineralize in vitro over 1 month in a solution super saturated with calcium 
phosphate.426 Copolymers of VPA and AAm have also been shown to increase 
attachment and proliferation of fibroblasts and osteoblast like cells.427, 428 The 
interactions shown between the macromers synthesized in the present study and 
calcium ions similarly reflect the ability of phosphonic acid containing materials to 
interact with cations such as those found in the inorganic matrix of bone. In the 
present study, the presence of phosphonic acid along with calcium ions at 
concentrations similar to those found in plasma significantly affect the sol-gel 
transition of the material in a dose dependent manner, thereby facilitating 
additional control over the handling and delivery of such macromers in addition to 
the previously shown effect on mineralization and cell-material interactions. 
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Dynamic light scattering 
DLS experiments were used to characterize the behavior of dilute 
concentrations of macromers in aqueous solutions. The approximate critical 
micellar concentration (CMC), reported in Table 4.1, was determined by 
analyzing the size distributions of macromers over a range of concentrations and 
identifying the concentration at which there was a consistent increase in the peak 
particle size. Additionally, the effect of calcium ions on macromer conformation 
was analyzed through the addition of CaCl2. Representative size (Rh) 
distributions are shown in Figure 4.7. Control solutions containing NaCI were 
also examined at twice the molar concentration as the tested CaCI2 solutions to 
clearly elucidate the effect of divalent ions versus monovalent (Na+, CI") ions. 
In general, the CMC decreased with increasing VPA content. At 25 °C, 
the presence of calcium ions led to the disruption or prevented the formation of 
micelles for the experimental macromers at concentrations above the CMC but 
did not affect micelle formation of a control macromer that did not contain VPA 
(Figure 4.7). Increasing VPA content also led to decreased calcium sensitivity 
with respect to micelle formation, evidenced by lower concentrations of calcium 
eliciting a greater effect on the size distribution of macromers with low VPA 
content (not shown). For example, at 25 °C a 500 ^M CaCI2 solution consistently 
shifted the Rh peak intensity of the macromer containing the lowest relative VPA 
(VPA_L) content back to the radius observed at concentrations below the CMC, 
while for the macromer containing the highest relative amount of VPA (VPA_H), 
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similar changes were only observed in solutions containing greater than 500 JUM 
CaCb. This is potentially due in part to the larger size of macromers containing 
lower VPA content, as intramolecular salt bridging may be more likely in these 
macromers than for smaller VPAJH chains. Additionally, in the VPA_H chains, 
interactions of hydrophilic charged moieties with surrounding water are not 
stabilized in the presence of CaCk relative to VPA_L or VPA_M macromers, 
resulting in a greater propensity to form micelles to shield hydrophobic moieties 
from water, as reflected in the general trend for the CMC. 
Similar changes in the presence of calcium salts were previously observed 
for dispersions of poly(1,3-butadiene-co-methacrylic acid).429 In solutions with 
high enough pH that RCOO" groups were present, ionic crosslinking of with 
calcium ions prevented particle aggregation and swelling. In the present study, 
calcium ions were needed to prevent or disrupt micelle formation; however, NaCI 
did not have the same effect (not shown). NaCI decreased the CMC of all tested 
formulations, probably due to charge stabilization and reduced repulsion within or 
between macromers,430 whereas calcium ions may have facilitated 
intramacromer or intermacromer ionic crosslinking or, as a divalent ion in excess, 
may not have resulted in charge stabilization in binding to single phosphonic acid 
moieties. 
At 37 °C, all macromer formulations showed peak Rh greater than three 
times those observed above the CMC at 25 °C. This is likely due to micellar 
aggregation as the stearate chains of PEDAS probably still reside in the core of 
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the micelles, thus as NIPAAm undergoes hydrophobic collapse, stabilization of 
the hydrophobic moieties located oh the shell of the micelles is likely achieved 
through aggregation in a manner similar to that observed in previously studied 
PNIPAAm-based polymers.431"433 Below the CMC as determined at 25 °C, 
macromers tended to form micelles or aggregates upon temperature increases 
above 37 °C. The addition of NaCI and CaC^ did not have a noticeable effect on 
the peak Rh for macromers at 37 °C, as aggregation following hydrophobic 
collapse of the NIPAAm moieties likely drives micelle formation or chain 
aggregation rather than charge stabilization or ionic crosslinking, although when 
taken over a series of temperatures it is likely that the addition of salts would lead 
to a more discrete point at which micelles aggregate.434 Similarly, it is important 
to note that while 37 °C is below the LCST reported for some of the macromer 
formulations and conditions tested, Rh representing micellar aggregates were 
uniformly seen as the dominant species; however, the intensity weighted 
CONTIN method used to analyze the DLS exaggerates the proportion of large 
particles, thus for these samples, micellar aggregates may not have been the 
dominant species.435 
Polymeric micelles that can serve as nanocarriers for drug delivery are 
currently being investigated for a number of applications, including intracellular 
drug delivery.436"438 Micelles that respond to environmental stimuli present within 
pathological cell populations, such as decreased pH within cancerous tissue, or 
within specific intracellular domains, have been proposed as potential delivery 
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agents whereby disruption or rearrangement of the micelle conformation could 
result in environmentally-cued drug release.439 In the current study, VPA-
containing thermosensitive macromers did not form micelles in the presence of 
calcium ions below the LCST of the materials. Modifications such that the 
materials gel above body temperature or do not gel could enhance the potential 
for use of these materials in drug delivery applications to specific sites with higher 
local calcium content than surrounding environments, such as the lysosome.440 
4.4 Conclusions 
In conclusion, thermosensitive macromers based on PNIPAAm and other 
functional monomers, including VPA, were synthesized and characterized with an 
end goal of creating functional, environmentally responsive materials for 
biological applications. Because of this, macromers were characterized over 
temperatures ranging from room temperature to body temperature at 
physiological pH. The synthesized macromers incorporated the monomers in 
ratios close to those of the molar feed ratios and underwent a sol-gel transition 
close to body temperature. Due to the addition of vinylphosphonic acid, the 
macromers interacted with calcium ions in solution and underwent ionic 
crosslinking and subsequent decreases in the sol-gel transition temperatures at 
physiologically relevant calcium ion concentrations. This effect was dependent 
on the relative amount of vinylphosphonic acid incorporated in the macromer. At 
temperatures below the transition temperature, calcium ions prevented or 
disrupted micelle formation while at temperatures above the transition 
142 
temperature, hydrophobic interactions promoted aggregation of macromer 
micelles. Based on previous efforts in this area and the results presented, these 
macromers hold potential in drug and cell delivery applications as well as bone 
tissue engineering applications. 
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Table 4.1. Compositions, Molecular Weights, and Characteristics of Synthesized 
Macromers 
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O CH3 
+ ^ ^ N ^ C H s + 
H 
a b 
NIPAAm 
O ,? 
HO 
c d 
HEA VPA 
H3C' 8 
PEDAS 
AIBN/THF 
60 °C / N2 
H 3 C 7 8 
H3C CH3 
Scheme 4.1. Simplified schematic of the radical copolymerization of experimental 
macromers from pentaerthritoi diacrylate monostearate (PEDAS), N-
isopropylacrylamide (NIPAAm), 2-hydroxyethyl acrylate (HEA), and 
vinylphosphonic acid (VPA). A indicates possible branching sites in the highly 
simplified schematic of the branched statistical copolymer structure. 
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Figure 4.1. (A) 1H-NMR of the three experimental macromers of the form 
poly(PEDAS1-stef-VPAn-sfaf-HEA4.5.n-stef-NIPAAm1o.5) where the spectra represent: 
(1) VPA_H (n=3.375), (2) VPA_M (n=2.25), and (3) VPA_L (n=1.125). 
(B) Representative 31P-NMR of VPA_M verifying the presence of polymerized VPA 
in the macromer. 
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Figure 4.2. (A) TGA curve showing the degradation of the three experimental 
macromers (— VPA_H5 —• VPA_M, - VPA_L, — Control_AAm) thermally degraded 
at a rate of 10 °C/min in a nitrogen atmosphere. (B) Differential % weight loss as a 
function of increasing temperature. 
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VPA_H VPA_M VPA_L 
Macromer 
Control AAm 
Figure 4.3. Residual weight % (n=3, means ± SD) remaining after thermal 
degradation of macromer samples from 100 °C - 800 °C. 
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Figure 4.4. (A) Representative complex viscosity (\r\*\) rheograms of VPA_H. (B) 
Representative phase angle changes of VPA_H in aqueous solutions with and 
without added salts. Rheograms were obtained by increasing the temperature at 
a rate of 1 °C/minute and with a constant displacement of 1 x10~4 rad. 
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Figure 4.5. Gelation temperatures (n=3, means ± SD) or LCST as determined by 
rheology or DSC for all VPA-containing macromers and the control macromer. 
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Figure 4.6. Calcium binding or complexation for macromers was measured 
spectrophotometrically using a colorimetric calcium assay. The millimoles Ca++ 
bound per gram of macromers (inset depicts binding at low CaCI2 concentrations) 
is shown for macromers dissolved at 7.5 % w/v in H20. Data points and error bars 
represent means ± SD (n=3). 
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Figure 4.7. Representative hydrodynamic radius plots of (A) VPA_M and (B) 
ControLAAm macromers at different concentrations in water and in aqueous 
solutions with 2.5 mM CaCI2 at 25 °C. 
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Chapter 5 
Donor age and cell passage affects differentiation potential of murine bone 
marrow-derived stem cells+ 
Abstract 
Background: Bone marrow-derived mesenchymal stem cells (BMSCs) are a 
widely researched adult stem cell population capable of differentiation into 
various lineages. Because many promising applications of tissue engineering 
require cell expansion following harvest and involve the treatment of diseases 
and conditions found in an aging population, the effect of donor age and ex vivo 
handling must be understood in order to develop clinical techniques and 
therapeutics based on these cells. Furthermore, there currently exists little 
understanding as to how these two factors may be influenced by one another. 
Results: Differences in the adipogenic, chondrogenic, and osteogenic 
differentiation capacity of murine MSCs harvested from donor animals of different 
age and number of passages of these cells were observed. Cells from younger 
donors adhered to tissue culture polystyrene better and proliferated in greater 
number than those from older animals. Chondrogenic and osteogenic potential 
t
 This chapter was published as: Kretlow, J. D.; Jin, Y. Q.; Liu, W.; Zhang, W. J.; Hong, 
T. H.; Zhou, G.; Baggett, L. S.; Mikos, A. G.; Cao, Y., Donor age and cell passage 
affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol 
2008, 9, 60. 
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decreased with age for each group, and adipogenic differentiation decreased 
only in cells from the oldest donors. Significant decreases in differentiation 
potentials due to passage were observed as well for osteogenesis of BMSCs 
from the youngest donors and chondrogenesis of the cells from the oldest 
donors. 
Conclusions: Both increasing age and the number of passages have lineage 
dependent effects on BMSC differentiation potential. Furthermore, there is an 
obvious interplay between donor age and cell passage that in the future must be 
accounted for when developing cell-based therapies for clinical use. 
Abbreviations 
AdMSC(s) 
BMSC(s) 
eGFP 
FBS 
GAG 
IGF 
IHC 
MSC(s) 
PPARv 
TGF-pi 
TNFa 
adipose-derived mesenchymal stem cell(s) 
bone marrow-derived mesenchymal stem cells(s) 
enhanced green fluorescent protein 
fetal bovine serum 
glycosaminoglycan 
insulin-like growth factor 
immunohistochemistry 
mesenchymal stem cell(s) 
peroxisome proliferator-activated receptor y 
transforming growth factor (31 
tumor necrosis factor a 
158 
5.1 Introduction 
As the prospect of stem cell based therapeutics entering the clinic 
becomes more of a reality, researchers and clinicians must account for variability 
among stem cell populations used to evaluate therapeutic modalities in 
regenerative medicine and also among the patient populations that will potentially 
provide autogenous or allogeneic stem cells.441"443 As hinted by the role of stem 
cell senescence and dysfunction in natural aging,444"447 donor or patient age will 
be a critical factor that must be accounted for in clinical and laboratory 
evaluations of stem cell based technology. 
There is currently little consensus and in many cases conflicting reports 
regarding the effect of donor age and cell processing on adult mesenchymal 
stem cell (MSC) function. A number of studies have previously shown no age 
related differences in differentiation using human BMSCs;448"451 however, many 
studies demonstrating no change in differentiation have found changes in 
proliferation, attachment, senescence or self-renewal in mouse,452 rat,453,454 and 
human455 456 BMSCs. Using mouse adipose derived MSCs (AdMSCs), Shi et al. 
found an age related decrease in adipogenic differentiation but no difference in 
osteogenic differentiation,457 while Wall et al. found that with increasing passage, 
human AdMSCs tended towards osteogenic differentiation over adipogenic 
differentiation.458 Similarly, work by Kirkland et al. found that advanced age in 
rats results in decreased levels of mRNA associated with adipogenic 
differentiation in preadipocytes,459 a change that has since been linked to 
159 
decreased expression of CCAAT/enhancer binding protein (C/EBP)-a,460 caused 
by overexpression of C/EBP homologous protein, and increased release of 
TNFa.461 In contrast, studies have found an age related decrease in osteoblastic 
but not adipogenic differentiation in BMSCs from rats462 and humans.463, 464 
Numerous other studies have found significantly decreased differentiation 
capability with increasing BMSC donor age, particularly for osteogenic,465"467 
chondrogenic,468 and myogenic469 differentiation. 
Another important parameter that must be considered, particularly 
because of decreased proliferation and the propensity towards senescence 
observed in cells from aged donors, is the effect of cell passage on the 
differentiation capability of adult MSCs. BMSCs largely lose their in vitro 
differentiation capability at or around the 6th passage,470,471 but there is evidence 
of adverse changes as early as the first472 or second passage.467 In vivo benefits 
from MSC based therapies are also abated with increased passage.473 
Interestingly, however, while some reports indicate an age related decline in 
adipogenic differentiation capability for AdMSCs457 and a similar passage related 
decline in osteogenic differentiation capability with a simultaneous enhancement 
in adipogenic differentiation,471 previous results and hypotheses suggested that 
with increasing passage cells progressed through a lineage hierarchy, whereby 
bone marrow derived progenitors would retain a capacity towards osteogenic 
differentiation and adipose derived progenitors towards adipogenicity.474 Recent 
comparisons of human BMSC and AdMSC differentiation475 and 
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transcriptomes476 supports this hierarchical model of preferential or retained 
differentiation. 
In the only published study that examined the combined effects of 
increased in vitro passages and donor age on BMSC differentiation, Stenderup et 
al. examined osteogenic and adipogenic differentiation of human BMSCs.456 
They found decreased osteoblastic and adipogenic differentiation with increased 
number of passages for BMSCs from both young and old donors, but did not 
observe effects on differentiation when comparing across the two age groups. 
To simultaneously evaluate the effects of both age and passage on BMSC 
differentiation, we utilized a full factorial study design investigating the 
adipogenic, chondrogenic, and osteogenic differentiation of mouse BMSCs from 
postnatal, adult, and aged mice at passage 1 and passage 6. The objective of 
such a study design was to provide a controlled analysis of two variables (age 
and passage) and possible interaction between these crucial factors in 
developing adult stem cell based therapeutics and for which no consensus exists 
regarding their role in MSC differentiation. 
5.2 Methods 
5.2.1 Experimental design 
This study uses a factorial design to investigate the effects of donor age 
and cell passage on BMSC differentiation into 3 mesenchymal lineages. Murine 
bone marrow derived mesenchymal stem cells were harvested from donors aged 
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6 days (postnatal), 6 weeks (adult), and 1 year (aged) and cultured through either 
1 or 6 passages before differentiation was induced. The harvested and cultured 
cells used were the adherent population of cells within the bone marrow and are 
often referred to as either marrow stromal cells or mesenchymal stem cells (a 
sub-population of marrow stromal cells). For this study, the adherent cell 
population examined will be referred to as bone marrow derived mesenchymal 
stem cells or BMSCs. 
5.2.2 BMSC harvest and culture 
All experiments followed protocols approved by the Animal Experiment 
and Care Committee of Shanghai Jiao Tong University School of Medicine. 
Postnatal (6-day old), adult (6-weeks old), and aged (1-year old) transgenic male 
eGFP C57BI/6 mice were obtained from a local breeder colony. Mice were 
euthanized via cervical dislocation and bilateral thoracotomy and then immersed 
in 75% ethanol for 15 minutes. The bilateral femurs and tibias were aseptically 
excised, stripped of connective tissues, and the epiphyses and metaphyses were 
then removed. The remaining diaphyses were placed in a culture dish with 7.5 
ml sterile PBS, and the bone marrow was flushed from the shafts via 3-5 minutes 
of vigorous pipetting of the PBS. The PBS/marrow suspension was then filtered 
through a 70-^ ym cell strainer (BD Biosciences, Mississauga, ON, Canada), 
collected and centrifuged for 5 minutes at 524xg. After removal of the 
supernatant, the resulting pellet was resuspended in a-MEM supplemented with 
10% fetal bovine serum (FBS, HyClone, Logan, UT), 2mM L-glutamine and 
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plated at a density of 1.7-2.0x1 o4 cells/cm2. Media were changed every 3 days, 
and cells were passaged when confluent (~5xio4 cells/cm2) with 0.05% trypsin in 
0.02% ethylenediaminetetraacetic acid (Gibco, Canada). Cells were replated at 
a density of 3X10 3 cells/cm2. First and sixth passage cells were used as indicated 
for all experiments. Each experiment was performed with cells pooled from 2-7 
mice for each age group. Experiments were repeated in triplicate using different 
batches of marrow isolates. 
5.2.3 Cell attachment and proliferation 
After harvesting and resuspension, cells from postnatal, adult, and aged 
mice were plated individually in wells of 6-well tissue culture plates at a density of 
1xio4 cells/cm2. At Vz, 1, 2, 4, 8, 16, and 24 hours after plating, media were 
gently aspirated and the remaining cells were fixed with 4% paraformaldehyde 
(Sigma, St. Louis, MO) in phosphate buffered saline (PBS) for 15 minutes. Cell 
adhesion was measured by counting the total cell number per well under 
fluorescence. 
For proliferation, first passage cells from postnatal, adult, and aged mice 
were plated individually at 2xio3 cells/cm2 in wells of 6-well tissue culture plates. 
At days 1, 2, 4, 6, and 8 cells were trypsinized and counted using a 
hemacytometer. 
Attachment and proliferation assays were performed in triplicate. Cell 
doublings were calculated as:477 doublings = log2 (number of cells at 
passage/number of cells seeded). 
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5.2.4 Adipogenic differentiation and characterization 
As previously described,478 the first or the sixth passage cells were 
seeded in 2 wells each of a 6-well plate at a density of 3000 cells/cm2. Cells 
were maintained for 24 hours in regular culture media, after which adipogenic 
differentiation was induced using Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10% FBS, 0.5 mM isobutylmethylxanthine, 10 JUM insulin, 1 
fjM dexamethasone, and 200 /vM indomethacin (all from Sigma) for 3 weeks with 
full medium changes performed every 3 days. 2 control wells were maintained in 
DMEM with 10% FBS over the same time course. Each experiment was 
repeated in triplicate, resulting in 6 total wells for adipogenic differentiation and 6 
control wells. 
Differentiated and control wells were stained with Oil Red O. At 3 weeks 
post-induction, wells were gently rinsed with PBS and then fixed with cold 4% 
paraformaldehyde for 10 minutes. Wells were then washed with 60% isopropyl 
alcohol (Sigma), incubated for 5 minutes at room temperature in 2% (w/v) Oil Red 
O reagent (Sigma), and then washed once with isopropyl alcohol followed by 
repeated washes with distilled water. 
For each well, 3 fields were randomly chosen and examined by light and 
fluorescence microscopy. The number of total cells per field was determined 
under fluorescence followed by determination of the number of cells containing 
Oil Red O stained inclusions. A cell containing a visibly stained vacuole was 
considered to be positively stained. Additionally, for each view the percent area 
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of positive staining was determined using ImageJ (NIH, Bethesda, MD). The 
area stained was determined by quantifying the actual area stained rather than 
the area covered by cells containing stained vacuoles. The average percentage 
was determined from total 3 views of each well and means plus standard 
deviation were derived from the average percentage of total six wells. 
5.2.5 Chondrogenic differentiation and characterization 
As previously described,478 following monolayer culture until the first or the 
sixth passage, cells were trypsinized, counted, and centrifuged into pelletted 
micromass cultures (5x1 o6 cells/pellet) in 15 ml conical tubes (BD Biosciences). 
After centrifugation and culture in regular culture media for 24 hours, 
chondrogenesis was induced using low glucose DMEM supplemented with 10% 
FBS, 10 ng/ml TGF-(31, 100 ng/ml IGF (Peprotech, Rocky Hill, NJ), and 10 nM 
dexamethasone (Sigma). Cells were cultured in induction or control media (low 
glucose DMEM with 10% FBS only) in incubators with the conical tube lids 
loosely fastened for 3 weeks and half media were changed every other day. 
Four pellets (2 for induction, 2 for control) per age/passage batch were cultured, 
and each batch was repeated in triplicate. 
Following culture, 3 pellets from each group were analyzed for type II 
collagen expression and glycosaminoglycan (GAG) quantification. 
Immunohistochemical staining was performed as previously described.479 Briefly, 
pellets were fixed with 4% paraformaldehyde for 2h and embedded in Tissue-Tek 
OCT (Fisher Scientific, Pittsburgh, PA) and sliced into 10 (jm thick sections. 
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Samples were blocked and incubated overnight at 4°C in 1:100 diluted mouse 
anti-Collagen-ll (Lab Vision, Fremont, CA) in 1% bovine serum albumin (Sigma) 
PBS solution. Samples were then incubated with horseradish peroxidase (HRP)-
conjugated goat anti-mouse antibody (DAKO, Carpinteria, CA) diluted in 
phosphate buffered solution (PBS, 1:100) for 30 minutes at room temperature 
and developed with diaminobenzidine tetrachloride (DAB). Cells were 
counterstained with hematoxylin. Slides were also stained with Safranin O by 
being fixed for 10 minutes in 10% formalin in PBS, rinsed with distilled water, and 
then stained for 2 minutes with 6% Safranin O (Sigma) in distilled water. 
Sulfated GAG production was measured from the remaining 3 pellets per 
group using an Alcian blue binding assay as previously described.480 
5.2.6 Osteogenic differentiation and characterization 
As previously described,478 the first or the sixth passage cells were 
seeded in 2 wells each of a 6-well plate at a density of 3000 cells/cm2 as similarly 
performed in 2.3. Cells were maintained for 24 hours in regular culture media, 
after which they were cultured in low glucose DMEM supplemented with 10% 
FBS, 0.1 jL/M dexamethasone, 50 /JM ascorbate-2-phosphate, and 10 mM |3-
glycerophosphate (all from Sigma) to induce osteogenic differentiation. The 
induction culture was maintained for 3 weeks with full medium changes every 3 
days, whereas the control cells were cultured for 3 weeks in low glucose DMEM 
with 10% FBS. Experiments were performed in triplicate. 
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Following culture, 3 wells per group were stained with Alizarin Red to 
visualize calcified deposits. Wells were gently rinsed with PBS and then fixed 
with 70% ice-cold ethanol for 1 hour. After washing with distilled water, Alizarin 
Red solution (40 mM Alizarin Red-Tris-HCI, pH 4.1; Sigma) was left at room 
temperature in wells for 10 minutes. Wells were then extensively washed with 
distilled water to remove any nonspecific staining, and the stained area was 
quantified using ImageJ as in 2.4. For the remaining 3 wells per group, calcium 
cation (Ca2+) concentration was determined via a colorimetric assay (Diagnostic 
Chemicals, Charlottetown, PEI, Canada) as previously described.481 
5.2.7 Statistical analyses 
Analyses of variance (ANOVA) were performed using SAS software (SAS 
Institute Inc., Cary, NC), followed by Tukey's multiple comparison tests to 
determine pairwise statistical significance within 95% confidence intervals 
(p<0.05). All results are reported as means ± standard deviations. Due to quasi-
complete separation, binary logistic regression was not performed on the data for 
collagen II staining of pellets. 
5.3 Results 
5.3.1 Postnatal BMSCs exhibit more rapid proliferation and greater 
attachment than BMSCs from aged donors 
Following primary harvest, equal numbers of BMSCs were plated in 6-well 
plates and attachment was measured over 24 hours. Overall, donor age was 
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found to have a statistically significant effect on cell attachment (p<0.0001). As 
shown in Figure 5.1, at 8 hours and beyond there were significant differences 
(p<0.05) in attachment between cells harvested from both 6-day and 6-week-old 
donors and cells harvested from 1 -year-old donors. Over 24 hours there were no 
significant differences in attachment between cells from 6 day and 6-week-old 
donors (p>0.05). 
Proliferation was assessed for 8 days following primary harvest. After 2 
days there was significantly greater proliferation among cultures harvested from 
6-day-old donors compared to cultures from 6-week and 1-year-old donors 
(p<0.Q5, Figure 5.2). This significant difference persisted throughout the 8 days 
of culture. At 6 and 8 days, significant differences in proliferation were also 
observed between cultures from 6 week and 1-year-old donors (p<0.05). Overall, 
donor age was found to have a statistically significant effect on cell proliferation 
(p<0.0001). There was a 4.9 ± 0.2 fold increase in cell number in cultures of 
postnatal BMSCs after 8 days compared to cell number after 24 hours, and 
confluence in these cultures was reached by day 6. An increase of 3.9 ± 0.2 and 
3.0 ± 0.1 fold was observed in cultures from adult and aged donors compared to 
cell numbers after 24 hours, respectively. For the differentiation experiments, 
passage 1 cells had undergone approximately 2.7 cell doublings, while passage 
6 cells had undergone 11.4 doublings. Cells from 6-day-old donors doubled in 
approximately 2.3 days, with little variation between passage 1 and 6, while cells 
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from 6-week-old and 1-year-old donors had approximate cell doubling times of 
3.1 and 3.5 days over the entire culture duration, respectively. 
5.3.2 Adipogenic potential is diminished in BMSCs from aged donors 
To assess the adipogenic potential of BMSCs, Oil Red O staining was 
quantified following 3 weeks of culture in standard adipogenic media. 
Quantification was performed in 2 ways, firstly by determining the percentage of 
cells that contained Oil Red O stained lipid laden vacuoles, and secondly by 
determining the overall area within a field of view that was stained by Oil Red O. 
Figure 5.3 shows results of both quantification methods along with representative 
histology from each group. 
Based on the percentage of cells staining positive for lipid inclusions, there 
were no significant differences between cells from 6-day and 6-week-old donors, 
and within these groups there were no differences between cells at passage 1 or 
6. A significantly lower percentage of cells stained positive with Oil Red O was 
found in 1 -year-old donors comparing to passage matched numbers of 6-day and 
6-week groups fp<0.05). Additionally, within 1-year old group there was also a 
statistically significant difference between passage 1 and passage 6 cells (52.9 ± 
14.7 percent versus 37.7 ± 8.9 percent, p < 0.05). Based on the percentage of 
cells stained, all groups were significantly different from corresponding age and 
passage matched controls (p<0.05), and there were significant overall effects 
related to both donor age (p<0.0001) and cell passage (p<0.05). Additionally, 
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there was a significant statistical interaction effect (p<0.05) between donor age 
and cell passage for this method of quantifying adipogenic differentiation. 
Quantifying the area stained with Oil Red O showed no statistically 
significant differences in adipogenic differentiation of BMSCs between 6-day and 
6-week-old donors when compared at the same passage (passage 1: 17.7 ± 4.2 
percent versus 17.7 ± 4.4 percent, passage 6: 13.4 ± 3.3 percent versus 11.0 ± 
3.9 percent, 6-day and 6-week donors respectively). At the same passage, 
BMSCs from 1-year-old donors revealed statistically significantly less adipogenic 
staining area (passage 1: 8.1 ± 2.8 percent, passage 6: 5.2 ± 1.7 percent) than 
similarly passaged cells from younger donors (p<0.05). For cells from aged 
donors, there was also no significant effect of increased passages (p>0.05), 
whereas in the other two donor age groups, passage significantly decreased the 
area stained (p<0.05). In all groups BMSCs displayed significantly different 
stained areas than age and passage matched controls (p<0.05) except for 
passage 6 BMSCs from 1-year-old donors (5.2 ± 1.7 percent vs. 2.3 ± 1.6 
percent stained, p>0.05). Significant overall effects were determined for donor 
age (p<0.0001) and cell passage (p<0.0001); however, there was no statistically 
significant interaction between donor age and passage based on the area stained 
(p>0.05). 
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5.3.3 Chondrogenic potential decreases with age and repeated passage 
abrogates chondrogenic differentiation in aged donors 
Sulfated glycosaminoglycan content was quantified for pellets cultured for 
3 weeks in chondrogenic media. As shown in Figure 5.4, compared across 
donor age groups at constant passage, sulfated GAG content per pellet 
significantly decreased with each progressive increase in donor age (p<0.05). 
Increased passage of cells yielded statistically significant differences within donor 
age matched groups only for BMSCs from 1-year-old donors (2.9 ± 1.2 /vg per 
pellet versus 0.6 ± 0.6 ^g per pellet, p<0.05). Additionally, passage 6 BMSCs 
from 1-year-old donors did not display significantly more sulfated GAG per pellet 
than passage and donor age matched controls (1-year, passage 6 control: 0.1 ± 
0.1 /vg per pellet, p>0.05). All other groups had significantly greater GAG content 
per pellet than passage and age matched controls (p<0.05). Overall, donor 
animal age (p<0.005) but not cell passage (p>0.1) was found to have a 
significant affect on the amount of sulfated GAG per pellet. 
To further evaluate chondrogenesis, pelleted tissue was 
immunohistochemically stained for collagen II. As shown in Table 5.1, with the 
increase of donor age and cell passage, the number of collagen ll-positive pellets 
decreased. In addition, a typical lacunar structure was observed in histology of 
collagen ll-positive pellets as shown in Figure 5.4. 
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5.3.4 Osteogenic potential decreases with age and passage only affects 
postnatal -harvested BMSCs 
Osteogenic potential was determined by quantifying the percent area 
stained with Alizarin Red, a dye that stains calcium deposition, and by 
determining the amount of extracellular calcium within a well. Both measures 
showed that within age groups, the only statistically significant difference based 
on passage was found in BMSC cultures from postnatal donors (Figure 5.5, 
p<0.05), where passage 1 cultures displayed 46.7 ± 9.0 percent area stained and 
0.27 ± 0.06 mM Ca2+ versus 31.1 ±10.1 percent area stained and 0.2 ± 0.04 mM 
Ca2+ for passage 6 cultures. BMSCs from 6-week-old and 1 -year-old donors did 
not show significant differences in osteogenic potential for cultures at different 
passages. For both passage 1 and passage 6 cultures, an overall decreased 
osteogenic potential was found with increased donor age for all ages of donor in 
term of both area and calcium content (p<0.05). Tukey's multiple comparison 
tests revealed a significant difference of any two passage-matched groups 
comparisons in either stained area or calcium content (p<0.05), except for 
passage 6 stained area between 6-day-old and 6-week-old donors (31.1 ± 10.1 
percent versus 27.2 ± 8.0 percent, p>0.05). Representative micrographs 
showing Alizarin Red stained samples are also displayed in Figure 5.5. The 
percent area stained using Alizarin Red was significantly different from age and 
passage matched controls (p<0.05); however, the calcium assay showed no 
significant difference between control and induced groups for both passage 1 and 
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6 BMSC cultures of 1 year old donors (p>0.05). Analysis of both stained area 
and calcium content showed a significant effect of donor age (p<0.001); however, 
analysis of stained area showed a significant overall effect for passage (p<0.001) 
while analysis of calcium content did not show an overall effect for passage 
(p>0.05). No statistically significant interaction was found between donor age 
and passage for either method of evaluation of osteogenic differentiation. 
5.4 Discussion 
In the present study, we investigated the effects of both donor age and 
passage on murine BMSC differentiation potentials towards adipogenic, 
chondrogenic, and osteogenic lineages. Murine BMSCs were used to facilitate 
future studies performed in vivo, where implantation of tissue engineering 
constructs containing fluorescently labeled progenitor cells allows histologic 
determination of the cell source for regenerated tissues.482"485 Additionally, the 
availability of transgenic mice and mouse cell lines presents the opportunity for 
tissue engineers to investigate emerging strategies in more clinically appropriate 
disease models.486 It is important, however, to note that transgenic animals do 
not uniformly express GFP, and this expression is variable between tissues with 
values for murine bone marrow reported at close to 90%487 in some studies but 
significantly lower in others,488 thus necessitating a careful comparison of light 
and fluorescence microscopy when cell numbers are quantified. Routine flow 
cytometric characterization of the breeder colony used in this study has 
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repeatedly shown over 90% of adherent marrow cells express GFP, even after 
multiple passages (unpublished data). 
No standardized practice exists for the harvest, expansion, and in vitro 
differentiation of BMSCs. As noted in the Materials and Methods section, 
BMSCs in this study and many others refers to the adherent marrow stromal 
cells456, 476, 489. Within the adherent BMSC-containing population, our data 
suggest that a more rapid decline occurs in differentiation potential for 
osteoblastic and chondrogenic lineages relative to the decline in adipogenic 
differentiation. 
We found that osteogenic and chondrogenic potentials are adversely 
affected by increased donor age across all three tested donor age groups, while 
adipogenic differentiation potential is maintained in all but the aged donors (1 
year). These results are in agreement with previous work which found that donor 
age affected osteogenic differentiation of BMSCs more than it affected 
adipogenic differentiation.464 Analysis of the transcriptomes of human BMSCs at 
passage 2 from young donors (average age = 13) suggested that BMSCs should 
preferentially form bone and cartilage over adipose tissue.476 Peng et al. recently 
found similar results, noting that expression of osteogenesis-related genes 
peaked very early following induction in BMSCs.490 Other studies addressed the 
hypothesis that age related decreases in bone regeneration were due to BMSC 
aging, resulting in a decreased osteogenic potential with a concurrent increase in 
adipogenic potential.448 In this study BMSCs maintained their potential for 
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adipogenic differentiation in early aging but exhibited decreased potential for 
chondrogenic and osteogenic differentiation, and, although no absolute increase 
in adipogenic potential was observed with increasing age, the relative differences 
between differentiation potentials with age would thus favor adipogenesis over 
osteogenesis and chondrogenesis. Age related cellular dysfunction has been 
hypothesized to be the cause of multiple diseases of bone and cartilage 
associated almost exclusively with aging including osteoarthritis and 
osteoporosis, and loss of progenitor cell differentiation potential could contribute 
to these diseases.491 The present study supports these hypotheses. 
The effect of in vitro culture period prior to the induction of differentiation 
was also investigated by expanding cells through 6 passages and comparing 
differentiation to cells after a single passage. For chondrogenesis, increased 
passage only affected cells from 1-year-old donors, rendering them equal to 
control groups at the level of significance (p>0.05). For osteogenesis, the 
opposite effect was observed; a difference in osteogenesis due to passage alone 
was only observed in BMSC cultures from postnatal mice. Previous work using 
human BMSCs observed a greater passage related decrease in osteogenic 
differentiation in cells from young donors compared to cells from aged donors.456 
Early passage postnatal BMSCs may be preferentially inclined towards 
osteogenesis and this preference may be quickly eliminated with repeated 
passages and aging, leading to the observed differences between passage 1 
postnatal BMSCs and all other groups with respect to osteogenic differentiation. 
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The effect of passage on adipogenesis was more obscure. Quantifying 
the percentage of cells stained with Oil Red O showed significant passage 
related differences only in cultures from aged donors, whereas quantifying the 
percentage area stained showed significant differences in cultures from postnatal 
and adult donors but not those from aged mice. A previous study investigating 
adipogenic differentiation with increasing BMSC passages found that the size of 
adipocytes decreased with increased passage.456 Thus for postnatal and adult 
derived BMSCs, passage related changes in area might be largely due to 
decreased cell volume rather than a decrease in the number of differentiated 
cells. In cultures of BMSCs from aged donors, the relatively decreased number 
of cells undergoing adipogenic differentiation may render this effect statistically 
insignificant at the designated sample size (n=6). When characterizing 
adipogenic differentiation via quantification of the percentage of cells stained with 
Oil Red O, the statistically significant interaction effect of donor age and passage 
reflects that cultures from aged donors were the only group to be both 
significantly decreased from other age groups and to have a significant decrease 
in cells stained between passage 1 and passage 6 cultures. This may reflect a 
loss of adipogenic differentiation capacity only experienced by MSCs from aged 
donors that is not detected when quantifying the stained area due to passage-
related decreases in adipocyte size experienced in cultures from all donors. It is 
also important to note that the selected adipogenic cocktail utilized indomethacin, 
a commonly used chemical for these applications that inhibits cyclooxygenase. 
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Indomethacin has been shown to both positively and negatively effect PPARy in a 
concentration dependent manner.492 Although adipogenic differentiation can be 
induced via PPARy dependent and independent signaling,493 PPARy2 activation 
may be critical in BMSC differentiation as this pathway this pathway promotes 
terminal differentiation and suppresses Osf2/Cbfa1.494 A PPARy ligand such as 
rosiglitazone may therefore be a more ideal component for adipogenic induction 
media for BMSCs. 
Working with human BMSCs, Banfi et al. found decreased adipogenic, 
chondrogenic, and osteogenic potentials when increasing from passage 1 to 
passage 5 and found adipogenic potential to be compromised prior to osteo- or 
chondrogenic potential.472 In the present study, passage effects were variable 
when considered along with specific donor ages. For example, for 6-week-old 
donors, osteogenesis and chondrogenesis were unaffected by passage, but 
adipogenesis as measured by percent area stained was significantly decreased 
with increased passage. These results correlate well to published studies using 
human BMSCs;472, 474 however, it should be noted that due to the use of 
biochemical characterization methods in addition to histology to characterize 
osteogenic and chondrogenic differentiation, the sample size for these methods 
was smaller (n=3) than for evaluation of adipogenic differentiation (n=6). Passage 
adversely affected osteogenic potential in BMSCs from postnatal donors, while 
chondrogenesis was only diminished by passage in BMSCs from 1-year-old 
donors, suggesting differences in passage effects for different differentiation 
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lineages at different ages. When evaluating changes associated with passage, it 
is important to note that the adherent marrow stroma is a heterogeneous cell 
population, therefore there is concern that changes attributed to altered MSC 
function could actually be due to the preferential proliferation of one or several 
type(s) of cell(s) over others. The observed variable effects of passage with age 
suggest that different or additional factors other than BMSC number and 
differences in attachment/proliferation contribute to differences in differentiation 
potential, as, in the case that heterogeneity and subsequent differential 
proliferation, one would expect effects due to frequency or proliferation to be 
exhibited across all lineages. 
5.5 Conclusions 
Based on the results of this study and many other previous studies, it 
appears that many variables must be considered when choosing an ideal or 
appropriate cell source for a specific application. Future studies should address 
tissue regeneration in vivo, as this will allow parameters such as aging and 
passage to be compared using criteria more closely related to the clinical goal of 
regenerating destroyed or dysfunctional tissues. As more is learned regarding 
aging and passage of adult stem cells, it may be determined that a certain 
population of cells is more appropriate for specific therapies based on patient age 
and the tissue of interest. While the present study offers little in the way of 
mechanistic explanations for the observed phenomena, it provides one of the first 
analyses of age in combination with passage in an animal model that will be 
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useful for developing future tissue engineering strategies. There is little doubt 
that aging of adult stem cells plays a role in the spectrum of changes during 
normal aging and that consideration of age and passage in combination will 
prove to be critical to the success of any strategy that seeks to regenerate tissue 
through the use of implanted progenitor cells. 
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5.6 Figures 
Table 5.1 The ratio of collagen II positive pellets 
6 day 6 week 1 year 
Passage 1 3/3 3/3 1/3 
Passage 6 3/3 2/3 0/3 
Table 5.1. The ratio of collagen II positive pellets to pellets cultured per group, 
denoted as x:3, where x is the number of pellets staining positively for collagen II. 
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Figure 5.1. BMSC attachment. Results from the 24-hour assessment of BMSC 
attachment immediately following harvest. The '#' sign indicates significant 
differences between cells harvested from both 6-day and 6-week-old mice and 
those harvested from 1-year-old mice. Error bars designate means ± standard 
deviation (n=3, p<0.05). 
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Figure 5.2. BMSC proliferation. Resuits from the 8-day assessment of BMSC 
proliferation during primary cell expansion. The '±' symbol indicates significant 
differences between cells harvested from 6-day-old mice and all older donors. 
The '*' symbol indicates significant differences between groups from all donors. 
Error bars designate means ± standard deviation (n=3, /x0.05). 
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Figure 5.3. Adipogenic differentiation. Results of adipogenic differentiation after 
3 weeks. (A) Representative micrographs showing Oil Red O stained lipid 
inclusions in cultured BMSCs from each experimental group. Magnification bars 
represent 100 pm in all images. (6) Percentage of cells that had intracellular Oil 
Red O stained inclusions after 3 weeks. Passage related significant difference in 
staining was only observed in BMSC cultures from 1-year-old donors (p<0.05). (C) 
Percentage of total area that was positively stained with Oil Red O. Passage 
related significant differences were observed for BMSC cultures from 6-day and 
6-week-old donors, and age related differences were only observed between 1-
year-old donors and the other groups. The '#' sign indicates a significant 
difference between passage 1 and passage 6 cultures from similarly aged donors, 
'$' indicates a significant difference between the indicated group and any 
passage 1 groups from younger donors, and '¥' indicates a significant difference 
between the indicated group and any passage 6 groups from younger donors 
(p>0.05). Error bars designate means ± standard deviation (n=6). 
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Figure 5.4. Chondrogenic differentiation. Results of chondrogenic differentiation 
of pelletted micromasses after 3 weeks. (A) Representative micrographs of 
differentiated micromasses from passage 1 cells of 6-day-old donors. Safranin O 
(left), hematoxylin and eosin {middle), and immunohistochemical staining for 
collagen II (right) staining were used to show the morphological structure and 
biochemical components of induced pellets. The inset demonstrates the lacunar 
morphology typically observed in cartilage. Magnification bars represent 100 j/m 
in all images. (B) Micrograms of sulfated GAG per pellet. The '#' sign indicates a 
significant difference between passage 1 and passage 6 cultures from similarly 
aged donors, '$' indicates a significant difference between the indicated group 
and any passage 1 groups from younger donors, and '¥' indicates a significant 
difference between the indicated group and any passage 6 groups from younger 
donors (p<0.05). At a constant number of passages, significant differences were 
found across all age groups. Passage related differences were only significant in 
BMSCs from 1-year-old donors. Error bars designate means ± standard deviation 
(n=3). 
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Figure 5.5. Osteogenic differentiation. Results of osteogenic differentiation after 
3 weeks. {A) Representative micrographs showing Alizarin Red stained mineral 
deposits on cultured BMSCs from each experimental group. Magnification bars 
represent 100 ym in all images. (B) Percentage of total area viewed that was 
positively stained with Alizarin Red. (C) Quantified calcium cation (mM) 
determined using a colorimetric calcium assay. For B and C, The '#' sign indicates 
a significant difference between passage 1 and passage 6 cultures from similarly 
aged donors,'%' indicates a significant difference between the indicated group 
and any passage 1 groups from younger donors, and '¥' indicates a significant 
difference between the indicated group and any passage 6 groups from younger 
donors (p<0.05). Age-related decreases in staining and calcium were significant 
across all age groups, and significant passage related decreases were only 
observed in BMSCs from 6-day-old donors. Error bars designate means ± 
standard deviation (n=3). 
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Chapter 6 
Uncultured marrow mononuclear cells delivered within fibrin glue to 
porous scaffolds enhance bone regeneration within critical size rat cranial 
defects1 
Abstract 
For bone tissue engineering, the benefits of incorporating mesenchymal 
stem cells (MSCs) into porous scaffolds are well established. There is, however, 
little consensus on the effects of or need for MSC handling ex vivo. Culture and 
expansion of MSCs adds length, cost, and likely increases risk associated with 
treatment. We evaluated the effect of using uncultured bone marrow 
mononuclear cells (bmMNCs) seeded within porous scaffolds to regenerate bone 
over 12 weeks in an 8 mm diameter, critical size rat cranial defect. A full factorial 
experimental design was used to evaluate bone formation within poly(L-lactic 
acid) and corraline hydroxyapatite scaffolds with or without platelet rich plasma 
(PRP) and bmMNCs. Mechanical push-out testing, microcomputed 
tomographical IJJCT) analyses, and histology were performed. PRP showed no 
benefit for bone formation. Cell-laden PLLA scaffolds without PRP required 
t
 This chapter is in preparation as the following: Kretlow JD, Spicer PP, Picozza E, 
Kasper FK, Mikos AG. Uncultured marrow mononuclear cells delivered within fibrin glue 
to porous scaffolds enhance bone regeneration within critical size rat cranial defects. 
Tissue Engineering 2010. 
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significantly greater force to displace from surrounding tissues than control (cell-
free) scaffolds, but no differences were observed during push out testing of coral 
scaffolds. For bone volume formation as analyzed by /vCT, significant overall 
effects were observed with bmMNC incorporation. These data suggest that 
bmMNCs may provide therapeutic advantages in bone tissue engineering 
applications without the need for culture, expansion, and purification. 
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6.1 Introduction 
Tissue engineering approaches to regenerating lost or damaged tissues 
often focus on the use of adult stem cells. Among many available sources, 
mesenchymal stem cells (MSCs) derived from bone marrow or adipose tissue 
are commonly used as multipotent autologous cell sources and can be collected 
through relatively noninvasive methods.495 A number of studies have 
demonstrated the advantages of using MSCs for the repair or regeneration of 
multiple tissue types,69, 496502 and multiple clinical trials are underway 
investigating the use of MSCs for the treatment of both acute and chronic 
conditions.503 
Despite many studies establishing the benefits of MSCs, a number of 
factors remain unaddressed regarding their widespread use. First, there is little 
to no standardization of MSC harvest, expansion, and characterization,504"507 and 
studies suggest that these factors may play a significant role in the success or 
failure of applications employing these cells.508"514 
In addition to raising questions about the standardization and optimization 
of culture techniques, ex vivo expansion of autologous MSCs requires a delay 
between harvest and treatment, a likely increased cost of treatment to the 
patient, and introduces the risk for contamination or adverse cellular changes 
related to the expansion.472, 515, 516 Limited long-term data is available to 
adequately understand the risks of using culture-expanded MSC in clinical 
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therapy, and, while early reports are promising,517 a number of concerns, 
including those of genomic instability and resultant tumorigenesis, remain.518"522 
Additionally, it is unclear how patient-to-patient variability and changes in cellular 
function related to age or other demographic factors may impact the use and 
success of such cell-based therapies.441'443'456'457'523"525 
One potential method to avoid many of the problems associated with 
harvest and subsequent culture of MSCs is to use uncultured cell sources that 
may contain MSCs. Such an approach greatly diminishes the number and purity 
of the available multipotent cell population and, in certain cases of cardiovascular 
repair and regeneration, has been shown to limit the efficacy of cell-based 
therapies.526 527 In contrast, Samdani et al. directly compared bone marrow 
mononuclear cells (bmMNCs) to culture expanded MSCs in a spinal cord injury 
model and found that bmMNCs offered a greater protective benefit and reduced 
scar formation relative to MSC treated injuries.528 
Previous studies in bone and cartilage tissue engineering have shown 
significant therapeutic benefits associated with the use of uncultured whole bone 
marrow or brnMNCs.529"532 The ability to perform the necessary cell harvest and 
any purification steps perioperatively and the relative ease of clinical translation 
for these one-step processes were cited as advantages to more commonly 
investigated techniques involving culture-expanded MSCs.528,533 Gan et al. found 
that marrow mononuclear cells enriched perioperatively using a cell processor 
performed as well as bone grafts in spinal fusion.533 Muschler et al. found similar 
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results for spinal fusion using a matrix-enrichment procedure to increase bmMNC 
engraftment.534 Further supplementing uncultured whole marrow with growth 
factors such as transforming growth factor-(31 (TGF-|31) has also been shown to 
have a beneficial effect on healing of critical sized bone defects.535 
Due to the decreased number of multipotent cells available without in vitro 
expansion and purification and the decreased amount of time available for 
seeding cell-scaffold constructs during perioperative construct fabrication, cell 
delivery vehicles have been used to ensure MSC localization to a defect site or 
within a scaffold. The presence and properties of these delivery vehicles, which 
are primarily hydrogels such as fibrin glue,536"538 alginate,65 
hydroxypropylmethylcellulose,226 and platelet-rich gels,539 can greatly influence 
cell survival and differentiation. Catelas et al. and Ho et al. previously 
demonstrated the balance between MSC proliferation and differentiation 
achieved by modulating the fibrinogen concentration within fibrin gels.281, 282 
Similar effects have also been seen in collagen gels.540 
In the present study, we hypothesized that bone formation within a critical 
sized defect would be enhanced using uncultured bone marrow mononuclear 
cells encapsulated in fibrin gels for delivery of the cells within scaffolds made of 
poly(L-lactic acid) (PLLA) or coralline hydroxyapatite. Platelet rich plasma (PRP) 
was included for potential growth factor delivery to the encapsulated cells. All 
materials used were FDA-regulated, and an attempt to minimize processing 
procedures was made in order to simulate an entire harvest and construct 
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fabrication protocol that could be reasonably completed over the course of a 
single operation. 
6.2 Materials and Methods 
6.2.1 Experimental design 
This study used a full factorial design with 3 factors tested at two levels 
each (scaffold material - coral or PLLA, platelet rich. plasma - presence or 
absence, and uncultured marrow mononuclear cells - presence or absence), 
resulting in a total of 8 experimental groups. The groups are described in Table 
6.1. For each group, a total sample size of 14 was used, with 6 samples per 
group randomly assigned for mechanical (push-out) testing and the remaining 8 
used for microcomputed tomography (JJCT) and histology. 
6.2.2 Materials 
Coralline hydroxy apatite scaffolds (Pro Osteon 200, Interpore Cross 
International, Irvine, CA) measuring 8 mm in diameter x 2 mm in height and 
sterilized by gamma irradiation were used as supplied by the manufacturer. 
Nonwoven PLLA fiber mesh scaffolds (Concordia Medical, Warwick, Rl) 
measuring 8 mm in diameter x 1 mm in height with a volumetric porosity of 90%, 
300-500 ym pore sizes, and a 40 (jm fiber diameter were sterilized using 
ethylene oxide and placed in a sterile biosafety cabinet to ventilate for a minimum 
of 24 hours before use. Fibrin glue (Tisseel™, Baxter Healthcare Corp., 
Biosurgery, Bioscience, Westlake Village, CA) consisting of a human fibrinogen 
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complex (or sealer protein) and human thrombin was used as described below. 
The fibrinogen complex possibly contains osteogenic growth factors such as 
TGF-|31 and basic fibroblast growth factor.282 
6.2.3 Animal use 
All animal work was performed in accordance with protocols approved by 
the Rice University Institutional Animal Care and Use Committee. A total of 134 
healthy, male syngeneic Fisher 344 rats (Harlon Bioproducts, Indianapolis, IN) 
aged 12 weeks old and weighing 225-249 grams were used in this study. 
Twenty-two rats were used as bone marrow and/or blood donors, and the 
remaining 112 rats were used in surgery. 
6.2.4 PRP harvest and processing 
PRP was freshly harvested the day of surgery from donor rats. Rats were 
euthanized under general anesthesia via C02 asphyxiation and upon 
confirmation of death, a cardiac puncture was performed to withdraw ~5 ml_ of 
blood into a sterile syringe containing 500 fjL sterile filtered 3.8% sodium citrate 
(Sigma-Aldrich, St. Louis, MO). Blood from multiple donors was pooled into 
sterile 15 ml_ centrifuge tubes (BD Biosciences, Mississauga, ON, Canada) and 
placed on ice. PRP was isolated using a standard laboratory centrifuge 
(Precision Durafuge 100, Thermo Fisher Scientific, Waltham, MA) according to a 
previously established method.541 Briefly, following centrifugation at 400 x g for 
10 minutes with no brake applied, the supernatant was sterilely pipetted to a 
second sterile centrifuge tube, which was then centrifuged at 800 x g for 10 
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minutes with a brake applied at the end of the cycle. The supernatant of platelet 
poor plasma was then removed, and the remaining PRP was returned to ice. 
Platelet enrichment between peripheral blood and PRP from 8 donor rats was 
confirmed during a preliminary study using a veterinary hematology analyzer (scil 
Vet abc, scil animal care company, Gurnee, IL). Prior to use, PRP fibrinogen 
content was quantified using a spectrophotometric method.542 
6.2.5 Bone marrow harvest and construct preparation 
On the day of surgery, bone marrow was harvested from the long bones of 
the hind limbs of euthanized donor rats. Under sterile conditions, the femora and 
tibiae were isolated, stripped of soft tissue, and placed into sterile a-MEM 
(HyClone Laboratories Inc., Logan, UT). The epiphyses were then removed. 
Bone marrow was flushed by piercing the diaphyses with a 16-gauge syringe and 
delivering heparinized phosphate buffered saline (PBS, HyClone Laboratories 
Inc.). Marrow was disaggregated by serially passaging through 18 followed by 
20 gauge syringes. A cell suspension was created by vacuum filtering the 
marrow through a 100-/L/m nylon filter (Millipore Corporation, Billerica, MA). 
Mononuclear cells were then isolated by Ficoll density gradient centrifugation 
(Accuspin™ System Histopaque®-1077, p=1.077 g/mL, Sigma-Aldrich) performed 
according to the manufacturer's instructions. Cells were washed 3 times and 
resuspended in sterile Tris-buffered saline (TBS, Sigma-Aldrich) or PRP to a final 
concentration of 6 x 107 cells/mL. 
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PLLA and coral scaffolds were prewet in gradient ethanol beginning 24 
hours before seeding and/or implantation. Both the fibrinogen complex and 
thrombin components of the fibrin glue were freshly prepared each morning 
according to the manufacturer's instructions, and the fibrinogen concentration 
was verified using the Ellis method.542 The fibrinogen concentration was diluted 
with TBS to 102 mg/mL, and the thrombin solution was diluted with 30 mM sterile 
CaCI2 in TBS to a concentration of 200 lU/mL. 
For all experimental groups, 50 ^L each of fibrinogen complex and 
thrombin were delivered to the scaffold, resulting in 100 /;L of fibrin glue with final 
concentrations of 17 mg fibrinogen/mL and 100 IU thrombin/mL For scaffolds 
loaded with bmMNCs without PRP, volumes of cells suspended in TBS and 
fibrinogen complex were added in a 2:1 ratio to a sterile centrifuge tube and 
vortexed. For scaffolds loaded with PRP, the bmMNC/PRP suspension or PRP 
alone was added to an equal volume of fibrinogen complex diluted with TBS and 
vortexed such that the final fibrinogen concentration within the PRP/fibrinogen 
complex solution was 34 mg/mL. For all experimental groups, after vortexing, 50 
fjL of the fibrinogen complex solution were then pipetted onto each prewet 
scaffold within separate wells of an ultra-low attachment 24-well plate (Corning 
Inc., Corning, NY) that was then placed within a 37°C incubator for 5 minutes to 
allow the fibrinogen complex to soak the scaffold. After this, 50 fjL of thrombin 
solution were pipetted onto the scaffolds, which were then returned to the 
incubator for 15 minutes. After 15 minutes, a thin layer of a-MEM was added to 
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the well to cover the scaffold. Scaffolds were returned to the incubator until 
implantation. 
6.2.6 Animal surgery, euthanasia, and implant harvest 
Critical sized, 8 mm diameter defects within the rat calvarium were created 
under general inhalational anesthesia, filled with freshly prepared implants, 
closed, and cared for postoperatively as previously described.19 After 12 
postoperative weeks, animals were euthanized according to established and 
approved methods,19 and the implants and surrounding tissues were harvested 
with a high-speed surgical drill (TPS®, Stryker, Kalamazoo, Ml) and 701 cutting 
bur. Prior to harvest, samples were randomly designated for mechanical testing 
or jL/CT/histology. After harvest, samples to be mechanically tested were stripped 
of any extraneous soft tissues superficial or deep to the implant, immediately 
placed in ice cold PBS, and mechanically tested within 20 minutes. Samples 
designated for ^/CT/histology were individually placed in 10% neutral buffered 
formalin and stored on a shaker table at 4 °C for 72h. 
6.2.7 Mechanical push-out testing 
Push-out testing was performed to determine the interfacial shear strength 
of the implanted constructs after 12 weeks. Test were performed on a 
mechanical testing bench (858 Mini Bionix II, MTS Systems Corp., Eden Prairie, 
MN) using a custom made push-out and support jigs allowing 1 mm of clearance 
between the construct and the support jig around the entire circumference of the 
construct to minimize the effect of the testing jig on the interfacial stress 
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distribution.543 Tissue samples were oriented with the construct centered over the 
support jig, and the push-out jig was applied a vertical force on the constructs at 
a constant rate of 0.5 mm/min. Testing was stopped after a peak force was 
reached. 
6.2.8 Microcomputed tomography imaging and analysis 
Bone volume and extent of bridging within the explanted samples were 
analyzed by /JCT (SkyScan 1172 high-resolution micro-CT, SkyScan, Aartselaar, 
Belgium) as previously described.544 For PLLA constructs, lower and upper 
threshold indices were 70 and 255, respectively. For coral constructs, threshold 
indices of 90 and 255 were used. For PLLA samples, axial maximum intensity 
projections (MIPs) were generated, and bony bridging was evaluated by three 
observers (JDK, PPS, FKK) according to the scoring system described in Table 
6.2. 
6.2.9 Histological processing 
Fixed samples were serially dehydrated in graded ethanol (70-100%). 
Samples with PLLA constructs were left undecalcified and embedded in 
methylmethacrylate. Samples with coral constructs were mildly decalcified with 
EDTA and embedded in methyl methacrylate. Serial 5-/7m coronal sections 
through the center of the construct were then cut using a rotation microtome 
(Leica) and stained with hematoxylin and eosin (H&E), von Kossa/van Gieson 
(PLLA constructs only), or Goldner's trichrome according to established methods. 
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6.2.10 Light microscopy and histological scoring 
Stained sections will be analyzed and imaged using a standard light 
microscope with attached digital camera (Eclipse E600, Nikon Instruments Inc., 
Melville, NY). Three observers (JDK, PPS, FKK) will evaluate each of the 
sections according to a previously used scoring system, shown in Table 6.3, for 
assessing the construct-bone interface and the bone growth within the construct 
pores.544 
6.2.11 Statistical analyses 
Continuous variable data are represented as means ± standard deviation. 
Ordinal variables are presented as frequencies. All analyses were performed 
using R version 2.10.0 (R Foundation for Statistical Computing, Vienna, Austria). 
The a priori defined significance level for all statistical tests was 0.05. 
Peak loads obtained from push-out testing and percentage bone volumes 
were analyzed using two-way analyses of variance (ANOVA, bmMNC x PRP). 
Post hoc multiple comparisons were made using the step down Holm-Sidak 
test.545 
MIP and histology scoring were analyzed using a nonparametric method 
for analyzing two way ordinal data from factorial experiments.546, 547 Statistical 
significance for main effects and interaction were determined using ANOVA-type 
statistics, and multiple comparisons were made based on estimated 95% 
confidence intervals. 
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6.3 Results 
6.3.1 PRP processing 
Approximately 250 jUl_ of PRP were obtained from 4.5 ml_ peripheral blood 
per donor rat. Preliminary studies showed an 8.6 ± 3.2 fold platelet enrichment in 
the PRP compared to peripheral blood. Fibrinogen concentrations in the PRP 
were 14.2 ± 4.5 mg/mL. In order to keep the fibrinogen concentration constant in 
the gel fraction of all constructs, the fibrinogen complex concentration in 
constructs with PRP was slightly lower than in those without. 
6.3.2 Construct fabrication and animal surgeries 
Constructs were successfully fabricated, with each construct containing 
100 JUL of gel with, where appropriate, 1.5 x 106 bmMNCs/scaffold, 17 mg/mL 
fibrinogen and 100 lU/mL thrombin within the gel, and 25 fjL PRP. Gel was well 
formed within the pores of the scaffolds approximately 1 minute after the addition 
of thrombin. 
One animal died intraoperatively and was replaced prior to the completion 
of the study. All other animals survived the surgery and postoperative period 
without complications. At the time of euthanasia and sample harvest, there were 
no signs of gross infection or adverse tissue response surrounding the implants. 
6.3.3 Mechanical push-out testing 
Push-out testing results in the form of peak loads are shown in Figure 6.1. 
Due to differences in the Young's moduli of the scaffold materials, direct 
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comparisons between coral and PLLA constructs cannot be made.543 For the 
PLLA constructs, the group containing only bmMNCs (P-M) required significantly 
more force to displace the construct than the control (P-) constructs. Among the 
PLLA constructs, no other significant differences were found. Overall, the 
presence of bmMNCs had a significant effect on the push-out force (p < 0.005), 
while PRP and the interaction of PRP and bmMNCs were not significant. 
No significant differences in push-out strength were found for the coral 
constructs. The overall effect of bmMNCs seeded onto the scaffolds, the 
presence of PRP, and any interaction between these factors were also 
insignificant. 
6.3.4 Microcomputed tomography analysis 
Results from fjCT imaging were analyzed to determine the volume 
percentage of regenerated bone within the constructs (Figure 6.2). For PLLA 
constructs, significant differences in bone formation again existed only between 
the control constructs and the group containing only bmMNCs (P-M). For coral 
constructs, no significant differences were present in pairwise comparisons; 
however, for both PLLA and coral constructs, the addition of bmMNCs had a 
significant overall effect on bone formation, The effect of PRP and the interaction 
of PRP and bmMNCs were not significant for both types of constructs. 
Bony bridging across defects filled with PLLA constructs was evaluated by 
scoring MIPs as shown in Figure 6.3. Again, the presence of bmMNCs had a 
significant effect on bony bridging, but the effect of PRP and the interaction of 
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PRP with bmMNCs were not significant. Pairwise comparisons found the 
observed bridging between both groups containing bmMNCs (P-M, PPM) to be 
significantly different from both groups without bmMNCs (P--, PP-). Complete 
bridging through the midline of the defect was only observed in one sample from 
group PPM. 
6.3.5 Histology 
Representative histological samples are shown in Figure 6.4. 
6.4 Discussion 
To facilitate the translation of many tissue engineering technologies for 
clinical use, standardization or simplification of the approaches taken is 
necessary.486 In the present study, we hypothesized that a process which could 
be completely performed over the course of a single surgical intervention could 
be developed incorporating uncultured bmMNCs within FDA-regulated materials 
for enhanced bone formation within a critical sized rat cranial defect. For many of 
the analyses used, this was indeed the case. Uncultured bmMNCs encapsulated 
within a fibrin gel inside the pores of PLLA scaffolds regenerated significantly 
more bone within the defect, achieved greater bony bridging of the defect, and 
were better incorporated into the cranium as measured by mechanical testing 
than were cell-free controls. 
When comparing cell-laden and cell-free coral constructs, the results were 
not as clear. The presence of bmMNCs did not significantly increase the bone 
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formation within the scaffolds as detected by fjCT, and the peak force needed to 
display the cellular constructs was smaller than that needed to displace the cell-
free scaffolds, although not significantly so. The presence of platelet rich plasma 
had no effect on bone formation regardless of scaffold material or whether 
bmMNCs were also present. 
Scaffold material played an obvious role in bone formation, mechanical 
integrity of the implanted constructs, and the effect of bmMNC incorporation. 
PLLA was chosen as a polymeric scaffold due to its regulatory status, long-term 
maintenance of mechanical properties, and because MSCs have previously been 
demonstrated to differentiate well on PLLA fiber meshes.548 Polymeric fiber 
meshes with similar fiber diameters and densities have previously been used to 
characterize the effect of MSC culture and differentiation in the rat cranial 
defect.549 
Coralline HA bone grafts have long been used both in research and 
clinical applications.549 In this study, bone formation in coral scaffolds was not 
significantly different across groups; however, for /;CT analysis of bone formation 
there was an overall significant effect of bmMNC incorporation. This result was 
somewhat surprising, as previous work has demonstrated MSC osteogenic 
differentiation and ingrowth on similar scaffolds.550"552 Although reports showing 
little to no osteogenesis on coralline HA scaffolds do exist,553 bony ingrowth did 
occur in all of the tested formulations using coral. 
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The use of PRP did not significantly affect bone formation in this study. 
This result is similar to those reported elsewhere in rats,554 although there are 
multiple reports in humans555 and animals556, including rats,557, 558 enhancing 
bone formation. Still, evaluating the efficacy of PRP remains complicated. PRP 
in combination with uncultured bmMNCs has been found to increase bone 
regeneration in humans,559 and rat PRP gels have similarly been shown to 
increase in vitro osteogenic differentiation of rat MSCs.560,561 Other studies have 
shown that PRP does not increase in vitro or in vivo differentiation of rat MSCs 
when compared with the effect of growth factors such as bone morphogenetic 
protein-7 (BMP-7)562 and was found to inhibit MSC differentiation in a study 
comparing PRP and bone morphogenetic protein-2 (BMP-2).563 
A number of considerations regarding the variability and evaluation of PRP 
must be factored in when analyzing the discordant results for PRP use found in 
the literature. First, processing techniques, donor factors, and overall platelet 
enrichment play a significant role in the determining the actual composition of any 
p R p 564-569 Furthermore, there is an established interspecies variation in the 
growth factors contained in and osteogenic capability of PRP, with human PRP 
having higher growth factor concentrations and eliciting an increased osteogenic 
response compared to rat or goat PRP.561, 570 Additionally, PRP effectiveness 
may in part be modulated by scaffold and cell differentiation state for applications 
involving cell-laden constructs.571, 572 Kasten et al. found that PRP increased 
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alkaline phosphatase activity in undifferentiated MSCs but not in those 
precultured in osteogenic media.571 
The present study had a number of strengths. First, it further establishes 
the utility of uncultured bmMNCs in bone formation, including demonstrating a 
mechanical benefit for cell-laden PLLA scaffolds. Additionally, the study uses 
only commercially available materials that have already been approved for 
clinical use, meaning other parameters, such as the explicit role of fibrin glue in 
cell delivery, the relative effect of culture and expansion of bmMNCs on bone 
formation, and optimal seeding densities can be explored with minimal variability 
in the substrate materials. This may also allow for more rapid clinical evaluation 
of the results. The effect of the scaffold on bone formation using PRP and 
bmMNCs was also demonstrated by the difference in results for PLLA and coral 
constructs. Finally, mechanical effects of substrate stiffness were carefully 
controlled by maintaining a constant fibrinogen concentration across samples, 
thus any effect seen for PRP addition would have likely been based on bioactive 
factor delivery. 
The primary weaknesses of the present study lie primarily in scope, and 
thus future studies are necessary to draw more definitive conclusions from the 
current study. As mentioned in the previous paragraph, future studies are 
needed to determine whether the benefits of using a simplified process that can 
be performed over the course of a single operation outweigh any benefits that 
may exist with MSC expansion and culture. Similarly, future studies should 
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incorporate more time points to determine if there are any temporal effects of 
PRP addition. Finally, more sophisticated analyses should be done to determine 
the role of the delivered bmMNCs in bone formation, as the ability of a seeded 
cell population to recruit host osteoprogenitors may be more important for bone 
regeneration than the regenerative capability of the seeded cells.573 
A number of interesting results were found in this study. First, bmMNCs 
increased bone formation and construct incorporation for PLLA scaffolds but the 
benefit in coral scaffolds was not clear. For mechanical testing of coral 
constructs, bmMNC incorporation within scaffolds did not provide a significant 
change in implant mechanical properties, although a significant overall effect was 
found for ^/CT analysis. In a similar study by Le Nihouannen et al., fibrin glue and 
granules of 60/40 HA/(3-tri-calcium phosphate ((3-TCP) cement were mixed with 
and without freshly isolated bone marrow and placed within defects in rabbit 
femora.574 After 12 weeks, there was no difference in bone formation within the 
defects as detected by ^CT. Ueno et al. did, however, demonstrate bone 
regeneration in rat calvarial defects filled with (3-TCP granules and whole 
marrow.570 Similarly, Becker et al. compared bone marrow and concentrated 
bmMNC seeding on (3-TCP scaffolds and found that constructs seeded with bone 
marrow induced significantly more bone regeneration than those with bmMNCs, 
which were not statistically different from controls.576 
Based on these studies, whole marrow may be a better cell source for 
scaffolds where significant adsorption of potentially osteogenic proteins from the 
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acellular marrow fraction may occur. Additionally, bone formation within the coral 
scaffolds was similar to that of PLLA scaffolds, but not significant when analyzed 
by pairs, when the object volume of control (unimplanted) coral scaffolds was not 
considered (Figure 6.5). Since the coral scaffolds cannot be differentiated from 
newly regenerated bone by /JCT, variability in scaffold volume may have masked 
any effect of differences between the experimental groups. Furthermore, we 
noticed bone resorption around some of the coral scaffolds during IJCT imaging. 
Although the resorption did not vary between groups as determined by imaging 
and quantifying the bone around the border of the scaffolds (Figure 6.6), this 
resorption likely affected the relatively high variability of the mechanical testing 
results. 
The use of fibrin glue may also have confounded the findings with respect 
to PRP use. Platelet enriched fibrin glue has been shown to be an effective 
substrate for bone-tissue engineering applications both in the presence and 
absence of encapsulated MSCs.577, 578 Ito et al. showed an increase in bone 
regeneration in a canine mandibular defect using MSC/PRP/fibrin glue hybrid 
constructs compared to MSC/fibrin glue constructs alone after 4 and 8 weeks;579 
however, other studies have reported no benefit to similar hybrid constructs.580 
Fibrin glue encapsulation alone likely imparts a benefit in the delivery and 
retention and cells within the scaffold or defect.536, 581, 582 In previous studies 
demonstrating a benefit for PRP and MSCs in combination but not in comparison 
with other delivery methods or encapsulation substrates,357,583 the benefit may 
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be due in large part to the role of the PRP as a delivery vehicle for the MSCs,584 
given the otherwise short term survival of seeded MSCs.585 
The need for a cell delivery vehicle may be dependent on the type of 
scaffold used; in a study by Haasper et al., no benefit of cellular delivery by fibrin 
glue to scaffolds to which cells adhere more efficiently, such as bone matrix, has 
been demonstrated.586 Fibrin glue may still play an important role in applications 
where bioactive factor delivery is appropriate and controllable and easily tuned 
release kinetics are desired.587"589 
Because previous experiments have explicitly established that the 
fibrinogen concentration within the fibrin glue affects MSC differentiation and 
proliferation,281 282 an intermediate fibrinogen concentration (17 mg/mL), close to 
reported optimal values,280 was selected in order to allow cells to proliferate while 
still providing some substrate stiffness. In constructs with PRP, the amount of 
fibrinogen complex incorporated into the final glue was reduced in order to keep 
the fibrinogen concentration constant. Because the fibrinogen complex may also 
contain growth factors, this reduction in concentration may have offset any 
benefits of growth factor delivery by PRP. 
6.5 Conclusions 
The many emerging technologies in tissue engineering provide a number 
of options and important considerations for researchers and clinicians. Efficacy, 
cost, and risk must be assessed, and researchers focused on quickly translating 
technologies must weigh regulatory pathways as well. The present study 
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characterized scaffold, uncultured bmMNC, and PRP combinations to determine 
their relative effectiveness in regenerating bone within a critical sized rat cranial 
defect. PLLA scaffolds laden with bmMNCs delivered within fibrin glue 
regenerated significantly greater bone than control groups. Cells seeded on 
coral scaffolds had no significant effect on bone formation. PRP was not found to 
have a benefit in any formulation. Taken in the context of previous reports in the 
literature, these results provide further indication that a complex interplay occurs 
between scaffolds, cells, growth factors, and the host environment. A 
translational approach employing freshly harvested bmMNCs is likely beneficial 
compared to a strictly biomaterials-based approach in some cases; however, 
further work is needed to better understand when such an approach is warranted. 
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6,6 Figures 
Table 6.1 Experimental groups tested 
Designation S e r i a l P R P b m M N C 
p -
pp-
P-M 
PPM 
C-
CP-
C-M 
CPM 
PLLA 
PLLA 
PLLA 
PLLA 
Coral 
Coral 
Coral 
Coral 
-
+ 
-
+ 
-
+ 
-
+ 
-
-
+ 
+ 
-
-
+ 
+ 
Key: PRP=platelet rich plasma, bmMNC=bone 
marrow mononuclear cell, PLLA= poly(L-lactic acid) 
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Table 6.2. Scoring Guide for Bony Bridging and Union Using Maximum 
Intensity Projections from Microcomputed Tomography 
Description Score 
Bony bridging over entire span of defect at longest point (8 mm) 4 
Bony bridging over partial length of defect 3 
Bony bridging only at defect borders 2 
Few bony spicules dispersed throughout defect 1 
No bone formation within defect 0 
1 2 3 4 
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Table 6.3. Quantitative histological scoring parameters 
Description Score 
Hard tissue response at scaffold-bone interface 
Direct bone to implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule 2 
Unorganized fibrous tissue (majority of tissue is not arranged as capsule) 1 
Inflammation marked by an abundance of inflammatory cells and poorly organized tissue 0 
Hard tissue response within the pores of the scaffold 
Tissue in pores is mostly bone 
Tissue in pores consists of some bone within mature, dense fibrous tissue and/or a few 
inflammatory response elements 
Tissue in pores is mostly immature fibrous tissue (with or without bone) with blood vessels 
and young fibroblasts invading the space with few macrophages present 
Tissue in pores consists mostly of inflammatory cells and connective tissue components in 
between (with or without bone) OR the majority of the pores are empty or filled with fluid 
Tissue in pores is dense and exclusively of inflammatory type (no bone present) 0 
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Figure 6.1. Results of mechanical push-out testing. Immediately after harvest, 
constructs were placed on a custom testing jig and a vertical force was applied. 
The peak load required to displace the implants from the surrounding tissues was 
recorded for both PLLA constructs (A) and coral constructs (B). Data are 
reported as mean ± standard deviation (n=6). Statistical significance between 
groups and the corresponding control is denoted by *. 
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Implant Type 
Figure 6.2. Percent object volume of bone formation within the cranial defect. 
Explanted constructs and surrounding tissues were scanned by fjCT and 
analyzed to determine the percentage of volume within the defect space occupied 
by mineralized tissue for both PLLA constructs (A) and coral constructs (B). The 
reported values for the coral constructs include the volume of the scaffold. Data 
are reported as mean ± standard deviation (n=8). Statistical significance between 
groups and the corresponding control is denoted by *. 
215 
[jCTMIP score 
P- PP- P-M PPM 
Figure 6.3. Scores of bony bridging across the cranial defects. Explanted PLLA 
constructs were scored by 3 observers for according to the criteria in Table 6.2. 
Histograms of the scores are reported for each type of construct, and significant 
differences between construct scores and the control (P-) score are denoted by 
*. Images depict representative MIPs along with the corresponding score 
assigned to these samples (upper left corner of each image). Scale bars (lower 
right corners) indicate 1 mm. 
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Figure 6.4. Representative histological sections demonstrating the three types of 
staining used. Scale bars represent 100 jum. 
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Figure 6.5. Average volume of regenerated bone within coral scaffolds. The 
average volume of unimplanted coral scaffolds (n=10, mean volume 70.89 ± 4.79 
%) was subtracted from the volume of explanted samples (n=8), leaving an 
estimate of the bone regeneration within each coral construct. Data shown are 
means ± adjusted standard deviations. 
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Figure 6.6. Bone growth or resorption around the outer volume of the coral 
constructs was quantified. Representative images (top) denote with false 
coloring the border where bone was quantified around the defect. Scale bars 
represent 1 mm. The figure (bottom) shows the average percent bone volume 
present in the outer ring (n=8, error bars = standard deviation). No significant 
differences were found. 
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Chapter 7 
Porous Poly(methyl methacrylate) space maintainers promote soft tissue 
coverage of clean/contaminated alveolar bone defects1 
Abstract 
Current treatment of traumatic craniofacial injuries often involves early free 
tissue transfer, even if the recipient site is contaminated or lacks soft tissue 
coverage. There are no current tissue engineering strategies to definitively 
regenerate tissues in such an environment at an early time point. For a tissue 
engineering approach to be employed in the treatment of such injuries, a two-
stage approach could potentially be used. The present study describes the 
fabrication, characterization and processing of porous polymethylmethacrylate 
(PMMA) space maintainers for temporary retention of space in bony craniofacial 
defects. Carboxymethylcellulose (CMC) hydrogels were used as a porogen. 
Implants with controlled porosity and pore interconnectivity were fabricated by 
varying the ratio of hydrogekpolymer and the amount of CMC within the hydrogel. 
The in vivo tissue response to the implants was observed 12 weeks after 
placement within a non-healing rabbit mandibular defect that included an oral 
1
 This chapter has been submitted as the following: Kretlow JD, Shi M, Young S, Spicer 
PP, Demian N, Jansen JA, Wong ME, Kasper, FK Mikos AG. Evaluation of soft tissue 
coverage over porous poiy(methyi methacrylate) space maintainers within non-healing 
alveolar bone defects. Tissue Engineering, Part C: Methods 2010. 
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mucosal defect to allow open communication between the oral cavity and the 
mandibular defect. Oral mucosal wound healing was complete at 12 weeks over 
3/6 defects filled with solid PMMA implants and 5/6 defects filled with either a low 
or high porosity PMMA implant. The tissue response around and within the 
pores of the two formulations of porous implants tested in vivo was characterized, 
with the low porosity implants surrounded by a minimal but well formed fibrous 
capsule in contrast to the high porosity implants, which were surrounded and 
invaded by almost exclusively inflammatory tissue. Based on these results, 
PMMA implants with limited porosity hold promise for temporary implantation and 
space maintenance within clean/contaminated bone defects. 
Abbreviations 
ANOVA analysis of variance 
CMC carboxymethylcellulose 
FDA United States Food & Drug Administration 
MM A methyl methacrylate 
PMMA poly(methyl methacrylate) 
SEM scanning electron microscopy 
^iCT microcomputed tomography 
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7.1 Introduction 
The incidence of traumatic facial injuries relative to injuries at other 
anatomic locations has risen sharply during combat operations in Iraq and 
Afghanistan compared to previous military conflicts.590 The predominant cause of 
these wounds is improvised explosive devices, which often cause extensive 
damage to bone and soft tissues.591 Similarly, combat related ballistic injuries 
often involve high velocity projectiles that cause significant and widespread 
damage to multiple types of tissue.592 
Even in the civilian population, traumatic craniofacial bone injury is often 
accompanied by injury or loss of surrounding soft tissues.593 One of the major 
difficulties reconstructive surgeons face when treating injuries involving 
significant bone loss is contracture and scarring of the overlying soft tissue 
envelope, which compromises facial projection and makes staged repair of bony 
structures difficult.594, 595 Previously, definitive bone reconstruction was delayed 
until soft tissue coverage and a sterile wound environment were achieved.596,597 
More recently, despite reports of local complications and wound infection rates as 
high as 100% in civilians suffering gunshot wounds to the face,598, 5 " early 
definitive repair of facial gunshot wounds via free tissue transfer has become 
common as the well vascularized tissues that are transferred survive well in 
hostile wound environments.597,600 
The field of regenerative medicine and the technologies borne from tissue 
engineering offer great hope towards providing an alternative and possibly better 
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approach to regenerating injured or destroyed tissues. Most proposed tissue 
engineering strategies, however, currently require planning in the form of material 
fabrication, autologous cell harvest and expansion, and/or ex vivo tissue 
generation. Additionally, little to no evaluation of tissue engineering approaches 
is currently performed in wound environments involving infection, significant 
vascular injury, and large-scale tissue devitalization such as that encountered in 
a battlefield wound. Therefore, the successful use of a tissue engineering 
approach to provide immediate, definitive regeneration of tissues injured during 
craniofacial trauma such as those encountered during military service is unlikely 
using current approaches. 
In the absence of immediate reconstruction, clinical management of facial 
bone loss can involve the placement of an alloplastic space maintainer to provide 
a template for future definitive reconstruction and prevent wound contracture into 
the space normally occupied by bone.601 Poly(methyl methacrylate) (PMMA), is 
commonly used in such space maintenance applications601,602 and others within 
the craniofacial complex.603 Although PMMA has many desirable characteristics 
for such applications (moldable, FDA-regulated, familiar to surgeons), a number 
of problems exist with respect to wound healing around PMMA implants and 
other alloplastic craniofacial implants.604"606 
For the purposes of facilitating a long-term tissue engineering approach to 
treating composite craniofacial defects, a temporary implant or space maintainer 
would allow time for a regenerative medicine approach to be used to definitively 
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regenerate the injured or absent tissue. In addition to providing space 
maintenance, such a temporary implant could be used to "prime" the defect site, 
enabling better long-term success of the definitive regenerated tissue construct. 
Previous work has shown that recipient site characteristics such as vascularity 
are important for the regeneration of new bone tissue and support of grafted 
tissue.607,608 For mandibular reconstruction, the defect site and surgical approach 
along with recipient site complications such as infection, intraoral exposure, and 
prolonged antibiotic use have been significantly linked to graft failure.609,610 An 
ideal temporary space maintainer will therefore not only maintain the osseous 
void and prevent soft tissue collapse or contracture into the space but also will 
allow or promote soft tissue coverage and healing without serving as a nidus for 
local infections. 
Despite the aforementioned shortcomings associated with solid PMMA 
implants, we hypothesized that an implant made of modified PMMA could fulfill 
many of these criteria. Previously, a number of groups have explored different 
methods for making porous PMMA.611"616 Based on this work, we hypothesized 
that porous PMMA implants with reproducibly tunable pore structure could be 
fabricated using a carboxymethylcellulose (CMC) hydrogel as an aqueous 
porogen. When tested in a clean/contaminated rabbit mandibular defect, we 
hypothesized these implants would be able to maintain the defect space while 
promoting soft tissue coverage of the implant. 
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7.2 Materials and Methods 
7.2.1 Experimental design 
For the first part of this study, porous PMMA implants were synthesized 
and characterized using a CMC hydrogel as an aqueous phase to impart porosity 
on the implants. The percent of CMC in the aqueous phase and the ratio of 
aqueous phase:polymer phase were varied in order to control the bulk and 
surface characteristics. Following characterization of the porous implants, two 
formulations, one with high bulk porosity and pore interconnectivity and one with 
lower porosity and less pore interconnectivity, were compared over 12 weeks in 
vivo to a solid PMMA implant within a modified rabbit mandibular defect. 
7.2.2 Implant fabrication and characterization 
Solid and porous PMMA implants were fabricated using a clinical grade 
PMMA bone cement (SmartSet High Viscosity, DePuy Orthopaedics, Warsaw, 
IN) consisting of a powder of methyl methacrylate / methyl acrylate copolymer, 
benzoyl peroxide, and zirconium dioxide and a liquid phase with methyl 
methacrylate (MMA), N,N-dimethy!-p-toluidine, and hydroquinone. For the solid 
implants, the solid and powder phases were mixed according the manufacturer's 
specifications for approximately 90 seconds and, once they reached a dough-like 
consistency, packed into 10 mm diameter x 6 mm height cylindrical Teflon® 
molds. The solid implants were then allowed to harden at room temperature for 
30 minutes before being removed from the molds and vacuum-dried overnight. 
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For porous implants, 7 wt% and 9 wt% CMC hydrogels were prepared by 
dissolving the appropriate amount of United States Pharmacopeia grade low 
viscosity CMC (Spectrum Chemical Manufacturing Corp., Gardena, CA) in 
distilled water. The powder component of the PMMA cement was then mixed 
with the CMC hydrogel such that the powder was uniformly suspended within the 
aqueous phase. The liquid component of the PMMA cement was then added to 
the mixture of aqueous/powder phases. Aqueous phase weight percentages of 
30, 40, and 50 wt% were used to fabricate the implants, resulting in 6 
experimental groups. The aqueous and polymer phases were then stirred by 
hand for approximately 90 seconds and packed into Teflon® molds of the same 
size as the solid PMMA implants. The porous implants within molds were then 
allowed to harden for 30 minutes before being removed from the molds, placed 
within individual cassettes, and the aqueous phase was then leached from the 
implants in deionized, distilled water. The porous PMMA implants were then 
vacuum dried overnight. 
Implant porosity and pore interconnectivity were analyzed using 
microcomputed tomography (£/CT) as previously described.544 Briefly, implants 
(n=3) from all experimental groups were scanned using a SkyScan 1172 fjCT 
imaging system (SkyScan, Aartselaar, Belgium). High resolution 1280 x 1024 
pixel images were created by scanning at an 8 ^ m/pixel resolution with no filter at 
voltage and current settings of 40 kV and 250 /;A, respectively. Serial 
tomograms were reconstructed, resliced, and analyzed using NRecon and CTAn 
227 
software packages provided by SkyScan. For porosity and pore interconnectivity 
analyses, the scanned object volumes were binarized using a global threshold of 
60-255. Porosity and interconnectivity were determined using a 9 mm diameter x 
5 mm height cylindrical volume of interest to eliminate edge effects. Pore 
interconnectivity was determined by repeatedly applying a shrink wrap algorithm 
with minimum interconnection sizes ranging from 40-320 jjm. Interconnectivity is 
reported as the percentage of pore volume accessible from outside the volume of 
interest with pores considered accessible only if the interconnection to that pore 
allowed a sphere with diameter of the user defined minimum interconnection size 
to pass through. 
Scanning electron microscopy (SEM) was also used to examine the 
external surface of the implants. Implant surfaces were sputter-coated with gold 
for 40 s at 100 mA using a CrC-150 sputtering system (Torr International, New 
Windsor, NY) and observed at an accelerating voltage of 10 kV using a FEI 
Quanta 400 field emission scanning electron microscope (FEI company, 
Hillsboro, OR). 
7.2.3 In vivo implant evaluation 
Solid PMMA implants and porous implants (9 wt% CMC within the 
aqueous phase and both 30 and 40 wt% total aqueous phase in the implant) 
were evaluated in vivo using a modification of a nonhealing rabbit mandibular 
defect model.617 All surgical procedures followed protocols approved by the 
Institutional Animal Care and Use Committees at both Rice University and the 
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University of Texas Health Science Center at Houston. Eighteen healthy male 
adult New Zealand White rabbits (n = 6 per group), at least 6 months old and 
weighing 3.5-4 kg were purchased from Myrtle's Rabbitry (Thompson Station, 
TN). Prior to implantation, all implants were sterilized using ethylene oxide. 
Briefly, each animal was given preoperative intramuscular doses of 
buprenorphine hydrochloride (O.Tmg/kg body weight) for postoperative analgesia 
and 0.5 mL Durapen® (150,000 U/mL penicillin G benzathine and 150,000 U/mL 
penicillin G procaine) for perioperative antibiotic coverage. Prior to induction, 
ketamine hydrochloride (40 mg/kg body weight) and xylazine hydrochloride (7.5 
mg/kg body weight) were given, after which rabbits were placed in a supine 
position, intubated and placed under general anesthesia using an isoflurane/02 
mixture (2.5-3% isoflurance for induction, 2% for maintenance) with constant 
cardiac and respiratory monitoring. The animals were then surgically prepped 
and draped, after which a 7 cm midline incision through the skin and superficial 
fascia was made beginning 0.5 cm posterior to the mentum. Using blunt 
dissection and electrocauterization, the left masseter was exposed and the soft 
tissue along the inferior border of the body of the left hemimandible was 
mobilized such that the periosteum covering the body of the mandible could be 
incised and elevated, exposing a 4 cm x 1.5 cm area on the lateral surface of the 
mandible. A 10 mm titanium trephine (Ace Surgical Supply, Inc., Brockton, MA) 
attached to a Stryker TPS® surgical handpiece (Stryker, Kalamazoo, Ml) 
operating at 15,000 rpm was used to create a bicortical defect through the 
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exposed body of the left mandible. A 701 bur in combination with the surgical 
drilling unit was used to cut a 2-3 mm window through the alveolar ridge in the 
middle of the defect to provide access for removal of the crowns of the 
associated teeth and provide intraoral exposure of the defect. The defect site was 
thoroughly washed with normal saline, after which an implant was placed within 
the defect. Prior to closure, a titanium supporting plate (1.5 mm 6-hole heavy 
gauge titanium; Synthes, West Chester, PA) was secured in place to prevent 
iatrogenic fracture during the course of the study. The incision was then closed 
in 3 layers (muscle, fascia, and skin) using degradable sutures (Vicryl polyglactin 
sutures, Ethicon, Somerville, NJ). Following wound closure, anesthesia was 
reversed, and the animals were extubated. 
Postoperatively, the animals were given access to food and water ad 
libitum. Food was limited to a soft recovery diet (Critical Care for Herbivores, 
Oxbow Pet Products, Murdock, NE) and shredded or mashed fruits and 
vegetables to reduce stress on the mandible. All animals survived the 12-week 
post-operative period without complications. 
7.2.4 Gross characterization 
After 12 postoperative weeks, each rabbit was euthanized via intravenous 
injection of 1 mL Beuthanasia-D® (390 mg/mL pentobarbital sodium and 50 
mg/mL phenytoin sodium). The left hemimandibles were then carefully dissected 
from the cranium with care taken to preserve the soft tissue surrounding the 
implant and within the oral cavity. The oral mucosa and dentition covering the 
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alveolus of each specimen was examined to detect any areas of implant or bone 
exposure. Specimens were individually placed in 10% neutral buffered formalin 
and stored on a shaker table at 4 °C for 72h. 
7.2.5 Histology 
After fixation, samples were dehydrated and stored in 70% of ethanol and 
then embedded in MMA. Following polymerization of the MMA, 3 coronally 
oriented 10 JL/M thick sections through the center of each implant were cut using a 
modified diamond saw technique618 and subsequently stained using methylene 
blue/basic fuchsin. 
Each of the stained sections was analyzed using light microscopy (Zeiss 
Axio Imager ZT and AxioCam MRc 5, Carl Zeiss AG, Oberkochen, Germany) by 
two blinded observers (SY and FKK). A quantitative scoring system (Table 6.1) 
was used to score the tissue response at the implant interface and within the 
pores of the porous implants. 
7.2.6 Statistical analyses 
Implant porosity data were analyzed using single factor analyses of 
variance (ANOVA) with post hoc pairwise comparisons made using Tukey's 
HSD. Oral mucosal wound healing, as observed grossly and confirmed by 
microscopy, was analyzed using a Fisher-Freeman-Halton test. Histological 
scoring was analyzed using nonparametric statistics. The tissue response at the 
implant interface was analyzed using a Kruskal-Wallis one-way analysis of 
variance with subsequent pairwise analyses made using the Dwass-Steel-
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Critchlow-Fligner test. A Mann-Whitney U test was used to analyze the tissue 
response within the pores of the two porous implant types. The a priori level of 
significance for all analyses was chosen as a = 0.05. All analyses were 
performed using R version 2.10.0 (R Foundation for Statistical Computing, 
Vienna, Austria). 
7,3 Results 
7.3.1 Implant fabrication and characterization 
Porous PMMA/CMC implants were reproducibly fabricated as described in 
the Materials and Methods section. MicroCT analyses showed that porosity 
increased as expected with increasing incorporation of the aqueous phase 
(Figure 7.1). Significant differences in implant porosity were observed between 
all groups as the aqueous phase incorporation increased. Varying the amount of 
CMC within the aqueous phase did not significantly alter the implant porosity. 
Pore interconnectivity also increased with increasing aqueous phase 
incorporation (Figure 7.2). Interconnectivity appeared to be affected by the 
percentage of CMC in the aqueous phase; the more negative slope observed for 
implants with 9% CMC within the aqueous phase indicates that more of the 
interconnections in these implants were smaller than for those implants 
fabricated with 7% CMC in the aqueous phase. 
SEM images and /L/CT reconstructions also showed differences in the 
porosity and surfaces of the fabricated implants (Figure 7.3). The porosity 
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increases with increasing aqueous phase incorporation quantitatively detected 
with £/CT are seen in cross sections and surface images of the implants. 
Furthermore, the pore size appears more consistent within implants fabricated 
using 9% CMC in the aqueous phase, likely resulting in the relative abundance of 
smaller pore interconnections within these implants when compared to those 
fabricated using 7% CMC. 
7.3.2 In vivo implant evaluation 
Based on the implant characterization, solid PMMA implants, 9% CMC 30 
wt% (16.9 ± 4 .1% porosity, 39.7 ± 9.4% interconnectivity at a 40 jjm minimum 
connection size) and 9% CMC 40 wt% (44.6 ± 2.1% porosity, 81.2 ± 1.0% 
interconnectivity at a 40 /urn minimum connection size) implants were chosen for 
implantation in the in vivo phase of the study. All animals survived the surgery 
and post-operative period without complications. No changes in eating habits or 
activity were noted by the investigators, husbandry staff, or veterinary staff. 
7.3.3 Gross characterization 
At the time of animal euthanasia and implant/hemimandible harvest, no 
signs of mobility or infection were noted in any of the animals or visible tissues 
following harvest. Wound healing (closure) of the oral mucosa over the alveolar 
ridge at the site of the intraoral communication was assessed grossly (Figure 7.4) 
and correlated to histological results (Table 7.2) to confirm the gross 
observations. Wound healing was considered incomplete when any exposed 
bone or implant could be grossly observed and histology also indicated a failure 
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of soft tissue coverage over the implant or within the defect. The increase in oral 
mucosal wound healing observed in defects filled with both low and high porosity 
implants (83% of defects healed) versus non-porous PMMA implants (50% 
healed) was not statistically significant. 
7.3.4 Histology 
Histology and histological scoring were performed to assess the ability of 
the implants to maintain space within the surgically created osseous void and to 
view and quantify the soft tissue response around and within the implants. At low 
magnifications allowing coronal views of the entire implant and defect in cross 
section, all implants successfully maintained the defect space within the 
hemimandible, as confirmed by the lack of tissue collapse or contracture into the 
space occupied by the implants with the exception of tissue invading the pores of 
the porous implants (Figure 7.5). 
At higher magnification, the tissue response at the implant-tissue interface 
and within the implant pores could be observed (Figure 7.6). At the implant-
tissue interface, both the low porosity and solid implants were in many cases 
surrounded by a thin, well-organized fibrous capsule. The low porosity implants 
were also in direct contact in many areas with any newly formed bone observed 
at the implant interface. The high porosity implants were primarily surrounded by 
an abundance of inflammatory plasma cells at the implant interface, and a similar 
inflammatory cell population was observed within the pores of the highly porous 
implants. When a quantitative scoring system was applied, the interfacial tissue 
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response for the highly porous implants was statistically significantly different 
from the response observed around both the solid and low porosity implants 
(Figure 7.7). Similarly, the difference in tissue response within the pores of the 
low and high porosity implants was statistically significant (Figure 7.7), 
7.4 Discussion 
Temporary space maintainers have historically been used clinically to 
prevent soft tissue collapse into bony defects and provide a template for delayed 
bone healing or grafting.601,619 Recently, however, space maintenance has been 
used infrequently, particularly in the staged repair of traumatic injuries, as 
immediate free tissue transfer has eliminated the need for space maintenance 
and staged repair. Additionally, problems with existing biomaterials such as 
problems with healing of surrounding tissues, implant extrusion, or bacterial 
colonization have further limited the use of space maintainers, particularly in 
applications where soft tissue healing or infection may be a concern.620, 621 
Unfortunately, due to limitations in current tissue engineering technology, injuries 
involving lacking or devitalized soft tissues or the possibility of infection are 
precisely the type a staged repair using temporary space maintenance might 
allow a regenerative medicine approach to be undertaken. 
The present study aimed to fabricate and characterize porous PMMA 
implants using a CMC porogen and test selected formulations in a non-healing 
bone defect that approximated a more toxic wound environment than most 
traditional animal models. In the first part of the study, porous PMMA implants 
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were fabricated in a one step process by incorporating a CMC hydrogel that 
could be leached away rapidly in vitro or in vivo. Varying both the amount of 
CMC within the aqueous phase and the relative amount of aqueous phase to 
polymer phase allowed for well controlled porosity and pore interconnectivity. As 
expected, higher percentages of porogen resulted in greater implant porosity, 
while increasing the viscosity of the aqueous phase porogen by incorporating of 
greater amounts of CMC within the hydrogel led to a more consistent pore size 
and higher pore interconnectivity when the minimum interconnection size was 
decreased. 
In the second part of the study, two formulations of porous PMMA implants 
and solid PMMA implants were implanted into non-healing rabbit mandibular 
defects that had been contaminated through an open communication with the 
oral cavity. Porous PMMA formulations were selected such that both a highly 
porous, highly interconnected implant and an implant of lower porosity and lower 
interconnectivity could be compared. Healing of the communication into the oral 
cavity was assessed as well as the tissue response both around and within the 
implants. All formulations successfully maintained space within the defect. Soft 
tissue was only observed within the defect when it was penetrating the pore 
network in the two formulations of porous implant. The oral mucosal defects 
created to allow communication into the bone defect healed in more cases (5/6 
healed for both low and high porosity implants) when the bony defects were filled 
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with porous implants than when filled with solid implants (3/6 healed), although 
the differences between groups was not statistically significant. 
Although the gross mucosal defect closure over the high and low porosity 
implants was equivalent, microscopically, the tissue response around and within 
the pores of the low porosity implants was more favorable. At the implant -
tissue interface, a small, well formed capsule or direct tissue - implant contact 
was typically observed around the low porosity implants. Immature fibrous tissue 
with few inflammatory elements was generally seen within the filled pores of the 
low porosity implants. Contrastingly, the tissue surrounding and within the pores 
of the highly porous implants was almost exclusively inflammatory, consisting 
mostly of plasma cells. A well-formed fibrous capsule was only observed 
surrounding one of the six high porosity implants implanted within the mandibular 
defect. Thus while all the implants tested in vivo successfully maintained the 
defect space, the low porosity and solid implants elicited a more favorable soft 
tissue response than the highly porous implants, while the porous implants may 
have provided a template for improved wound healing in comparison to the solid 
implants. 
The current study has a number of strengths. First, although porous 
PMMA has been well studied,612' 615' 622"625 including porous PMMA fabricated 
using an aqueous phase consisting of a CMC hydrogel as a porogen,613 626 the 
present study is one of the first systematic studies to quantitatively examine the 
effect of both the ratio of aqueous phase to polymer phase but also the effect of 
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the aqueous phase viscosity as done by varying the amount of CMC within the 
aqueous phase. Increasing the viscosity of the aqueous phase by using a 9 wt% 
CMC hydroge!, as opposed to a 7 wt% CMC gel as has been previously used,627 
resulted in a more consistent pore architecture with smaller, more consistently 
sized pore interconnections. Because of this, both porous implant formulations 
chosen for the in vivo study were fabricated with 9 wt% CMC hydrogels. An 
additional benefit of the chosen materials is that both PMMA and CMC are FDA 
regulated for craniofacial applications, and the fabrication of the implants can be 
done in a standard operating room with only minor alterations in the manufacturer 
recommended preparation of PMMA. 
A strength of the in vivo portion of the study was the use of a more 
clinically relevant animal model that may better simulate the type of clinical 
situation in which the technology investigated may be used. The animal model 
was based on a previously developed rabbit mandibular defect617 that was 
modified to allow contamination of the wound through an opening into the oral 
cavity. This conferred several advantages. First, mucosal wound healing within 
the rabbit oral cavity is a well established method for evaluating wound 
healing,628"632 particularly when evaluating biomaterial-guided wound healing.633" 
638
 Second, in the clinical setting, the presence of intraoral communication is 
significantly correlated to decreased bone graft survival time,610 and thus an 
implant evaluation strategy that focuses on the closure of these communications 
is relevant for a situation where definitive repair will be performed using a 
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standard or tissue engineered bone graft. With relation to the presence of these 
intraoral communications, infection is a major concern when dealing with any 
implantable biomaterial,639 particularly PMMA,640, 641 and thus evaluating the 
tissue response to the implant in an environment where it will most likely be 
exposed to bacteria strengthens any conclusions drawn with respect to optimal 
material formulations. Finally, although the observed differences in oral mucosal 
wound healing does not allow one to draw any definitive conclusions about how 
the presence of porosity affected the oral mucosal wound healing, this study 
establishes the statistical parameters necessary to determine the statistical 
power needed to achieve significance in future studies using this model. While a 
difference in healing clearly existed between both the high and low porosity 
implants and the solid PMMA implants, the difference was not significant. 
Somewhat surprisingly, the difference in tissue response to the porous implants 
based on histological scoring was significantly different and may be an important 
parameter not only for initial wound healing but also for subsequent bone 
regeneration.642"644 
This study is not, however, without weaknesses. First, an ideal tissue 
engineering solution to the problem of complicated craniofacial bone defects 
would not involve multiple interventions and delayed reconstruction. An ideal 
solution would use a degradable material645 that could address the issues of soft 
tissue coverage, infection, and bone regeneration concurrently, thus eliminating 
the need for and risks associated with repeated operations. At present, such a 
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solution does not exist nor does there appear to be any such solution developed 
for use in the near future. While the animal model chosen is viewed by the 
authors as one of the strengths of the study, the complexity of the model may 
also be viewed as a weakness. Not only is the tooth bearing segment of the 
mandible more complicated in structure than many craniofacial bones, it also is 
exposed to very different mechanical stresses than other bones.646 Furthermore, 
the method of wound contamination was poorly controlled. Oral flora of the 
rabbits and the amount of flora that passed through the communication was likely 
variable between animals. Additionally, rabbits produce and eat caecotrophes, 
and it is not known whether this reingestion further complicates the model by 
exposing the implant to gut or colonic flora. 
Limited research is available investigating PMMA strictly for use as a 
space maintainer; however, PMMA has a long track record of use in craniofacial 
applications. In an early study using PMMA to repair canine mandibular defects, 
Worley reported that repair failed in 7 of 11 dogs due to wound dehiscence over 
solid PMMA implants.647 Kangur et al. reported similar problems with mucosal 
dehiscence over solid PMMA used to fix canine mandibular fractures and 
attributed the presence of an acute inflammatory tissue response to the PMMA to 
this oral communication.648 Despite these findings, a number of studies exist that 
report no complications with solid PMMA use in craniofacial applications.601, 621, 
649, 650 
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Porous PMMA, as previously mentioned has also been investigated in 
animal studies and limited clinical use. In a long term study in guinea pigs 
comparing porous and solid PMMA implanted in the hypodermis, van Mullem et 
al. reported implant extrusion occurred in 4/36 solid implants and none of the 
porous implants.614 Similar to the present study, the same study noted that foci of 
inflammatory cells were found more frequently around and within the porous 
PMMA implants (1:1 aqueous phase:polymer phase) than the solid implants. 
Clinically, the porous PMMA seems to have been used successfully with little 
note of complications,651 and, while reports of long-term results are rarely found, 
it should be noted that the current study differs from those previously published 
as the intent is for the porous implants to only be used as temporary implants. 
In the present study, the porous PMMA implants appeared to promote or 
allow wound healing of the oral mucosa better than the solid implants, although 
not significantly so. Significant differences in the tissue response to the two 
formulations of porous implants were also observed. A number of possible 
explanations exist for these two findings. The trend of improved wound healing 
with use of the porous implants may best be explained by increased tissue 
integration within the pores of the implants. This may have limited implant 
micromovement and improved the rate at which new tissue formed across the 
implant to close the communication. Similar improvements in wound healing and 
implant retention have been found when using porous polyethylene for the 
fixation of bone-anchored hearing aids.652,653 
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The inflammatory tissue response around and within the highly porous 
implants was likely caused by increased bacterial seeding of these implants. The 
increased porosity and interconnectivity of these implants compared to those of 
the low porosity and lower interconnectivity group likely led to bacterial 
accumulation deeper within the implant in areas where the bacteria could not 
effectively be cleared. Kiechel et al. compared infection control within porous 
and nonporous PMMA seeded with Staphylococcus aureus and implanted in the 
paravertebral fascia of rabbits and found increased infections occurred in animals 
implanted with porous PMMA implants.654 Sclafani et al. found that increased 
porosity increased the resistance to infection in implants inoculated 14 days after 
implantation but not if the implants were inoculated at the time of implantation.655 
Thus in applications and models where contamination or infection exists at the 
time of implant placement, an appropriate balance with respect to porosity is 
needed to allow tissue ingrowth and implant integration but not bacterial seeding 
deep within the implant. If contamination is not present at the time of 
implantation, fibrovascular ingrowth has been shown to occur rapidly and thus a 
more porous implant may be acceptable.656 Additionally, studies of induced 
membranes or capsules around PMMA implants suggest that the formation of 
well-formed capsule around the implants, as seen more frequently around the 
low porosity implants in this study, may facilitate greater success of later efforts 
aimed at definitive bone regeneration, provided the capsule is not destroyed 
during implant removal and any necessary debridement.642"644 Finally, it is 
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important to note that the method of fabrication of the porous PMMA implants 
may lead to particulate PMMA release,657 which could account for the 
inflammatory response elicited by the highly porous implants.658 
Based on the results of the present study, the low porosity space 
maintainers appear to be a promising alternative to solid PMMA for temporary 
implantation as part of a regenerative medicine approach to treating traumatic 
craniofacial injuries. Future work in this area should focus on tissue regeneration 
within the maintained space as well as release of any bioactive factors from the 
space maintainer such as antibiotics or growth factors that may better ensure 
success of later stage tissue engineering efforts. The characterized implants 
may provide a critical step in allowing the use of regenerative medicine 
approaches as an alternative to traditional approaches in treating contaminated 
or open traumatic defects. 
7.5 Conclusions 
Porous PMMA space maintainers can be reproducibly fabricated using a 
CMC hydrogel as an aqueous phase porogen. Porosity and pore 
interconnectivity can be controlled by varying the ratio of the aqueous phase to 
polymer phase and the concentration of CMC within the hydrogel, respectively. 
In vivo, porous space maintainers potentially improve oral mucosal healing over a 
clean/contaminated bone defect created in the rabbit mandible. The tissue 
response to a porous implant of low porosity and pore interconnectivity was more 
favorable than the response to a more porous and interconnected implant. This 
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low porosity implant may be ideal for temporary space maintenance within 
craniofacial defects. 
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Table 7.1. Quantitative histological scoring parameters 
Description Score 
Hard tissue response at scaffold-bone interface 
Direct bone to implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule 2 
Unorganized fibrous tissue (majority of tissue is not arranged as capsule) 1 
Inflammation marked by an abundance of inflammatory cells and poorly organized tissue 0 
Hard tissue response within the pores of the scaffold 
Tissue in pores is mostly bone 
Tissue in pores consists of some bone within mature, dense fibrous tissue and/or a few 
inflammatory response elements 
Tissue in pores is mostly immature fibrous tissue (with or without bone) with blood vessels 
and young fibroblasts invading the space with few macrophages present 
Tissue in pores consists mostly of inflammatory cells and connective tissue components in 
between (with or without bone) OR the majority of the pores are empty or filled with fluid 1 
Tissue in pores is dense and exclusively of inflammatory type (no bone present) 0 
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Table 7.2. Oral mucosal coverage over implant by 
implant type 
Implant type Healed/Non-healed 
Solid 3/3 
Low porosity 5/1 
High porosity 5/1 
246 
•4—* 
o 
o 
Q_ 
7% CMC 
O 9% CMC 
60 
50 
40 
30 
20 
10 
0 
0wt% 30wt% 40wt% 50wt% 
CMC Concentration (wt%) 
Figure 7.1. Porosity values as calculated by pCT. Samples were scanned and the 
resultant scans were reconstructed, reoriented, and binarized. Implant porosity 
was determined using a cylindrical (9 mm diameter x 5 mm height) volume of 
interest slightly smaller than the implant dimensions to eliminate edge effects. 
Data are reported as means ± standard deviation (n=3). The * over a bar denotes 
a statistically significant difference (p < 0.05) as detected using ANOVA and 
Tukey's post hoc tests between the group marked and the group with the same 
%CMC but lower aqueous phase in relation to polymer phase. No statistically 
significant differences in porosity were found as a result of changing the %CMC 
from 7% to 9%. 
247 
o 
d) 
c 
c 
o 
o 
i _ 
100 
80 
60-
40-
20-
0 
7% CMC-30 wt% 
9% CMC-30 wt% 
— 7%CMC-40wt% 
• - 9% CMC-40 wt% 
— 7% CMC-50 wt% 
• - 9% CMC-50 wt% 
i i i — i — | i i i i — | i i i i — | i i i i | — i — r — i — i — | — i i i — i | i i — i i | 
0 50 100 150 200 250 300 350 
Minimum Connection Size (urn) 
Figure 7.2. Implant interconnectivity percentages as a function of the minimum 
interconnection size. Samples were scanned and processed as reported in the 
methods section, and a built in software package was used to determine the 
percentage of the implant porosity that was accessible from outside the volume 
of interest. Data are reported as means ± standard deviation (n=3). 
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Figure 7.3. Representative images of implant cross sections and surfaces. 
Cylindrical implants (10 mm diameter x 6 mm height) from each experimental 
group were scanned by yCT or SEM. Virtual pCT cross sections of the implants 
were made by slicing through the center of the axially oriented implant. For 
electron micrographs, the scale bar represents 500 jvm. 
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Figure 7.4. Representative gross views of harvested tissue covering the alveolus 
and implant. (A) Failure of wound healing over a solid PMMA implant is shown. 
The exposed implant is denoted by white arrows. (B, C) Well healed soft tissue 
covering the intraoral exposure is seen where dentition is missing over low 
porosity (B) and high porosity (C) implants. 
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Figure 7.5. Representative light micrographs (25x magnification) of coronally 
sectioned tissue samples through the center of the A) Solid PMMA, (B) Low 
porosity, (C) High porosity space maintainers. The intraoral exposure of the solid 
implant (A) is shown with black arrows. Blue arrows denote the titanium plate 
used to stabilize the mandible. Tissue ingrowth is seen within both porous 
implants, and, for all implants, the original defect space appears well maintained 
with minimal tissue collapse or contracture. In B and C, soft tissue 
discontinuities at the left (buccal) side of the implant capsule are due to 
embedding and processing artifacts. Scale bars represent 1 mm. 
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Figure 7.6. Representative light micrographs (200x magnification) of the lingual 
surface of coronally sectioned tissue samples through the center of the implanted 
A) Solid PMMA, (B) Low porosity, (C) High porosity space maintainers. 
Regenerated bone is seen near the surface of all implants. A well-formed capsule 
is seen in (A), while only a thin layer of loosely organized fibrous is seen at the 
surface of the low porosity space maintainer (B). An abundance of plasma cells 
is seen at the surface and penetrating the surface porosity of the highly porous 
space maintainer (C). Scale bars represent 100 pm. 
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Figure 7.7. Score distributions for the graded (top) implant interface for all 
formulations tested in vivo and (bottom) tissue response within pores for the two 
porous implant formulations. Scoring criteria are defined in Table 7.1. 
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Statistically significant differences (p < 0.05) between groups, denoted by *, were 
determined using pairwise Dwass-Steel-Critchlow-Fligner tests for the implant 
interface scoring (top) and a Mann-Whitney U test for the tissue response within 
pores (bottom). 
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Chapter 8 
Summary 
The goals of this work were to investigate biomaterial-based strategies for 
tissue engineering in the craniofacial complex. A novel biomaterial with potential 
applications in cell delivery was investigated in the first objective, detailed in 
Chapter 4 and in two of the appendices, and a combination of physical gelation 
with increasing temperatures and ionic crosslinking in the presence of divalent 
ions was explored to increase gel mechanical stability. Increasing amount of 
vinylphosphonic acid incorporated into the synthesized macromers influenced 
macromer behavior in the presence of calcium ions, and the macromers 
underwent a reversible sol-gel transition around normal body temperature. 
In exploring the second objective of the study as described in Chapter 5, 
we found that donor age and extended cell passages in combination had a 
significant effect on the in vitro differentiation potential of mesenchymal stem 
cells taken from the bone marrow of donor mice. These results point to potential 
problems that may be associated with ex vivo cell culture for the purpose of 
expanding and isolating certain populations of progenitor cells. 
To explore the third and fourth objectives, described in Chapters 6 and 7, 
we limited our use of materials to novel formulations of FDA-approved products 
in order to potentially improve the rate at which these technologies could be 
translated. In Chapter 6, we determined that the use of uncultured bone marrow 
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mononuclear cells within a biomaterial scaffold can significantly improve bone 
regeneration when compared to the biomaterial scaffold alone. In the third 
objective, temporary space maintainers were fabricated and tested within a 
contaminated bone defect. We found that low porosity space maintainers 
allowed wound healing over the bone defect, maintained space effectively, and 
elicited a largely fibrous tissue response. 
These approaches demonstrate that biomaterial-encapsulated cell delivery 
to bony defects is beneficial for bone healing, and that cells can be used 
immediately after harvest, thus foregoing any lengthy ex vivo processing. 
Additionally, for injuries where immediate placement of a cell-scaffold construct 
for definitive bone repair is not possible, a porous space maintainer may be 
placed to retain bony volume, support surrounding tissues, and potentially aid 
soft tissue healing around the defect. 
Overall this project provides motivation for simplified biomaterial and stem 
cell based approaches in tissue engineering. Tailored biomaterials, such as 
those investigated in the first objective and in Chapter 4 hold promise and may 
alleviate some of the problems described in the subsequent chapters; however, 
the regulatory process is such that this promise may not be realized for some 
time. In fulfilling the subsequent aims, a strong case was made for simplified 
approaches utilizing currently regulated materials. Additionally, Chapter 7 
described work that may be translated in order to facilitate the use of 
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regenerative medicine approaches for traumatic injuries that involve non-ideal 
wound conditions. 
Finally, the work presented provides compelling evidence of the need for 
further investigation in these areas. First, a number of different animal models 
were utilized. Ideally, much of the work would be repeated within large animals 
and with human cells when possible, to further explore the validity of the 
conclusions drawn for clinical translation. Additionally, as more materials and 
methods for cell harvesting and processing become available for clinical use, the 
results presented here must be reevaluated, as better materials and methods 
may alleviate some of the problems which this study aimed to explore and 
address. 
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Chapter 10 
Appendices 
These appendices feature work in which the doctoral candidate 
participated and was a co-author on the resulting manuscript; however, the work 
was led by other researchers. Appendix A lists these publications and others 
that were not explicitly featured in this thesis. Appendices B and C are 
manuscripts that significantly influenced the work described in this thesis, in 
particular the study described in Chapter 4. 
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Appendix B 
Synthesis and Characterization of Injectable, Thermally and Chemically 
Gelable, Amphiphilic Poly(A/-isopropylacrylamide)-Based Macromers* 
Abstract 
In this study, we synthesized and characterized a series of macromers based on 
poly(N-isopropylacrylamide) that undergo thermally induced physical gelation 
and, following chemical modification, can be chemically cross-linked. Macromers 
with number average molecular weights typically ranging from 2000 - 3500 Da 
were synthesized via free radical polymerization from, in addition to poly(/V-
isopropylacrylamide), pentaerythritol diacrylate monostearate, a bifunctional 
monomer containing a long hydrophobic chain, acrylamide, a hydrophilic 
monomer, and hydroxyethyl acrylate, a hydrophilic monomer used to provide 
hydroxyl groups for further chemical modification. Results indicated that the 
hydrophobic-hydrophilic balance achieved by varying the relative concentrations 
of comonomers used during synthesis was an important parameter in controlling 
the transition temperature of the macromers in solution and stability of the 
resultant gels. Storage moduli of the macromers increased over 4 orders of 
magnitude once gelation occurred above the transition temperature. Furthermore, 
t
 This appendix was published as: Hacker, M. C; Klouda, L; Ma, B. B.; Kretlow, J. D.; 
Mikos, A. G., Synthesis and Characterization of Injectable, Thermally and Chemically 
Gelable, Amphiphilic Poly(N-isopropylacrylamide)-Based Macromers. 
Biomacromolecules 2008, 9, (3), 1558-1570. 
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chemical cross-linking of these macromers resulted in gels with increased 
stability compared to uncross-linked controls. These results demonstrate the 
feasibility of synthesizing poly(A/-isopropylacrylamide) based macromers that 
undergo tandem gelation and establish key criteria relating to the transition 
temperature and stability of these materials. The data suggest that these 
materials may be attractive substrates for tissue engineering and cellular delivery 
applications as the combination of mechanistically independent gelation 
techniques used in tandem may offer superior materials with regard to gelation 
kinetics and stability. 
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B.1 Introduction 
One of the primary problems facing researchers and clinicians in the 
broad field of tissue engineering and regenerative medicine is the fabrication of 
biomaterial substrates that provide appropriate 3-dimensional architecture, 
mechanical support, and the ability to deliver both cells and growth factors 
tailored to a specific tissue of interest. In situ gel formation is a concept of great 
interest for tissue engineers as it enables the delivery of a hydrogel matrix 
encapsulating cells and/or growth factors to defects of any shape using minimally 
invasive surgical techniques.1,2 
So far, no ideal technique towards achieving in situ gel formation exists. 
Various natural and synthetic polymers have been chemically modified with 
moieties for chemical cross-linking, including acrylic esters, methacrylic esters, 
cinnamoyl esters,3 fumaric esters,2 and vinylsulfone,4 to yield injectable 
biodegradable matrices.5 In situ gel formation by radical polymerization of 
electron-poor olefins can be induced photochemically or thermally without 
harming encapsulated cells.6,7 However, only low concentrations of radical 
initiators and cross-linking agents are tolerated by encapsulated cells,7,8 and thus 
certain important parameters such as gelation kinetics, cross-linking densities 
and resulting mechanical properties of the hydrogels can only be varied to a 
limited extent without compromising the cytocompatibility of the process. 
Polymeric materials that respond to a variety of environmental stimuli such 
as changes in temperature, pH, osmotic pressure, ionic strength, pressure, and 
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electric or magnetic field1,9,10 have become attractive materials in biotechnology 
and medicine9 and represent a viable approach to developing in situ gelling 
biomaterials. Temperature-sensitive hydrogel-forming polymers are among the 
most common of such materials and have been extensively studied as 
temperature-regulated drug delivery systems11"15 and injectable matrices for 
tissue engineering.1,16,17 While soluble below a characteristic temperature, 
solutions of these polymers undergo thermally induced, entropically driven phase 
separation above their lower critical solution temperature (LCST). 
Cytocompatible chemical gelation protocols typically yield firm hydrogels 
after several minutes, while thermally induced gelation of thermosensitive 
polymer solutions occurs almost instantaneously once the LCST is reached. For 
cell encapsulation applications, thermosensitive polymers must possess a LCST 
below 37 °C and the thermally aggregated polymer chains have to retain a 
significant amount of water. Polymer classes from which certain representatives 
have been shown to meet these characteristics include copolyethers of 
poly(ethylene glycol) (PEG) and polypropylene glycol),18 copolyesters of PEG 
and poly(lactic acid)19 or polypropylene fumarate),20 homo- and copolymers of 
poly(organophosphazenes),21 and copolymers of poly(A/-isopropylacrylamide) 
(PNiPAAm).22,23 PNiPAAm undergoes a sharp and reversible phase transition at 
a LCST of 32 °C, but when used at the physiological temperature of 37 °C, linear 
PNiPAAm collapses substantially and precipitates as a separate phase. 
PNiPAAm copolymers containing small amounts of hydrophilic molecules, such 
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as acrylic acid, PEG or hyaluronic acid, however, demonstrated reversible 
gelation around body temperature without significant syneresis.24"26 Another 
method to stabilize PNiPAAm copolymers above the LCST is to copolymerize the 
monomers in the presence of a cross-linker to yield polymer networks,17 which in 
part limits the injectability of the materials.14 Despite this limitation, combining 
functional groups within a macromolecule such that in solution there is physical 
gelation in response to physiological temperature upon injection and radical 
cross-linking at a slower kinetic rate in situ is a concept that can yield superior 
materials with regard to gelation kinetics and ultimate mechanical properties. In 
addition, control over hydrogel properties might be improved through the 
combination of two mechanistically and kinetically independent gelation 
techniques additionally. The few studies that have explored such tandem gelation 
concepts for biomedical applications have used modified PNiPAAm-based and 
polyether-type thermogelling materials that were chemically cured after physical 
in situ gelation by Michael-type addition reactions between thiols and acrylates.27" 
29 
This study describes the synthesis of novel injectable PNiPAAm-based 
thermogelling macromers that are modified with olefinic moieties available for 
chemical cross-linking in vivo and that contain biocompatible hydrophobic 
domains. This design is expected to yield novel water-soluble environmentally 
responsive amphiphiles that not only combine two independent gelation 
mechanisms but also incorporate hydrophobic domains for mechanical 
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reinforcement and increased hydrophobicity of the thermogelled and cross-linked 
hydrogel matrix. A radical polymerization strategy is proposed to copolymerize 
the thermosensitive component A/-isopropylacrylamide (NiPAAm) with other 
acrylic monomers to yield the functional amphiphiles. Pentaerythritol diacrylate 
monostearate (PEDAS), a bifunctional monomer consisting of the biocompatible 
tetravalent alcohol pentaerythritol esterified with two acrylic acids and stearic 
acid, a natural, metabolically resorbable fatty acid, provides the hydrophobic 
domain and NiPAAm the thermogelling properties, while acrylamide (AAm) was 
selected as a hydrophilic comonomer to adjust the transition temperature of the 
macromer and 2-hydroxyethyl acrylate (HEA) was introduced to increase the 
number of hydroxy! groups available for chemical modification to yield chemically 
cross-linkable macromers. This study presents a protocol to yield water-soluble 
thermogelling amphiphilic macromers composed of PEDAS, NiPAAm, AAm, and 
HEA. Specifically, two series of macromers, one consisting of poly(PEDAS-stef-
NiPAAm-stef-AAm) terpolymers and the other poly(PEDAS-stef-NiPAAm-staf-
AAm-sfaMHEA) copolymers, with different comonomer ratios were synthesized 
and characterized by nuclear magnetic resonance (NMR) spectroscopy and gel 
permeation chromatography (GPC). Solutions of the macromers were 
characterized for their phase transition properties by differential scanning 
calorimetry (DSC) and oscillation rheology. Macroscopic gelation studies were 
performed to identify the thermodynamic stability of the thermogels. Candidate 
amphiphiles were (meth)acrylated to yield chemically cross-linkable 
339 
thermogelling macromers, which were then analyzed for chemical composition 
and cross-linking characteristics. Thermally and chemically cross-linkable 
macromers are presented that are potential building blocks for novel hydrogel 
systems with improved mechanical properties for orthopedic applications. 
B.2 Materials and Methods 
B.2 1 Materials 
Pentaerythritol diacrylate monostearate (PEDAS), octadecyl acrylate 
(ODA), A/-isopropylacrylamide (NiPAAm), poly(NiPAAm) (PNiPAAm), acrylamide 
(AAm), 2-hydroxyethylacrylate (HEA), 2,2'-azobis.(2-methylpropionitrile) 
(azobisisobutyronitrile, AIBN), acryloyl chloride (AcCI), methacryloyl chloride 
(MACI), anhydrous sodium carbonate, 4-methoxyphenol, ammonium persulfate 
(APS), and /N/,A/,A/',A/-tetramethylethane-1,2-diamine (TEMED) were purchased 
from Sigma-Aldrich (Sigma, St. Louis, MO) and used as received. The solvents 
tetrahydrofuran (THF), diethyl ether and acetone were obtained from Fisher 
Scientific (Pittsburgh, PA) in analytical grade and were used as received unless 
stated differently. THF used during macromer (meth)acrylation was dried by 
refluxing over a potassium/sodium alloy for 3 days under nitrogen and distilled 
prior to use. 
340 
B.2.2 Methods 
Macromer synthesis 
Statistical copolymers were synthesized from PEDAS, NiPAAm, AAm, and 
HEA using free radical polymerization (Scheme B.1). Thermogelling macromers 
(TGMs) of various compositions were obtained by dissolving the acrylic 
monomers at corresponding molar comonomer ratios in THF at 60 °C under 
nitrogen and initiating polymerization through the addition of AIBN (1.5 mol%). In 
a typical experiment, 3 g of PEDAS and corresponding amounts of comonomers 
were dissolved in 250 mL THF. The reaction was continuously stirred at 60 °C 
over 16 - 18h and then refluxed for an additional 2h while the nitrogen 
atmosphere was maintained. The product was isolated by rotoevaporation and 
precipitation in cold diethyl ether. The filtrate was dried, dissolved in THF for a 
second time and again precipitated in diethyl ether. Precipitating the product in 
ether twice has been shown efficient to remove unreacted monomers and low 
molecular weight oligomers during method development. The final filtrate was 
vacuum dried at ambient temperature and ground to a fine powder. Table B.1 
summarizes the different TGMs that were synthesized and characterized. 
Macromer (meth)acrylation 
Methacrylated TGMs (TGM-MA) or acrylated TGMs (TGM-Ac) were 
obtained through the conversion of TGMs with MACI or AcCI in anhydrous THF in 
the presence of anhydrous sodium carbonate as scavenger for any acidic by-
products. In a typical reaction, 5 g of vacuum dried TGM, 2.5 g of sodium 
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carbonate, and approximately 120 mg of 4-methoxy phenol as radical inhibitor 
were weighed into a three neck flask, which was subsequently purged with 
nitrogen and sealed against moisture. The nitrogen stream was maintained 
throughout the entire reaction. THF (75 ml_) was added through a septum and 
the polymer was dissolved under vigorous stirring. Thereafter, the reaction was 
chilled to below -10 °C using an ice-sodium chloride bath. As soon as the 
temperature dropped below -10 °C, the (meth)acrylation agent (MACI or AcCI) 
was added dropwise by means of a plastic syringe with needle through the 
septum. This addition step was controlled by the reaction temperature, which was 
maintained below -10 °C at any time. Following the addition of the 
(meth)acrylation agent, the mixture was stirred for another 16 -18 h during which 
the ice was allowed to melt and the mixture warmed up to ambient temperature. 
The reaction mixture was filtered to remove any salt. Subsequently, the polymer 
solution was carefully concentrated by rotoevaporation, diluted with acetone, and 
again concentrated until almost dry. Enough acetone was added to redissolve the 
polymer. The solution was precipitated in cold diethyl ether. This step allows also 
for the removal of the radical inhibitor 4-methoxy phenol which is soluble in 
diethyl ether. The (meth)acrylated TGM was isolated by vacuum filtration and 
finally dried under vacuum at ambient temperature. 
Proton nuclear magnetic resonance spectroscopy (1H-NMR) 
1H-NMR spectra were obtained using a 400 MHz spectrometer (Bruker, 
Switzerland). Sample materials were dissolved in CDCI3 (typical concentration: 
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20 mg/mL) that contained 0.05 % tetramethylsilane (TMS) as internal shift 
reference. All postacquisition data processing was performed with the MestRe-C 
NMR software package (Mestrelab Research S.L., Spain). The free induction 
decay (FID) was Fourier transformed, manually phased, referenced using the 
TMS signal, baseline corrected, and integrated. To improve signal-to-noise, line 
broadening of 1.5 Hz was applied during transformation of the FID when 
meth(acrylated) TGMs were analyzed. To determine the comonomer composition 
of the macromers relative to PEDAS, the spectra were typically integrated 
between 0.85 and 0.94 ppm (11), 0.95 and 1.24 ppm (12), 1.25 and 1.34 ppm (13), 
1.35 and 2.45 ppm (14), and between 3.50 and 4.50 ppm (15) (Fig. B.1). 13, which 
was attributed to 28 (b in Fig. B.1) out of the 32 methylene protons of the stearate 
chain in PEDAS was set to 28. Consequently, 11, which represents the methyl 
protons in PEDAS (a in Fig. B1.), yielded values ranging between 2.8 and 3.4. It 
was found that the use of 13 instead of 11 as internal standard yielded more 
accurate results because 13 comprises a higher number of protons. The relative 
molar contents of the comonomers NiPAAm, AAm and HEA were calculated from 
the values obtained for 12, 14, and 15 according to the following equations (indices 
m, n, and o refer to Scheme B.1): 
12 = 6-nm(NiPAAm) 
(1) 
14 = 11 + 3nm(NiPAAm) + 3-nn(AAm) + 3n0(HEA) 
(2) 
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15 = 8 + nm(NiPAAm) + 5n0(HEA) 
(3) 
Integral 12 comprises the 6 methyl protons of the N-isopropyl group of 
NiPAAm (p in Fig. B.1) (equation 1). 15 measures the methine proton of the latter 
functional group (i in Fig. B.1), the 8 methylene protons of pentaerythrityl core in 
PEDAS (e,f in Fig. B.1) as well as the 5 protons of the hydroxyethyl residue of 
HEA (l,m,h in Fig. B.1) (equation 3). 14 summarizes the 4 methylene protons on 
C2 and C3 of the fatty acid in PEDAS (c,d in Fig. B.1), the free hydroxyl proton in 
PEDAS (g in Fig. B.1), the 6 protons of the polymerized acrylic moieties of 
PEDAS, as well as 3 protons from each of the other copolymerized monomers 
NiPAAm, AAm, and HEA (x,y in Fig. B.1) (equation 2). 
TGM conversion upon (meth)acylation was also determined relative to 
PEDAS. The integral 13 (1 25 -1.34 ppm) was set to equal 28 protons. The 
signals derived from the olefinic protons of the acrylate (typically: 5.9 ppm, 6.2 
ppm, and 6.5 ppm) or methacrylate groups (typically: 5,6 ppm, 6.15 ppm) were 
integrated individually and the upfield signal (5.9 ppm (TGM-Ac) or 5.6 ppm 
(TGM-MA)) was quantified to obtain the degree of (meth)acrylation relative to 
PEDAS. The olefinic signals located further downfield often overlapped with the 
broad signal of the -NHR proton (6 - 7 ppm) of NiPAAm, which lead to falsely 
increased signal integrals. 
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Gel Permeation Chromatography (GPC) 
Molecular weight distributions of the different TGMs and (meth)acrylated 
TGMs were determined by GPC. A GPC system consisting of an HPLC pump 
(Waters, model 510, Milford, MA), an autosampler/injector (Waters, model 717) 
and a differential refractometer (Waters, model 410) equipped with a series of 
analytical columns (Styragel® guard column 20 mm, 4.6 x 30 mm; Styragel® HR3, 
5 mm, 4.6 x 300 mm; Styragel® HR1 column, 5 mm, 4.6 x 300 mm (all Waters) 
was used with degassed chloroform (HPLC grade, Sigma) as the eluent at a flow 
rate of 1.0 mL/min. Samples were prepared in chloroform at a concentration of 25 
mg/mL and filtered prior to analysis. Macromer number average molecular weight 
(Mn), weight average molecular weight (Mw), and polydispersity index (PI) were 
determined relative to polystyrene. Three samples of each material were 
prepared and analyzed. 
Rheological characterization 
All rheological measurements were performed on a thermostated 
oscillating rheometer (Rheolyst AR1000, TA Instruments, New Castle, DE, USA) 
equipped with a 6 cm steel cone (1 degree). TGMs were dissolved at the desired 
concentration, 10% (w/v) unless otherwise stated, in sterile minimum essential 
media (a modification; a-MEM) (Sigma) and kept on an orbital shaker over 24h at 
room temperature. In case the transition temperature of the macromer solution 
was below 25 °C, samples were shaken in a cold room (4 °C) until the polymers 
were dissolved. The dynamic viscoelastic properties of the solutions, namely the 
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dynamic moduli, storage modulus (G') and loss modulus (G"), complex viscosity 
(|T)*J), and loss angle (6), were recorded using the TA Rheology Advantage™ 
software (TA Instruments) at a gap size of 26 ^ m. 
Gelation properties and transition temperatures 
In a typical experiment, TGM and control samples were loaded, cooled to 
5 °C, pre-sheared at a rate of 1 s"1 for 1 min, and equilibrated for 15 min at 5 °C. 
The viscoelastic properties of the samples were then recorded during a 
temperature sweep from 5 °C to 65 °C at a rate of 1 °C/min at an observing 
frequency of 1 Hz and a displacement of 1x10"4 rad. To characterize the phase 
transition temperature of the TGM solution, different characteristic temperatures 
were determined. Upon thermogelation different rheological properties show 
characteristic changes during the temperature sweep. The initial change in 
viscoelastic properties is characterized by an increase of G' over G" resulting in a 
decrease of the phase angle 6. T„ characterizes the temperature at the first 
inflection point of the temperature-phase angle curve. During thermogel formation 
the viscosity of the system increased notably. T, describes the location of the 
inflection point of the temperature-complex viscosity curve. 
Reversibility of the thermogelation 
Samples were loaded, cooled to 10 °C, pre-sheared at a rate of 1 s"1 for 1 
min, and equilibrated for 5 min at 10 °C. The viscoelastic properties of the 
samples were then recorded during a set of different steps with a solvent trap 
installed. To gel the samples, a temperature sweep from 10 °C to 37 °C was 
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performed at a rate of 4 °C/min with a frequency of 1 Hz and a displacement of 
1x10"4 rad (step I). The samples were kept at 37 °C for 2 min while maintaining 
frequency and displacement at 1 Hz and 1x10"4 rad, respectively (step II). For the 
next 2 min at 37 °C the displacement was increased to 1.5x10"3 rad (step III). 
Thereafter, the temperature setting was automatically changed to 15 °C and a 
time sweep was recorded over 90 min at a frequency of 1 Hz and a displacement 
of 1.5x10"3 rad (step IV). In a typical experiment, the temperature had 
equilibrated at 15 °C after around 2.0 min into the time sweep. G' and \v\*\ were 
analyzed at 15 °C in step I, at the end of step II and after 60' during step IV. 
Macromer cross-linking 
The cone-plate setup described above including the solvent trap was used 
to compare the gelation properties of solutions from (meth)acrylated TGMs with 
and without chemical initiation. Solutions of different (meth)acrylated TGMs with 
a concentration of 10% (m/v) were prepared in a-MEM and loaded on the 
rheometer at 15 °C. Before the geometry was lowered to gap size, TEMED and 
APS solution (100 mg/mL in water) were added to reach final concentrations of 
20 mM each. In control samples without chemical initiation, equal amounts of 
TEMED and water were added. The samples were pre-sheared at a rate of 1 s"1 
for 1 min at 15 °C before the viscoelastic properties were recorded in a two-step 
protocol. A temperature sweep from 15 °C to 37 °C was performed at a rate of 5 
°C/min with a frequency of 1 Hz and a displacement of 1x10"4 rad (step I). 
Thereafter, the thermogel properties were monitored at 37 °C over 30 min while 
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maintaining oscillation frequency and displacement (step II). For samples with a 
transition temperature below 20 °C, the temperature sweep (step I) was started 
at 10 °C. For sample comparison the complex viscosities of the different samples 
were determined at 15 °C during step I and at the end of step II (30' at 37 °C). 
Differential Scanning Calorimetry (DSC) 
The transition temperature of different TGM solutions was also determined 
by DSC. Solutions of different macromers (10% w/v) were prepared in sterile a-
MEM as described for the rheology samples and 20 |^ L were pipetted in an 
aluminum sample pan (TA Instruments, Newcastle, DE) and capped. 
Thermograms were recorded on a TA Instruments DSC 2920 equipped with a 
refrigerated cooling system against an empty sealed pan as reference. In a 
typical run, the oven was equilibrated at 5 °C for 10 min and then heated to 80 °C 
at a heating rate of 5 °C/min. For samples with a transition temperature below 20 
°C, the measurements were performed between -5 °C and 50 °C. The transition 
temperature (TDsc) of the TGM solution was determined as the "onset at 
inflection" of the endothermic peak in the thermogram using the Universal 
Analysis 2000 software provided with the DSC system. DSC has been shown to 
yield phase separation temperatures that are comparable to values obtained by 
optical cloud point measurements and UV turbidimetry;30,31 methods that are 
typically used to determine the LCST of a polymer solution. All DSC experiments 
were performed in triplicate. 
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Thermogel stability 
TGM solutions (10% m/v) in a-MEM were prepared as described above, 
pipetted (450 \xL) into glass vials, which were finally capped airtight. The vials 
were placed in an incubator at 37 °C and analyzed after 2h and 24h. Following 
macroscopic observation of the thermogels, any supernatant was removed 
carefully using a syringe with needle. The amount of aspirated solvent was 
determined gravimetrically on an analytical scale and recorded relative to the 
amount of media that could be removed from control vials that had been filled 
with 450 [il_ plain a-MEM. The relative amount of supernatant represents a 
means to characterize the amount of syneresis of the corresponding thermogel. 
Statistics 
Unless otherwise stated, all experiments were conducted in triplicate and 
the data were expressed as mean ± standard deviation (SD). Single-factor 
analysis of variance (ANOVA) in conjunction with Tukey's Post Hoc test was 
performed to assess the statistical significance (p < 0.05) within data sets. 
B.3 Results & Discussion 
B.3.1 Macromonomer design 
Statistical copolymers of different comonomer ratios were synthesized 
from PEDAS, NiPAAm, AAm, and HEA in a free radical polymerization reaction 
initiated by AIBN in THF (Scheme B.1). The main design criteria behind the 
amphiphilic NiPAAm-based macromers were the incorporation of a hydrophobic 
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moiety to improve intermolecular cohesion and hydrogel mechanics in the long 
run; the introduction of hydrolytically labile bonds to foster macromer 
biodegradability; the presence of thermoresponsive domains and of functional 
groups that can be modified to enable chemical cross-linking of the macromers. 
Hydrophobicity has been described as an important design criterion for polymers 
in bone tissue engineering.32 Hydrophobic domains also contribute to cell-
biomaterial interactions and can improve the mechanical properties of a material. 
Lipids and fatty acids are hydrophobic building blocks that have become popular 
in biomaterial research due to their biocompatibility, metabolic elimination and 
renewability.33"35 PEDAS was selected as a hydrophobic building block as it 
contains the natural fatty acid stearic acid. Further components of PEDAS are the 
biocompatible alcohol pentaerythritol and two acrylic moieties that allow for the 
incorporation of PEDAS in copolymers synthesized by radical polymerization. 
The ester functionalities in PEDAS are potentially prone to hydrolysis. Other 
polymeric pentaerythritol esters have shown reasonable tissue compatibility and 
biodegradation,36 PEDAS, therefore, was intended to function as a hydrophobic 
acrylic building block that mediates degradability to the copolymers. NiPAAm 
served as a well established building block for thermoresponsive polymers.25 
PNiPAAm is characterized by a LCST around 32 °C and is known to show 
extensive phase separation at higher temperatures. To form stable hydrogels, 
NiPAAm has been copolymerized with hydrophilic comonomers or cross-linked.16 
Since copolymerization with the hydrophobic comonomer PEDAS would 
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decrease the transition temperature, AAm was selected as a non-ionic, 
hydrophilic acrylic monomer to compensate for the hydrophobic contribution of 
PEDAS and adjust the hydrophilic-hydrophobic balance of the resulting 
macromer. Through HEA, free hydroxyl groups can be introduced into the 
macromer that are available for chemical modification. Acrylation or 
methacrylation of the hydroxyl group would lead to cross-linkable macromers in 
which the (meth)acrylate functionalities are connected to the polymer backbone 
via hydrolysable hydroxyethyl esters, a design that fosters degradability of the 
cross-linked hydrogels. 
Initial experiments identified THF as a more suitable solvent for the 
synthesis of uncross-linked low-molecular weight macromers than toluene (data 
not shown). The reaction protocol described in the "Materials and Methods" 
section yielded copolymers that remained dissolved in the reaction mixture 
without increasing its viscosity significantly. The copolymers were precipitated out 
in diethyl ether and a colorless water- and chloroform-soluble powder was 
obtained after vacuum drying at yields around 80% - 85%. Initial studies further 
identified a 1:20 ratio of bifunctional PEDAS to the monofunctional acrylic 
comonomers to yield copolymers of reproducible molecular weight and promising 
hydrophilic-hydrophobic balance (data not shown). In order to establish the 
synthetic protocol and identify structure-property relations, terpolymers of 
PEDAS, NiPAAm and AAm were first synthesized and characterized. Since 
PEDAS contains a free hydroxyl group, such terpolymers technically already fulfill 
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the design criteria. Copolymers that contain HEA as a fourth comonomer were 
later synthesized with the objective to increase the number of free nucleophilic 
moieties for chemical modification. All copolymers are referred to with their 
theoretical comonomer composition throughout this study. 
B.3.2 Synthesis and structural characterization of thermogelling 
poly(PEDAS-sfaf-NiPAAm-sfaf-AAm) terpolymers 
Statistical copolymers were synthesized from PEDAS, NiPAAm and AAm 
with the content of hydrophilic AAm varying between 0% and 30% (Table B.1). 
Qualitative 1H-NMR analysis of the purified polymers revealed the absence of 
any olefinic signals (5 -7 ppm) from unreacted monomers (data not shown) and 
the presence of all characteristic signals derived from the copolymerized 
monomers (Fig. B.1, trace a). Aliphatic signals derived from the stearic acid chain 
of PEDAS were found at 0.9 ppm (-CH3, 3H, triplet) and around 1.3 ppm (-CH2-, 
28H, broad signal). The integral of the signal between 1.25 and 1.34 ppm was 
set to 28 and used as internal reference to calculate comonomer composition 
relative to PEDAS. Further signals were derived from the N-isopropyl group in 
NiPAAm and found at 1.15 ppm (-NH-CH(CH3)2) and 4 ppm (-NH-CH(CH3)2), and 
the methine and methylene groups of the polyacrylate backbone together with 
some functionalities in PEDAS between 1.4 and 2.4 ppm. The signals at 2.9 ppm 
(Fig. B.1, trace a) and 2.5 ppm (trace b) were attributed to residual water. Due to 
interactions of the moisture with the macromer molecules in CDCI3, the signal 
was found to vary in intensity and chemical shift dependent on macromer 
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composition and concentration (data not shown). With increasing AAm content 
and correspondingly decreasing NiPAAm content (Table B.1), the relative signal 
intensities of the aliphatic signals at around 1.15 and 1.3 ppm accordingly shifted 
towards the signal at 1.3 ppm indicating the varied comonomer composition in 
the copolymer (Fig. B.2A). Quantitative analysis of the NMR spectra revealed 
that copolymers at the desired comonomer ratios could be synthesized with 
appropriate control (Table B.1). 
With regard to the applicability of these macromers as injectable materials, 
control over macromer molecular weight and branching is critical, especially 
since PEDAS is a bifunctional monomer. The free radical polymerization protocol 
was optimized to allow for the synthesis of macromers that contain one to two 
PEDAS molecules and comprise the other comonomers at the feed ratio. In any 
case, the formation of branched, high molecular weight products should be 
avoided. Living radical polymerization techniques, such as group transfer 
polymerization (GTP) or reversible addition-fragmentation chain transfer (RAFT), 
may likely provide better control over macromer composition and molecular 
weight, but the requirements towards comonomer chemistry and purity (GTP) 
and catalyst chemistry (RAFT) are far more specific 37. Using these techniques, a 
systematic screening of different comonomer compositions as presented here 
would involve laborious adaptation of the protocol to the different comonomer 
compositions. The versatility of a free radical polymerization protocol appeared 
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advantageous for this study especially when control of macromer composition 
and weight can be achieved. 
GPC analysis of the PEDAS-NiPAAm-AAm terpolymers with AAm 
contents up to 20% revealed number average molecular weights ranging 
between 1690 and 2250 Da (Table B.1). These values correlate well with 
theoretical molecular weights calculated for macromers that consist of one to two 
PEDAS precursors and the corresponding comonomers. The observed trend of 
decreasing molecular weights with increasing AAm and correspondingly 
decreasing NiPAAm content correlates with the difference in molecular weight 
between NiPAAm and AAm. Polydispersity indices between 2.3 and 2.7 were 
calculated. Figure B.3 shows representative chromatograms of different TGMs 
and precursors as obtained by GPC in chloroform. The polymer chromatograms 
were free of monomer signals at around 25 min, the elution time of NiPAAm 
monomers (Fig. B.3, trace a). PEDAS yielded a broad signal for which a PI of 
around 2 was determined (Fig. B.3, trace b). The copolymer chromatograms 
were characterized by a broad signal with a significant tail (Fig. B.3, trace c-e). 
As a similar shape was found for a control polymer containing ODA, a 
monofunctional lipophilic monomer, instead of the bifunctional PEDAS (Fig. B.3, 
trace c), the broad distribution was not attributed to macromer branching but to 
the amphiphilic properties and resulting possible interactions with the 
chromatographic system. Extensive branching, indicated by a high molecular 
weight peak at low retention time (Fig. B.3, trace f) was however observed for 
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polyCPEDASrSfaf-NiPAAm^-sfaf-AAme), the terpolymers with the highest AAm 
content. Quantitative analysis consequently revealed a low Mn with a high PI of 
almost 7 (Table B.1). Further studies revealed that macromer molecular weight 
and branching increased with increasing reactant concentrations and decreasing 
initiator concentration (data not shown). From the above described results one 
can conclude that good control over macromer architecture can be achieved with 
the established synthesis protocol for different comonomer compositions with 
AAm contents of up to 20%. 
B.3.4 Thermogelation properties of poly(PEDAS-sfaf-NiPAAm-sfaf-AAm) 
terpolymers 
The thermogelation properties of solutions of the synthesized macromers 
(10% (m/v)) were analyzed by oscillation rheology. It is known that thermally 
induced phase separation is strongly affected by solution pH and ionic strength. 
Therefore, cell culture medium (a-MEM) was used as solvent during these 
experiments to simulate physiological and in vitro cell culture conditions. Figure 
B.4 shows a typical rheogram of a TGM, here poly(PEDASi-steM\liPAAnrii5-sfa£-
AAm3.5-stef-HEAi.5). The temperature dependent profiles observed for the 
complex moduli G' (storage modulus) and G" (loss modulus), the complex 
viscosity m.*l and the phase angle 6 are typical for thermogelling materials.22,38 At 
low temperatures, G" far exceeded G', which was indicated by a phase angle 5 
» 45°, a property characteristic of viscous liquids (Fig. B.4). For temperatures 
below 25 °C, the storage modulus of the displayed TGM was below the detection 
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limit of the instrument. At temperatures below the phase transition, complex 
moduli and complex viscosity of the polymer solution decreased slightly with 
temperature, which is a typical behaviour of viscoelastic polymer solutions. Upon 
further heating and thermogelation (here past 26 °C), G' and G" both increased 
drastically with G' finally exceeding G" (6 < 45°), which indicated the formation of 
a viscoelastic hydrogel. The complex viscosity of the system increased by almost 
five orders of magnitude during this transition. Characteristic temperatures that 
were determined from the rheograms of different TGMs for sample comparison 
are the temperatures at the first inflection point of the temperature-phase angle 
curve (X) and the inflection point of the temperature-complex viscosity curve (T„). 
While T, represents the onset of phase transition that is associated with colloidal 
aggregation of the macromers and clouding of the solution, T„ depicts the 
temperature at which the molecules have aggregated into a coherent network 
and form a hydrogel. The transition temperatures determined for poly(PEDASi-
staf-NiPAAm2o) and the different PEDAS-NiPAAm-AAm terpolymers are 
summarized in Figure B.5A. The figure also contains the transition temperatures 
as obtained by DSC (TDsc) for the different TGM solutions (10% (w/v) in a-MEM). 
The characteristic temperatures determined for PNiPAAm are displayed in Figure 
B.5B, I. Almost identical transition temperatures T6 (27.4 ± 1.2 °C) and T„ (27.4 ± 
1.3 °C) were obtained for PNiPAAm by rheology. DSC analysis yielded a 
transition temperature of 30.7 ± 0.1 °C. The discrepancy between the different 
temperatures likely has methodical reasons especially since TDsc is derived from 
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a calorimetric signal and the other two temperatures are derived from viscoelastic 
parameters relevant for material application. Po!y(PEDASi-steM\liPAAm2o) was 
characterized by significantly lower values for Td (25.7 ± 0.1 °C) and T„ (26.8 ± 
0.0 °C) (Fig. B.5A). TDsc (23.5 ± 0.6 °C) confirmed the shift towards a lower 
phase transition temperature, which is caused by the hydrophobic structures in 
PEDAS. Increasing contents of the hydrophilic comonomer AAm in PEDAS-
NiPAAm-AAm terpolymers compensated for the hydrophobic effect of PEDAS 
and the characteristic temperatures increased above the values of PNiPAAm. For 
poly(PEDASi-sfaf-NiPAAm14-stef-AAm6)) the terpolymer with the highest AAm 
content investigated, transition temperatures of 34.7 ± 2.4 °C (T), 43.5 ± 2.3 °C 
(T„), and 36.6 ± 1.4 °C (TDsc) were measured. A similar correlation between 
TGM composition and the different transition temperatures was found. For all 
TGMs a difference between T„ and Tn was observed, which typically increased 
with AAm content. In comparison to pure PNiPAAm, for which identical values for 
T6 and T„ were obtained, the TGMs are amphiphilic molecules and the formation 
of micellar aggregates is likely involved in the colloidal aggregation of the 
macromers during phase transition,39 Upon thermogelation the micelles 
aggregate and packing interactions increase to form dense gels. As the NiPAAm 
residues of the amphiphilic TGMs drastically change their interactions with 
solvent molecules during thermogelation, the hydrophilic-hydrophobic balance of 
the micelle-forming macromers is also altered significantly and micelle structure 
affected. Complex structural changes of the TGM solution are expected during 
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thermogelation that involve micelle formation, aggregation and vesicle shrinkage 
upon macromer dehydration. With this transition, T8 depicts the onset of colloidal 
aggregation and sol-gel transition, while Tn describes the temperature at which 
the macromers finally assemble into a coherent physical network and a dense gel 
is formed. For hydrophobic monomers (systems with low phase transition 
temperatures), the calorimetric transition (TDsc) appears to correlate with the 
onset of phase transition T,. With increasing hydrophilicity of the macromers, TDsc 
shifts closer towards T„ (Fig. B.5 A,C). Since the different transition temperatures 
depend on solution concentration, trends between TDsc, T5 and T„ might differ at 
different concentrations. The relatively low TDsc observed for poly(PEDASi-staf-
NiPAAmi4-stef-AAm6) is likely attributed to the extensive branching of this 
macromer (Fig. B.5A, Table B.1). 
Due to thermodynamic instability, PNiPAAm-based thermogels show 
considerable syneresis and possibly full phase separation when the temperature 
is increased above the phase transition temperature.22,40 With regard to 
biomedical applications, it has been shown that the extent of phase separation 
correlates with the difference between transition temperature, commonly the 
LCST, and 37 °C. In order to test for the thermodynamic stability of thermogels 
formed by the different TGMs, solutions (10% (w/v) were incubated at a constant 
temperature of 37 °C and the extent of syneresis was determined after 1h, 2h 
and 24h. The results from the 2h time point are summarized in Figure B.6. Part A 
depicts the gross view of the thermogels after 2h at 37 °C. The residual gel mass 
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is summarized in part B (Fig. B.6). The solutions were prepared and pipetted into 
glass vials at ambient temperature below the transition temperature of the TGM 
solution. In a typical experiment thermogel formation occurred approximately 10 
min after the vials were placed into the incubator. Immediately after gelation, the 
gel volume equalled the volume of the polymer solution (450 nL). After 24h, the 
residual gel fractions of all thermogels ranged around 10 - 15%, which was 
assumed to correlate with full syneresis and phase separation (data not shown). 
In accordance with the literature, PNiPAAm solutions (Fig. B.6, sample a) show 
extensive syneresis and phase separation at 37 °C. Solutions of poly(PEDASr 
steMMiPAAm2o), which gelled at a lower temperature then PNiPAAm, shrunk to a 
comparable extent after 2h (sample b). With increasing AAm content, improved 
stability was observed for PEDAS-NiPAAm-AAm terpolymers (sample c, d) with 
poly(PEDASi-staf-NiPAAmi6-stef-AAm4) forming stable thermogels at 37 °C for 
2h (sample d). Solutions of poly(PEDASrStef-NiPAAm14-sfaf-AAm6) (T„ = 43.5 ± 
2.3 °C) did not gel at 37 °C; correspondingly, no gel fraction could be quantified 
after 2h (sample e). 
These results show that amphiphilic terpolymers were synthesized with 
controlled molecular composition and structure. TGM structure, especially the 
hydrophobic-hydrophilic balance, controlled the thermally induced gelation of 
corresponding aqueous macromer solutions. The thermodynamic stability of the 
resulting thermogels correlated with transition temperature. With regard to the 
intended chemical modification of the macromers, initial tests revealed that the 
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free hydroxyl group in PEDAS (Scheme B.1) was not sufficiently accessible for 
(meth)acrylation reaction possibly due to steric hindrance (data not shown). In 
order to incorporate additional hydroxyl groups, HEA was introduced as 
comonomer and initially copolymerized with PEDAS and NiPAAm. HEA is known 
as a hydrophilic monomer and was therefore considered as a building block that 
could provide chemically accessible hydroxyl groups in combination with a 
potential to balance the hydrophobicity of PEDAS and control the transition 
temperature of the macromers. Analogous to the synthesis of poly(PEDASi-staf-
NiPAAm16-sterf-AAm4), poly(PEDAS1-sfaf-NiPAAm16-sfaMHEA4) was synthesized 
at the desired composition and molecular weight (Table B.1). Analysis of the 
transition temperatures revealed values below 25 °C for T„, T„ and TDSC (Fig. 
B.5B, II). As a result of intra- or intermolecular hydrogen bond formation the 
hydroxyl group of HEA did not fully interact with water and the expected 
hydrophilic effect of HEA was diminished in solution. Correspondingly, extensive 
syneresis was observed for the corresponding thermogels (Fig. B.6, sample h). 
Consequently, copolymers of PEDAS, NiPAAm, AAm, and HEA were 
synthesized for further experiments. The molar ratio of PEDAS to NiPAAm + 
AAm + HEA was maintained at 1:20. 
B.3.5 Synthesis and characterization of thermogelling poly(PEDAS-sfaf-
NiPAAm-sfaf-AAm-sfaf-HEA) copolymers 
Copolymers containing 1 mol PEDAS, 15.4 mol NiPAAm and varying 
ratios of AAm and HEA (poly(PEDASi-stef-NiPAAm15.4-ste^-AAmm-sfaf-HEAn)) 
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were synthesized at the desired composition and molecular weight distribution 
(Table B.1, Fig. B.3). A trend between molecular weight and HEA content as a 
result of the molecular weight difference of AAm and HEA was observed. 1H-
NMR analysis confirmed the presence of HEA specific protons in the copolymers 
(l,h,m in Fig. B.1, trace b). The intensities of these signals were found to increase 
relative to the methine signal (4.0 ppm) of the A/-isopropyl group of NiPAAm with 
increasing comonomer contents of HEA (Fig. B.2B). Figure B.3 compares the 
molecular weight distribution of poly(PEDASi-staf-NiPAAmi54-stef-AAm3-staf-
HEAT
 6) (trace d) and poly(ODA1-sfaf-NiPAAmi54-sfaf-AAm3-stef-HEAi 6) (trace 
c). This comparison was motivated by the concern of network formation due to 
the use of the bifunctional monomer PEDAS. ODA is a monofunctional monomer 
comprising stearic alcohol and acrylic acid making the lipophilic component 
comparable to the stearic acid domain in PEDAS. The results illustrate that the 
molecular weight distributions of the different macromers do not differ 
significantly which indicates that PEDAS-containing TGMs are most likely 
branched but not networked and still contain individual macromers of controllable 
molecular weight (Mn) in the range of 2000 - 3500 Da (Fig. B.3, Table B.1). 
Despite its bifunctionality, PEDAS is considered advantageous over ODA 
because the lipophilic domain of PEDAS, stearic acid, can be metabolized 
following ester hydrolysis in contrast to stearic alcohol. Comparison of the 
transition temperatures of both copolymers (Fig B.5; B, III vs. C, data set on far 
left), revealed significantly higher values for poly(PEDASi-steM\liPAAmi54-staf-
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AAm3-steMHEA16), which likely indicates that the hydrophilic pentaerythrityl core 
of PEDAS positively affects the hydrophobic-hydrophilic balance within the 
macromer. Within the set of poly(PEDASi-sfaf-NiPAAm154-stef-AAmm-steMHEAn) 
copolymers, the transition temperatures follow the structure-property relations 
established in PEDAS-NiPAAm-AAm terpolymers (Fig. B.5C). With increasing 
HEA and decreasing AAm contents, the transition temperatures decrease. TDsc 
again approaches T, with increasing hydrophobicity of the TGMs. In correlation 
with the transition temperatures, the thermogel stability of poly(PEDASi-stef-
NiPAAmi5 4-sfaf-AAmm-steMHEAn) copolymers at 37 °C decreased with 
increasing n/m ratio (Fig. B.6, samples f and g). 
B.3.6 Thermogel stability of amphiphilic NiPAAm-based macromers 
The TGMs were designed to contain hydrophobic domains to promote 
disperse interactions among the macromers and potentially increase mechanical 
stability of a TGM-based hydrogel. With regard to the thermogelation properties, 
these domains necessitated the incorporation of hydrophilic domains to adjust 
transition temperature and thermodynamic stability of thermally gelled TGM 
solutions. To test for any effects of the resulting amphiphilic design on the 
stability of corresponding thermogels, rheological experiments investigating the 
reversibility of the physical gelation were performed with PNiPAAm as control 
polymer (Fig. B.7). Two TGMs, poly(PEDASi-ste£-NiPAAmi4-staf-AAm3-staf-
HEA3) and poly(PEDASi-staf-NiPAAm15.4-stef-AAm2-steMHEA26), with 
calorimetric transition temperatures (TDsc) surrounding the value determined for 
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PNiPAAm were selected considering the structure property relation established 
for TGM hydrogels. Comparison of PNiPAAm with the two TGMs that were 
characterized by comparable transition temperatures revealed significant 
differences for the gel-sol transition upon cooling below transition temperature. 
During the rheometric experiment, the macromers were first gelled during a 
controlled temperature sweep to 37 °C. After an isothermal phase of 2 min, the 
shear stress was increased and maintained for another 2 min before the 
temperature was set to 15 °C and changes in the complex viscosity were 
monitored (Fig. B.7). All systems underwent thermogelation upon heating to 37 
°C, which was associated with an increase in complex viscosity by 3-4 orders of 
magnitude. The PNiPAAm solution showed the highest complex viscosity at 5 °C 
and after 2 min at 37 °C. This can likely be attributed to the higher molecular 
weight of the PNiPAAm (Mn of 20 - 25 kDa according to manufacturer) as 
compared to the TGMs. In response to the temperature decrease to 15 °C, the 
PNiPAAm system degelled almost instantly into a solution with a complex 
viscosity as at the start of the experiment. Both TGM hydrogels, in contrast, 
maintained a significantly elevated complex viscosity for 60 min at 15 °C, while 
the systems became translucent once the temperature dropped below the 
transition temperature. Macroscopic observations revealed the full reversibility of 
the thermogelation for the TGM gels after 2-3 days at 20 °C and below (data not 
shown). This indicates that during thermally induced gelation of amphiphilic 
NiPAAm-based macromers colloids are formed, which are stabilized by additional 
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intermolecular forces than those arising from the entropically driven aggregation 
of PNiPAAm domains. PNiPAAm-based amphiphiies appear advantageous over 
pure PNiPAAm hydrogels when increased hydrogel stability is warranted and the 
kinetics of the gel-sol transition is of minor importance. 
B.3.7 TGMs with optimized composition and gelation properties 
In view of the established structure property correlations and the design 
objective to optimize the thermodynamic stability of the TGMs and to provide a 
sufficient number of hydroxyl groups available for chemical modification per 
macromer, TGMs with high AAm and HEA contents and reduced NiPAAm 
comonomer contents were synthesized and analyzed (Table B.1). Poly(PEDASi-
stat-N\PAAmu-stat-AAm3-stat-HEA3) could be synthesized at the desired 
composition and molecular weight. The NMR analysis of poly(PEDASi-staf-
NiPAAmi3 5-staf-AAm3 5-stef-HEA3) revealed overly high AAm contents and low 
NiPAAm contents, a phenomenon also observed for poly(PEDASi-stef-
NiPAAmi4-sfaf-AAm6). These findings are attributed to likely colloid formation of 
these strongly amphiphilic macromers in the NMR solvent CDCI3 and shielding of 
PEDAS and NiPAAm protons. Increased branching was observed for 
poly(PEDASi-sfaf-NiPAAmi5-sfaf-AAm3.5-stef-HEAi.5), which was designed to 
contain half of the HEA compared to poly(PEDASrstef-NiPAAmi4-stef-AAm3-
steMHEA3) and keep the molar AAm comonomer content below 4 (relative to 
PEDAS). Poly(PEDASi-stef-NiPAAm14-stef-AAm3-steMHEA3) solutions were 
characterized by a T,: of 33.7 ± 0.2 °C more than 5 °C above the T„ determined 
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for PNiPAAm (Fig. B.5C, I). The stability of thermogels formed from this TGM 
were also significantly increased (Fig. B.6, sample i). A further increase in AAm 
content resulted in a TGM (poly(PEDASi-ste?-NiPAAmi3.5-stef-AAm3.5-sfaf-
HEA3)) that yielded even more stable thermogels (Fig. B.6, sample k). The 
chemical characteristics of the macromers, however, were less definite (Table 
B.1), which explains the disperse results obtained for Ts, T„ and TDsc (Fig. B.5D, 
V). Another well balanced TGM was synthesized with poly(PEDASi-stef-
NiPAAmi5-sta£-AAm3.5-sta?-HEAi.5), which was characterized by Ts and T„ 
comparable to poly(PEDASrs^NiPAAm14-stef-AAm3-stef-HEA3) but a 
significantly increased TDSc (35.6 ± 0.5 °C) (Fig. B.5C, VI) and formed 
thermogels of appropriate stability (Fig. B.6, sample I). In view of their favorable 
thermogelation properties, poly(PEDASi-sta£-NiPAAm14-sfaf-AAm3-steMHEA3) 
and poly(PEDASi-sfaf-NiPAAmi5-sfaf-AAm3.5-sfaMHEAi.5) were chemically 
modified to yield chemically cross-linkable TGMs (Scheme B.1, step II). 
B.3.8 Synthesis and structural characterization of chemically crosslikahle 
TGMs 
With the objective to introduce chemically cross-linkable domains into the 
TGMs to yield macromers that can be gelled both physically and chemically, 
TGMs were reacted with AcCI or MACI. Anhydrous sodium carbonate was used 
to scavenge any acidic by-products during the reaction and upon termination any 
salt was removed by filtration.41 Triethylamine, which is a commonly used base to 
catalyze such (meth)acrylation reactions, could not be effectively removed from 
365 
the reaction products due to the lack of a suitable extraction solvent that would 
precipitate the amphiphilic macromers. As described for the hydroxy! group 
methacrylation of other molecules,42 the molar excess of the acrylation or 
methacrylation agent, AcCI or MACI, controlled the extent of hydroxyl group 
conversion (Table B.2, Fig. B.8). Figure B.8 shows representative 1H-NMR traces 
of poly(PEDASrStef-NiPAAm14-stef-AAm3-sfaMHEA3) as well as two acrylated 
and one methacrylated derivative. Characteristic changes of the proton signal 
indicate successful (meth)acrylation of the TGM. Upon (meth)acrylation, 
characteristic olefinic proton signals appear between 5.6 and 6.6 ppm 
representing three (TGM-Ac) or two (TGM-MA) olefinic protons per (meth)acrylic 
ester. In addition, a downfield shift of the methylene protons in a-position to the 
newly formed (meth)acrylic ester was observed (signal at 4.3 ppm). A signal at 
1.9 - 2.0 ppm representing the methyl group of the methacrylate ester group was 
found in the spectrum of TGM-MA. The conversion was calculated relative to the 
PEDAS molecules per TGM and an increased conversion was found with higher 
feeds of (meth)acryloyl chloride. Poly(PEDASi-stef-NiPAAmi4-stef-AAm3-stef-
HEA3), the TGM with the higher HEA content per macromer, showed a higher 
conversion relative to PEDAS. A maximum of 1.25 acrylic groups per macromer 
subunit identified by one PEDAS block was achieved with an acryloyl chloride 
excess of 2.5 (relative to the theoretical number of hydroxyl groups per macromer 
subunit). This means that 1.25 out of the 4 theoretical hydroxyl groups per 
macromer subunit (3 in HEA and one in PEDAS) were acrylated. Additional 
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experiments revealed that the hydroxy! group of PEDAS was not accessible for 
(meth)acrylation under the applied conditions (data not shown). Due to the lower 
reactivity of methacrylic chloride, a likely consequence of steric limitations, a 
lower conversion was found for the methacrylated TGMs as compared to the 
acrylation products at corresponding molar feeds of the reactive chlorides (Table 
B.2). The transition temperatures of the (meth)acrylated macromers, here TDSC, 
were found to decrease with the extent of (meth)acrylation. As hydrophilic 
hydroxyl functionalities are turned into considerably less hydrophilic (meth)acrylic 
esters, the hydrophilic-hydrophobic balance of the macromer was changed 
towards increased hydrophobicity and the phase transition temperature 
decreased. A stronger effect of macromer derivatization on transition temperature 
was found for TGM-MA, which is explained by the stronger hydrophobicity of the 
methacrylic ester as compared to an acrylic ester. 
B.3.9 Gelation properties of chemically crosslinkable TGMs 
Results of rheological experiments performed with solutions of the 
(meth)acrylated TGMs (10% (w/v)) with and without the presence of the thermal 
initiator system APS/TEMED (25mM each) are summarized in Figure B.9. Redox 
initiator system and concentration have been shown suitable and sufficiently 
biocompatible for direct cell encapsulation with in situ cross-linked hydrogels.7,43 
All (meth)acrylated TGMs except acrylated (Ac 2.5x) poly(PEDASi-stef-
NiPAAm14-sfaf-AAm3-staMHEA3) showed thermogelation during the initial 
temperature sweep to 37 °C, which was associated with a significant increase in 
367 
complex viscosity for samples with (APS/TEMED) and without (H20/TEMED) 
chemical initiation (Fig. B.9A.B). Acrylated (2.5x) poly(PEDASi-stef-NiPAAm14-
sfaf-AAm3-steMHEA3), which showed the highest degree of acrylation, had likely 
partially cross-linked during preparation of rheological samples. The high 
complex viscosity values determined for this sample at the beginning of the 
rheological experiment confirmed this assumption. For the other samples, low 
complex viscosities below 0.1 Pa*s were determined for the solutions at 15 °C 
and no significant differences were found between the APS containing samples 
and the control samples (H20/TEMED) at 15 °C (Fig. B.9B.C). At 37 °C, higher 
complex viscosity values were typically determined for initiated samples 
(APS/TEMED) compared to the non-initiated controls (Fig. B.9A). During the 
subsequent time sweep at 37 °C, the complex viscosity was monitored for 30 min 
at 37 °C. While the APS/TEMED groups typically maintained the values for 
complex viscosity during this time, decreasing complex viscosity values due to 
the thermodynamic instability of the physical gels were recorded for the 
H20/TEMED groups (Fig. B.9A). This result indicates thermally initiated cross-
linking of the (meth)acrylated TGMs in the presence of APS/TEMED during the 
temperature sweep within a few minutes. Based on these findings, that show that 
physical and chemical cross-linking occurred almost simultaneously, the tested 
initiator concentration appears high. If slower cross-linking kinetics are desired to 
achieve successive thermogelation and chemical cross-linking, a lower initiator 
concentration would be recommended. Comparison of the complex viscosities 
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after 30 min at 37 °C revealed a significant difference between the cross-iinked 
macromers and the physically gelled systems (Fig. B.9B,C). The viscosities 
determined for the highly acrylated po\y(PEDASrStat~N\PAAm:5-stat-AAm35-stat-
HEA15) were comparable to those achieved for poly(PEDASi-steM\liPAAmi4-
staf-AAm3-steMHEA3) acrylated using a low AcCI feed (0.75x). For this polymer 
higher acrylation rates could be achieved with AcCI feeds of 1.25x and 2.5x 
(Table B.2), but the viscosity of gels cross-linked from these macromers was 
decreased likely due to extensive phase separation of these hydrophobic 
macromers at 37 °C (Fig. B.9B). In general, high viscosities were reached by 
cross-linking the methacrylated macromers but their low transition temperatures 
significantly impair polymer processing with regard to biomedical applications. 
Macroscopically, the APS/TEMED systems remained as a coherent hydrogel film 
on the geometry upon disassembly of the rheometer, while the non-initiated 
samples resembled a highly viscous liquid (data not shown). The cross-linking 
density and (meth)acrylate conversion of the cross-linked hydrogels could be 
determined by total hydrolysis of the gels and subsequent chromatographic 
analysis.44 For all experiments, macromer solutions with a concentration of 10% 
(w/v) have been used. This concentration is comparably low with regard to other 
injectable hydrogels based on synthetic polymers such as poly(ethylene glycol), 
which typically range from 20 - 25%.43,45,46 The use of macromer concentrations 
higher than 10% is expected to yield TGM hydrogels with increased cros-linking 
densities. 
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B.4 Conclusions 
Amphiphilic TGMs with controlled polymer architecture and low molecular 
weight (~2 - 3.5 kDa) were synthesized from PEDAS, NiPAAm, AAm, and HEA at 
different compositions and selected macromers were subsequently 
(meth)acrylated to yield chemically cross-linkable thermogelling materials for 
biomedical applications. Structure-property correlations for non-modified TGMs 
were established and the hydrophilic-hydrophobic balance was characterized as 
an important design criterion to adjust the gelation temperature of TGM solutions 
and thermodynamic stability of the resulting thermogels. The amphiphilic design 
was shown to support intermolecular interactions, a property which could improve 
the mechanical stability of cross-linked TGM-based gels. (Meth)acrylated TGMs 
were synthesized and the combination of thermogelation and thermally induced 
chemical cross-linking was shown to improve hydrogel stability. The experiments 
further suggest that degree of acrylation and hydrophilic-hydrophobic balance of 
the macromers have to be well-adjusted to yield hydrogels of optimal stability. 
The synthesis of chemically cross-linkable, thermogelling, and potentially 
biodegradable macromers was realized and promising macromers for the design 
of injectable drug and/or cell delivery systems with improved properties and 
stability are presented. 
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B.6 Figures 
Table B.1. Compositions and molecular weight characteristics of thermogelling 
macromers. 
theoretical composition 
actual comonomer feed [mol] 
(based on 1 mol PEDAS) 
NiPAAm/AAm/HEA 
PEDAS/NiPAAm/AAm/HEA (b/c/d in Scheme 1) 
1/20/-/-
1/18.5/1.5/-
1/18/2/-
1/17/3/-
1/16/4/-
1/14/6/-
1/16/-/4 
1/15.4/1/3.6 
1/15.4/2/2.6 
1/15.4/2.6/2 
1/15.4/3/1.6 
1/15/3.5/1.5 
1/14/3/3 
1/13.5/3.5/3 
ODA/15.4/3/1.6 
' H N M R results 
(based on 1 mol PEDAS) 
NiPAAm/AAm/HEA 
(m/n/o in Scheme 1) 
Effect of AAm Content 
20.0/-/-
18.6/1.6/-
18.0/2.0/-
17.0/3.0/-
16.0/4.1/-
13.9/6.0/-
20.7/-/-
19.1/2.1/-
18.9/2.4/-
16.4/2.1/-
13.3/4.2/-
10.0/5.2/-
Effect of HEA Content 
15.9/-/4.0 
15.4/1.0/4.2 
15.3/2.0/2.6 
15.4/2.7/2.2 
15.1/3.0/1.9 
15.2/3.5/1.5 
14.0/3.0/3.0 
13.4/3.5/3.0 
17.5/-/5.8 
17.0/1.3/3.2 
17.4/1.8/2.0 
15.0/3.1/2.8 
14.0/4.0/0.9 
15.8/3.1/2.0 
15.2/2.0/3.4 
11.6/6.6/2.2 
Control (composition, comonomer feed and NMR data are based on 1 i 
15 4/3.1/1.7 15.5/5.1/1.8 
GPC 
Mn [Da] 
2660 ± 130 
2450 ± 280 
1 8 7 0 ± 1 3 0 
1860 ± 2 6 0 
1690 ± 8 0 
1470 ± 2 5 0 
3050 ± 140 
3810 ± 2 6 0 
2070 ± 90 
2 0 3 0 ± 1 9 0 
1930 ± 120 
2 1 1 0 ± 6 0 
2630 ± 200 
2770 ± 80 
•mol ODA) 
2450 ± 80 
results 
PI 
3.4 ± 0 . 2 
2.6 ± 0 . 2 
2.5 ± 0 . 3 
2.7 ± 0 . 2 
2.7 ± 0 . 1 
6.9 ± 2 . 1 
2.9 ± 0 . 2 
3.0 ± 0 . 3 
2.7 ± 0.1 
2.9 ± 0 . 2 
2.9 ± 0.4 
3.7 ± 0.6 
2.9 ± 0 . 0 
2.7 ± 0 . 2 
2.1 i 0.0 
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Table B.2. Methacrylated (TGM-MA) or acrylated (TGM-Ac) macromers 
synthesized from two different TGMs at increasing molar rations of the 
(meth)methacrylation reagents (XCI) methacryloyl chloride or acryloyl chloride, 
respectively. Conversion of TGM hydroxyl groups into (meth)acrylate esters as 
determined by 1H-NMR per PEDAS molecule (n0iefin/npEDAs) and corresponding 
transition temperature of a 10% macromer solution as determined by DSC (n = 3). 
TGM (PEDAS/NiPAAm/AAm/HEA) 
modification 
unmodified 
melhacrylation 
acrylatlon 
reagent leed 
( ixci '"on) 
n/a 
1.25 
2.5 
0.75 
1.25 
2.5 
'H NMR 
( 1< , IO I . . / "PEDAS 
n/a 
0.55 
1.12 
0.27 
1.01 
1.25 
1:14:3:3 
1 W (aC) 
33.1 :t 0.4 
13.6 ± 1.1 
13.8 ± 0.5 
25.1 ± 0.6 
22.3 ± 1.2 
19.6 ± 0.7 
1: 
'H NMR 
'^oiot! i/nP£DAS 
n/a 
0.19 
0.57 
0.15 
0.64 
0.98 
15:3.5:1.5 
) W l°c) 
35.6 ±. 0.5 
24.1 ± 0.6 
15.2 ± 0.9 
31.2 ± 0.2 
24.6 ± 0.3 
20.8 ± 0.9 
" Convory.ion of TGM hydroxyl groups inlo (meth)acrylate osiers, as determined by 'H-NMR per PtDAS molecule (nWf)l.n/'nr^[:,AS) and corresponding 
iransition temperature o! a 10% macromer solution as determined by DSC [n •- 3). 
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Scheme B.1. Synthetic scheme for thermogelling macromers (TGM) from the 
bifunctional monomer pentaerythritol diacrylate monostearate (PEDAS) and the 
acrylic monomers AAisopropylacrylamide (NiPAAm), acrylamide (AAm), and 2-
hydroxyethylacrylate (HEA) by radical copolymerization (Step I). The resulting 
macromer is a branched statistical copolymer. The schematic illustration of its 
structure is very simplified recognizing that a PEDAS repeating unit can be part of 
two linear chains thus contributing to the branched structure of the macromer (A 
indicates possible branching sites). All copolymers in this study are synthesized 
from a comonomer ratio of a:(b+c+d) = 1:20. Theoretically, three out of four 
indices (p,m,n,o) could equal zero in possible products. In the ideal case, the ratio 
p:m:n:o equals a:b:c:d. (Meth)acrylate moieties that enable chemical crosslinking 
of the macromer are introduced in the second reaction step. Pendant hydroxyl 
groups that can be reacted in this methacrylation step are found in the PEDAS 
and HEA repeating units of the macromer and will be converted to different 
degrees (s, s'). 
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Figure B.1. 1H-NMR spectra of (a) poly(PEDAS1-stef-NiPAAm16-stef-AAm4) and (b) 
poly(PEDASi-sfaf-NiPAAm16-sfaf-HEA4). The letters assigned to the peaks 
correspond to the protons at the positions labeled in the structural elements of 
the copolymers. 11 - 15 represent the integrals used to determine macromer 
composition. 
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Figure B.2. Close-ups of 1H-NMR spectra for different TGMs illustrating qualitative 
changes in signal intensities with changing comonomer ratios. (A) Poly(PEDAS1-
sfaf-NiPAAm(2o-m)-s'af-AAmm) with m = 0, 2, 4, 6 (a-d). (B) PolyfPEDASrSfaf-
NiPAAm(2o.m-n)-stof-AAmm-sfaf-HEAn) with m/n = 1/3.6 (a), 2/2.6 (b), and 3/1.6 (c). 
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Figure B.3. GPC traces of (a) NiPAAm, (b) PEDAS, (c) poly(ODA1-sfaf-NiPAAm154-
sfaf-AAm3-sfaMHEA16) (control synthesized with monofunctional monomers only), 
(d) polytPEDASrStef-NiPAArrdBa-sfaf-AAma-sfaMHEA^), (e) poly(PEDASrsfaf-
NiPAAm16-sfaf-AAm4), and (f) poly(PEDAS1-stef-NiPAAm14-sfaf-AAm6) (macromer 
that showed formation of branched networks). 
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Figure B.4. Representative rheogram of poly(PEDASi-sfaf-NiPAAm15-sfaf-AAm3.5-
stat-HEAim5) obtained during a temperature sweep between 5 and 45°C at 1 Hz. The 
complex moduli (C and G") and the complex viscosity ln*l are displayed on the 
left y-axis, while the right y-axis refers to the loss angle (5). The locations of the 
characteristic temperatures T5 and Tn are indicated by arrows. 
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Figure B.5. Phase transition temperatures determined from rheology (T5, Tn) and 
differential scanning calorimetry (TDSC) for different TGMs. (A) Co- and 
terpolymers composed of PEDAS, NiPAAm and different contents of AAm (m = 0-
6). (B) Polymeric controls: (I) PNiPAAm, (II) poly(PEDASi-sfaf-NiPAAm16-sfaf-HEA4) 
and (III) poly(ODA1-sfaf-NiPAAm15 4-sfaf-AAm3-sfaf-HEA1.6). (C) Poly(PEDAS1-sfaf-
NiPAAm15.4-sfaf-AAm(4.6.n)-sfaf-HEAn) with differents contents of HEA (n = 1.6, 2, 
2.6, 3.6) (D) TGMs with different NiPAAm:AAm:HEA comonomer ratios, (IV) 14:3:3, 
(V) 13:4:3, (VI) 15:3.5:1.5. 
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Figure B.6. Stability of thermogels of different comonomer composition at 37 °C. 
(A) Macroscopic images of thermogels after 2 h of incubation. (B) Mass fraction of 
thermogels after 2 h. Columns and error bar represent means ± standard 
deviation for n = 3. Samples: (a) PNiPAAm; poly(PEDASi-sfaf-NiPAAm(20-m)-sfaf-
AAmm) with m = 0, 3, 4, 6 (b-e); poly(PEDAS1-sfaf-NiPAAm(2o-mn)-sfaNAAmm-sfaf-
HEAn) with m/n = 2/2.6 (f), 1/3.6 (g), 0/4 (h), 3/3 (i), 3.5/3 (k), and 3.5/1.5 (I). 
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Figure B.7. (A) Representative rheograms of polyfPEDASrSfaf-NiPAAmu-sfaf-
AAm3-sfaf-HEA3) (TGM) and PNiPAAm as recorded during a test for reversibility of 
the thermogelation. For experimental conditions during steps I - IV please refer to 
the Methods section. (B) Values for complex viscosity lr|*l (left y-axis) for 
PNiPAAM, poly(PEDASi-sfaf-NiPAAmi4-sfaf-AAm3-sfar-HEA3) and poly(PEDAS1-
sfaf-NiPAAm15.4-sfaf-AAm2-sfaf-HEA2.6) as determined at 15 °C during step I (15 
°C), after 2 min at 37 °C, and after 60' into step IV at 15 °C. Transition temperatures 
as determined by DSC (TDSC) of the different polymers are assigned to the right 
y-axis. Columns and error bar represent means + standard deviation for n = 3. 
Statistically significant differences between the complex viscosities of the TGM 
samples (60 min at 15°C) as compared to the corresponding value for PNiPAAm is 
denoted by #. 
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Figure B.8. Close up (1.5 - 7 ppm) of 1H-NMR spectra obtained for (a) 
poly(PEDASrsfaf-NiPAAm14-sfaf-AAm3-sfaf-HEA3) (TGM) and (b-d) (meth)acrylated 
poly(PEDAS1-sfaf-NiPAAm14-sfaf-AAm3-sfaf-HEA3) at different molar excesses of 
(meth)acryloyl chloride: (b) TGM-Ac (0.75x), (c) TGM-Ac (2.5x), and (d) TGM-MA 
(2.5x). Proton signal derived from the (meth)acrylate groups are indicated by 
arrows. 
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Figure B.9. Rheological characterization of solutions of different (meth)acrylated 
TGMs with (APS/TEMED) and without (H20/TEMED) chemical initiation. (A) 
Representative rheograms of acrylated (0.75x) poly(PEDAS1-sfaf-NiPAAm15-sfaf-
AAm35-sfaM-IEAi5) (10% (m/v)) with and without chemical initiation during the 
combined temperature-time experiment. Complex viscosity In/I at 15 °C and after 
30' at 37 °C as determined for macromer solutions of (A) different (meth)acrylated 
poly(PEDASrsfaf-NiPAAm14-sfaf-AAm3-sfaf-HEA3) and (B) different 
(meth)acrylated poly(PEDAS1-sfaf-NiPAAm15-sfaf-AAm35-sfaf-HEA15) with 
(APS/TEMED) and without (H2C7TEMED) chemical initiation. Columns and error 
bar represent means + standard deviation for n = 3. A statistically significantly 
increased complex viscosity for the APS/TEMED samples after 30 min at 37 °C as 
compared to the H2C7TEMED samples at the same time point is denoted by #. 
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Appendix C 
Cytocompatibility evaluation of amphiphilic, thermally responsive and 
chemically crosslinkable macromers for in situ forming hydrogels+ 
Abstract 
The cytocompatibility of a new type of amphiphilic, thermoresponsive and 
chemically crosslinkable macromers was examined in vitro. Macromers 
synthesized from pentaerythritol diacrylate monostearate, N-
isopropylacrylamide, acrylamide and hydroxyethyl acrylate in different molar 
ratios and with varying molecular weights and lower critical solution temperatures 
were evaluated for cytocompatibility with rat fibroblasts. Cell viabilities of over 
60% percent for all and over 80% for most formulations were observed after 24-h 
incubation with macromers with molecular weights in the range of approximately 
1500 to 3000 Da. The chemical modification of the macromers with a 
(meth)acrylate group was shown to have a time- and dose-dependent effect on 
cell viability. Uncrosslinked macromers with lower degrees of (meth)acrylation 
allowed for cell viability of over 60% for up to 6 h. (Meth)acrylated macromers 
with lower critical solution temperature (LCST) closer to physiological 
temperature allowed for higher cell viabilities as opposed to those with lower 
1
 This appendix was published as: Klouda, L; Hacker, M. C; Kretlow, J. D.; Mikos, A. 
G., Cytocompatibility evaluation of amphiphilic, thermally responsive and chemically 
crosslinkable macromers for in situ forming hydrogels. Biomatehals 2009, 30, (27), 
4558-66. 
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LCST. The data suggest that when the (meth)acrylated macromers are 
assembled into a physical gel, their cytotoxicity is diminished. After gel phase 
separation, cytotoxicity increased. This study gives information on the 
parameters that enable viable cell encapsulation for in situ forming hydrogel 
systems. 
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C.1 Introduction 
Injectable, in situ forming materials represent an attractive option for 
cellular delivery in tissue engineering. Hydrogels in particular are excellent 
extracellular matrix equivalents due to their highly hydrated nature1 and can be 
delivered in liquid form and then solidify in situ. It is highly important that the 
solidification takes place in a clinically relevant time frame so that the material is 
localized at the point of interest. The solidification mechanism should be selected 
as not to cause necrosis to surrounding tissue by excessive heat formation and 
to be tolerated by encapsulated cells and/or any potentially sensitive molecules 
that are encapsulated for delivery. Moreover, fast solidification allows for 
homogeneous cell dispersion within the hydrogel matrix.2"5 Thermally responsive 
hydrogels, materials that solidify upon temperature change, form in situ in a mild 
and fast manner, but they often possess insufficient mechanical properties and 
stability.6 To circumvent this problem, thermogelling polymers have been 
modified by the addition of reactive groups that allow for covalent crosslinking. 
These polymers exhibit physical gelation triggered by temperature increase, 
followed by an irreversible chemical crosslinking after a Michael-type addition7"9 
or a photoinitiated polymerization reaction.10 
Our group has recently proposed a new type of thermally responsive, 
chemically crosslinkable macromer for the fabrication of in situ forming hydrogels 
based on A/-isopropylacrylamide.11 These macromers employ a hydrophobic core 
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molecule that increases cohesive interactions of polymeric chains, augmenting 
the mechanical stability of the resulting hydrogel. The addition of a methacrylate 
or acrylate group enables chemical crosslinking with the use of a biocompatible, 
water-soluble thermal initiator system. The macromers are designed to exhibit a 
rapid thermal gelation at temperatures slightly below physiological temperature, 
followed by a slower chemical crosslinking in situ. The advantage of this 
approach is that fast solidification is achieved in a mild process through thermal 
gelation, with the subsequent slow chemical crosslinking not requiring high 
amounts of initiator. The rate of the chemical crosslinking reaction is dependent 
on the amount of initiator used, and it has been shown that thermal initiator 
systems are less cytocompatible above a certain concentration.12"14 
The macromers are synthesized from pentaerythritol diacrylate 
monostearate, a bifunctional monomer containing a natural fatty acid as 
hydrophobic chain, /V-isopropylacrylamide, which provides thermoresponsive 
properties, acrylamide, a hydrophilic monomer, and hydroxyethyl acrylate, a 
hydrophilic monomer which provides hydroxyl groups for further chemical 
modification.11 The lower critical solution temperature (LCST) of macromer 
solutions and the resultant gel stability are shown to be a function of the 
comonomer ratios in the composition and the amphiphilicity of the macromers. As 
a further step, the modification of the macromers with the addition of a 
(meth)acrylate group allows for covalent crosslinking of gels with higher stability 
as compared to physically gelled, uncrosslinked controls. 
391 
The scope of this study is to evaluate the in vitro cytocompatibility of this 
novel type of macromer. Specifically, properties of unmodified macromers such 
as the molecular weight, the composition and the transition temperature are 
assessed for their effect on cytocompatibility. After chemical modification, 
(meth)acrylated macromers are evaluated to determine the optimal variables for 
viable cell delivery. The degree of modification, the concentration and the effects 
of acrylation versus methacrylation on cell viability are examined. Furthermore, 
cell viability is examined at intervals over 24 h in order to determine the length of 
exposure to (meth)acrylated macromers tolerable by cells. 
C.2 Materials and Methods 
C.2.1 Unmodified thermogelling macromers 
Amphiphilic, water-soluble thermogelling macromers (TGMs) were 
synthesized from pentaerythritol monostearate diacrylate (PEDAS), N-
isopropylacrylamide (NiPAAm) and varying contents of acrylamide (AAm) and 2-
hydroxyethyl acrylate (HEA) via a free radical polymerization reaction as 
previously described.11 The macromers were subsequently purified by 
precipitation in diethyl ether and were characterized by gel permeation 
chromatography (GPC), proton nuclear magnetic resonance spectroscopy (1H-
NMR), rheology and differential scanning calorimetry (DSC).11 Table C.1 
summarizes the composition of the macromers evaluated in the study, denoted 
by their molar feed composition, and their respective properties. The number-
average molecular weights (Mn) and polydispersity indices (PI) were obtained by 
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GPC for n=3. The lower critical solution temperature (Tn) had been previously 
determined Theologically as the inflection point of the temperature-complex 
viscosity curve (n=3). The structure of the TGMs is illustrated in Figure C.1. 
C.2.2 Cell culture 
A rat fibroblast cell line (ATCC, CRL-1764) was cultured on T-75 flasks 
using Dulbecco's modified Eagle medium (DMEM; Gibco Life, Grand Island, NY) 
supplemented with 10 % (v/v) fetal bovine serum (FBS; Cambrex BioScience, 
Walkersville, MD) and 1% (v/v) antibiotics containing penicillin, streptomycin and 
amphotericin (Gibco Life). Cells were cultured in a humidified incubator at 37 °C 
and 5% C02. Cells of passage numbers 7-9 were used in this study. 
C.2.3 Cytocompatibility assays of unmodified thermogelling macromers 
Leachables assay 
Solutions of thermogelling macromers were prepared at a 10% (w/v) 
concentration in cell culture media (DMEM, supplemented with antibiotics) 
without the addition of serum. The solutions were left on a shaker table overnight 
to dissolve. In the case of macromer solutions with LCST below room 
temperature, the solutions were left to dissolve at a temperature of 4 °C. After 
dissolution, macromer solutions were incubated at 37 °C for 24 h. During this 
time interval, the solutions first gel and subsequently phase-separate and 
collapse. After 24 h in the incubator, the supernatant of the macromer solutions 
was aspirated, sterile-filtered through a Nalgene 0.2 [im filter (Nalge, Rochester, 
NY) and diluted 10 times in cell culture media. Cells were seeded on a 96-well 
plate at a density of 28,300 cells/cm2 using a working volume of 100 uL cell 
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suspension per well. The cells were incubated for 24 hours to achieve 80-90% 
confluence and were then exposed to 100 uL of the solution supernatant. Two 
experimental groups were used, one without and one with 10-fold dilution (n=5). 
Following 24 h of incubation, the macromer-conditioned media were removed, 
and the cells were rinsed three times with phosphate-buffered saline (PBS, 
Gibco), followed by the addition of calcein AM and ethidium homodimer-1 in 2 u.M 
and 4 u.M concentrations in PBS, respectively (Live/Dead viability/cytoxicity kit, 
Molecular Probes, Eugene, OR). The cells were incubated with the Live/Dead 
reagents for 30 min in the dark at room temperature. Cell viability was quantified 
using a fluorescence plate reader (Biotek Instrument FLx800, Winooski, VT) 
equipped with filter sets of 485/528 nm (excitation/emission) for calcein AM (live 
cells) and 528/620 nm (excitation/emission) for EthD-1 (dead cells). Untreated 
cells that were cultured with primary media only served as the positive (live) 
control, whereas cells exposed to 70% ethanol for 15 min served as the negative 
(dead) control. The fluorescence of the cell populations was recorded and the 
fractions of live and dead cells were calculated according to the following 
equations:14 
P 
(1) Fraction of live cells = —— 
F 
rLC 
F 
(2) Fraction of dead cells = —— 
F 
1
 DC 
with 
(4) FLS = fluorescence sampie - average background fluorescence (noceiis) 
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(5) FLc = average (fluorescence live control - (average background fluorescence 
(no cells))) 
and 
(6) FDs = fluorescence samPie - average background fluorescence (noceiis) 
(7) FDC = average (fluorescence dead control - (average background fluorescence 
(no cells))) 
Following quantification, images of the cells were obtained with a fluorescence 
microscope (LSM 510 META, Carl Zeiss, Germany). 
Direct contact assay 
The macromers were vacuum-dried and sterilized under UV irradiation for 
3 h. Macromer solutions were prepared in 10% (w/v) concentration in DMEM 
without FBS as described above. Cells were seeded on 48-well plates at a 
seeding density of 28,300 cells/ cm2 with a working volume of 500 u,L cell 
suspension per well. After 24-h incubation, the media were aspirated and 150 uL 
of macromer solution was added to the cells (n=4-5). This quantity was 
calculated so that after gelation, a thin gel film would form above the cells. After 
30-minute incubation at 37 °C to ensure gel formation, 300 p.L DMEM without 
FBS was carefully added on top of the gel and the cells were incubated with the 
macromers for 24 h. Following this incubation period, the gel pellet was carefully 
removed with tweezers, and cells were rinsed three times with PBS before 
adding the Live/Dead reagents and evaluating cell viability as described above. 
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C.2.4 Modified (acrylated and methacrylated) thermogelling macromers 
In order to add chemically crosslinkable domains, the purified macromers 
were modified with the addition of an acrylate or methacrylate group through a 
reaction between the hydroxyl group of 2-hydroxyethyl acrylate (HEA) and 
(meth)acryloyl chloride. The hydroxyl group on PEDAS was not modified during 
this reaction. The reaction, purification and characterization processes were 
performed as previously described by Hacker et a/.11 The structure of modified 
macromers can be seen in Figure C.1. Macromers with varying acrylate or 
methacrylate group contents were synthesized by feeding different volumes of 
acryloyl chloride or methacryloyl chloride respectively. Table C.2 denotes the 
composition of the modified TGMs and the conversion of the hydroxyls to 
(meth)acrylate groups as determined by 1H-NMR. The thermal transition 
temperatures are also included in Table C.2, as the substitution of the hydroxyl 
group of HEA by the more hydrophobic (meth)acrylate moieties has an effect on 
the lower critical solution temperature of these macromers. LCST was previously 
obtained by differential scanning calorimetry for n=3. 
C.2,5 Cytocompatibility of modified (acrylated and methacrylated) 
thermogelling macromers 
The macromers were vacuum-dried and sterilized under UV irradiation for 
3 h. Macromer solutions were prepared in 10, 1 and 0.1% (w/v) concentrations in 
DMEM without FBS as described above, which will be denoted throughout the 
text also as 100, 10 and 1 mg/mL respectively. Cells were seeded on 96-well 
plates at a seeding density of 28,300 cells/cm2. After 24-h incubation, the media 
were aspirated. For the 1 and 0.1% solutions, 100 u.L of macromer solution was 
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added to the cells. These concentrations showed minimal gel formation at 37 °C 
and therefore the addition of media for nutrient supply was not required. For the 
10% solutions, 40 pl_ of macromer solution was applied, followed by 30-min 
incubation at 37 °C to ensure gel formation, and 60 u.L DMEM without FBS was 
carefully added on top of the gel. For all groups, a sample size of five was used 
(n=5). Cell viability was evaluated after 2, 6 and 24-hour incubation using the 
Live/Dead assay as described above. 
C.2.6 Osmolality measurements 
The osmolality of the solutions was measured with an Osmette automatic 
osmometer (Precision Systems, Natick, MA). In order to create a standard curve 
for cell viability versus osmolality of solution, the osmolalities of dextran (average 
molecular weight 68.8 kDa, Sigma, St. Louis, MO) solutions in concentrations 
from 0 to 30% (w/v) in DMEM were measured. Cells were then incubated with 
dextran solutions in that concentration range for 24 h, and their viability was 
recorded. Dextran was chosen because it is a known biocompatible 
polysaccharide and thus in case any toxic effects were observed, they would be 
due to changes in osmolality of the solution and not molecular composition. 
The osmolality of the 10% (w/v) macromer solutions as used in the study 
was measured. Moreover, the osmolality of the supernatant solutions was 
measured. The supernatant was obtained after incubating the macromer 
solutions for 24 h at 37 °C and following gel phase separation in order to simulate 
the properties of the solutions to which cells are exposed during the direct 
contact assay. 
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C.2.7 Statistical analysis 
Statistical analysis of the data was performed with a single-factor analysis 
of variance (ANOVA) with a 95% confidence interval (p<0.05). In the case of 
statistically significant differences, Tukey's post hoc test was conducted. Data are 
expressed as mean ± standard deviation. 
C.3 Results 
C.3.1 Effect of molecular weight on unmodified macromer 
cytocompatibility 
Viability of over 80% was observed for cells incubated with the 
supernatant of hydrogels composed of macromers with number-average weights 
ranging from 1750 to 2830 Da and polydispersity indices from 2.9 to 3.6 (Figure 
C.2A). In this experimental group, no statistically significant differences were 
found between undiluted and 10-fold diluted samples. For the direct contact 
assay, viabilities of above 80% were found for the lower molecular weight groups 
(Figure C.2B). The higher molecular weight group showed cell viability of 69±3 
%. 
C.3.2 Effect of composition on unmodified macromer cytocompatibility 
Cells incubated with hydrogel supernatant showed high viabilities (above 
75%) for all but one formulation, with a decrease in live cells with increasing 
acrylamide content in the composition (Figure C.3A). The formulation with the 
highest acrylamide content in the composition (20%) and no 2-hydroxyethyl 
acrylate showed lower viability values of 55±2%. No statistically significant 
difference was noted between undiluted and 10-fold diluted supernatant. When 
398 
cells were exposed to the thermogelling macromers in a direct contact assay, cell 
survival was above 80% (Figure C.3B). 
C.3.3 Effect of LCST on unmodified macromer cytocompatibility 
Among the formulations tested, lower cell viability was observed for the 
formulations with transition temperatures of 38.7 and 40.8 °C, both in the 
leachables (55±2% and 61 ±5% respectively) as well as in the direct contact 
assay (81 ±19% and 60±22%) (Figure C.4). Macromer solutions with lower or 
higher transition temperatures than the aforementioned showed viabilities of 70% 
or more for their leachable components and the direct contact assay. 
Characteristic fluorescence microscopy images of the cells after incubation with 
these macromers can be seen in Figure C.5. High densities of live cells (stained 
green) with morphology similar to the positive control were observed for most 
formulations, and no obvious damage to cells that were in direct contact with the 
hydrogel was noted. The composition with an LCST of 40.8 °C (molecular 
composition PEDASiNiPAAm16AAm4) showed an increased number of dead 
cells (stained red). 
C.3.4 Effect of macromer solution osmolality on cytocompatibility 
Cell viability showed a decreasing trend after 24-h incubation with 
increasing osmolalities of dextran solutions in various concentrations; 
differences, however, were not statistically significant (Figure C.6). For a solution 
osmolality of 451 mOsm/kg, cell viability was 85±7%. Thermogelling macromer 
solutions in 1% (w/v) concentration in cell culture media showed similar 
osmolalities to that of DMEM (330 mOsm/kg). Solutions of 10% (w/v) 
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concentration had osmolalities on the order of 406-462 mOsm/kg. The 
supernatant of gels after 24-h incubation at 37 °C and full phase separation 
showed even lower values (340-408 mOsm/kg). 
C.3.5 Cytocompatibility of (meth)acrylated fhermogelling macromers 
Effect of macromer concentration 
At the 2 h time interval, most formulations had similar cell viabilities in 1, 
10 and 100 mg/mL concentrations or showed trends of decreasing viability 
(Figure C.7). A formulation with a 32% degree of acrylation showed values of 
0.95±0.09, 0.71 ±0.08 and 0.68±0.10 at 1, 10 and 100 mg/mL respectively. A 
formulation with a 49% acrylation had cell viabilities of 1.23±0.06, 0.99±0.05 and 
0.12±0.01 at the above concentrations. The effect of concentration was even 
more pronounced with decreasing trends in viability at the 6- and 24-h intervals. 
At 24 h, the cell viabilities for the 32% acrylated formulation decreased from 
0.75±0.02 at the 1 mg/mL concentration to 0.16±0.05 at 100 mg/mL. 
Effect of time 
In addition to the aforementioned results, the effect of incubation time on 
cell viability can be seen in Figure C.8 for a concentration of 100 mg/mL. An 
unmodified composition showed a statistically significant decrease in viability at 6 
h. The fraction of live cells at 24 h was 0.61 ±0.05, which did not change from the 
viability at 6 h. For all acrylated formulations, a statistically significant decrease in 
viability was observed after 24 h. At 6 h, the compositions with lower degrees of 
acrylation showed cell viabilities of 60% and higher. A composition with low 
methacrylation also showed a statistically significant decrease in 
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cytocompatibility at 24 h, whereas the macromers with higher methacrylation 
exhibited high toxicity as soon as 6 h after incubation. 
Effect of modification 
The macromers were rendered less cytocompatible with increasing 
degrees of modification. Figure C.9 depicts cell viability after 24-h incubation with 
100 mg/mL macromer solutions. Unmodified macromers showed a viability of 
61 ±5%, which was very similar for macromers with 8% acrylation. For 
macromers with higher acrylation degrees of 32% and 49%, only 16±6% and 
2±1 % of the cells respectively were viable after 24 h. Methacrylation seemed to 
be less tolerable by the cells from these results. After 24-h incubation, cell 
viability was only 3±1% for both formulations, which had methacrylation degrees 
of 10% and 29%, respectively. 
C.4 Discussion 
The evaluation of cytocompatibility is a crucial step in the characterization 
of every new class of biomaterials. In the case of in vitro testing of hydrogels, 
prior to performing a viability assay where cells are in direct contact with the 
material, an assay with the hydrogel leachable products in the supernatant phase 
is often included. This experiment allows for the identification of any potential 
toxicity caused by leachable substances after syneresis of the hydrogel. In our 
case of physical, uncrosslinked hydrogels, there was substantial phase 
separation of the hydrogels over 24 h. For the leachables assay, cells were 
exposed to undiluted supernatant as well as its 10-fold dilution. Preliminary 
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results showed no difference in cytocompatibility between 10-fold and 100-fold 
dilution of supernatant liquid (data not shown), therefore the higher dilutions were 
omitted from subsequent studies. Dilution of the supernatant allows for the 
evaluation of concentration effects and accounts also for osmotic effects. Cell 
viability was compared to a positive control, which was untreated cells cultured 
on tissue-culture polystyrene wells. A negative control, cells treated with 70% 
ethanol, was also included in order to confirm trends obtained by the live assay.13 
The numbers of dead cells are not reported in these studies, as dead cells tend 
to detach from the culture plates, making their count inaccurate. 
The effects of molecular weight, monomer ratios in the composition and 
solution thermal transition temperature were the parameters investigated for their 
effect on macromer cytocompatibility. A second set of studies examines the 
cytocompatibility of the macromers after the addition of a reactive (meth)acrylate 
group over time and for different compositions and concentrations. Although 
these macromers can be physically gelled and chemically crosslinked, all 
experiments were performed with the non-crosslinked macromers to evaluate 
toxicity of the reactive groups and macromer composition, mainly hydrophilic-
hydrophobic balance. 
C.4.1 Cytocompatibility of unmodified thermogeiling macromers 
Macromer molecular weight is a factor that influences the compatibility of 
hydrogels with cells. Low-molecular weight oligomers are often associated with 
toxicity issues in hydrogels.1 Generally, hydrogels for cell encapsulation are 
fabricated with macromers of molecular weights above 3000 Da,15 as they 
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otherwise may enter the cell. The cytocompatibility of macromers with same 
composition but different molecular weights was assessed in this study. No 
adverse effects of thermogelling macromers of all molecular weights, ranging 
from 1750 to 2830 Da, were observed on cell viability. Cell viability was over 80% 
for most formulations, both in the leachables as well as in the direct contact 
assay. Moreover, broad molecular weight distributions as indicated by 
polydispersity indices of 2.9-3.6 suggested that the presence of any lower-
molecular weight chains in this composition did not prove to be overly cytotoxic. 
As for the macromer composition evaluation, it had been shown 
previously11 that increasing acrylamide contents correlates with higher transition 
temperatures of the macromer solutions (Table C.1). Therefore, whether the 
decreasing cytocompatibility observed with increasing acrylamide in the 
formulation was an effect of transition temperature rather than composition had to 
be evaluated. Macromers with transition temperatures higher than the incubation 
temperature stay in solution or show minimal gel formation as opposed to those 
with transition temperatures close to physiological temperature which gel rapidly 
at 37 °C. It was hypothesized that due to their amphiphilic nature, solubilized 
macromers could potentially interact with the cell membrane. This effect was 
expected to be diminished when polymer chains do not stay in solution for a long 
time and form a gel. The experimental data showed a decrease in cell viability for 
the macromer solutions with transition temperatures of 38.7 and 40.8 °C. 
Interestingly, a macromer solution with a transition temperature of 43.5 °C, which 
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did not gel after 24-h incubation at 37 °C, allowed for cell viability of over 70%, 
whereas solutions with transition temperatures significantly lower than 
physiological temperature (27.2 and 30.6 °C respectively) showed similar cell 
survival values. The differences in the relative amphiphilicity may explain these 
observations. The lower critical phase separation phenomenon is imparted by 
hydrophobic interactions between macromolecular chains.16 Macromers with 
transition temperatures lower than the incubation temperature of 37 °C had more 
hydrophobic compositions. Associations between polymer chains were more 
pronounced, leading to gel formation. On the other hand, increase in the 
hydrophilicity of the macromers facilitated polymer-water interactions, not 
allowing gel formation at this temperature. The macromers with the highest 
transition temperature have also the highest content of hydrophilic acrylamide. 
This hydrophilic structure, as suggested by the viability data, caused minimal 
interactions with the cells. The macromers with transition temperatures around 
physiological temperature exhibited such a hydrophilic/hydrophobic balance at 37 
°C that might have caused increasing interactions with the cell membrane and 
could explain the lower cell viability values observed. 
Another possible source of toxicity evaluated, solution osmolality, does not 
seem to be a contributing factor in these studies. Cells would be first exposed to 
the macromer solution until the gelation takes place and later to the supernatant 
solution after gel syneresis. Even though high osmotic stress has been shown to 
suppress growth17 and induce apoptosis18 in mammalian cells, the osmolality of 
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solutions was within the range tolerable by cells as suggested the dextran 
osmolality-cell viability curve (Figure C.6). This is in accordance with the 
observations of Zhu et a/.19 No obvious changes in viable density of CHO cells 
were noted when medium osmolality was increased to 400-450 mOsm/kg, but a 
further increase in osmolality to 460-500 mOsm/kg led to an 8% decrease in cell 
viability as compared to the control. 
C.4.2 Cytocompatibility of modified thermogelling macromers 
Some of the macromer solutions were too viscous for sterilization by 
filtration. Therefore, the macromers were dried in a vacuum oven and sterilized 
under UV irradiation for 3 h. In order to assess the effect of UV sterilization of the 
macromers, the presence of the olefinic protons was confirmed by 1H-NMR, 
indicating that after UV irradiation the structure of the (meth)acrylated macromers 
was preserved (data not shown). The macromers selected for (meth)acrylation 
were chosen based on their amphiphilic character and lower critical solution 
properties, and their molecular composition prior to modification was found to be 
cytocompatible. The parameters tested in this study were concentration, time, 
degree of modification and modification type (acrylation or methacrylation) on 
their effect on cytocompatibility. It is valuable to obtain correlations between cell 
viability, concentration and chemical structure of the macromers as a function of 
time if the hydrogel is used for cell encapsulation, as cells will be in direct contact 
with the macromer chains until the crosslinking of the hydrogel is completed.13 
This study was designed to answer questions about the optimal variables for cell 
delivery. 
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Exposure to (meth)acrylated macromers was shown to have a dose-
dependent effect on cell viability (Figure C.7). This effect was more pronounced 
with higher modification and after longer exposure. The cytotoxicity of hydrogel-
forming macromers is often reported in concentrations of up to 1 mg/mL in cell 
culture media.20, 21 We have opted to evaluate higher concentrations, since a 
relevant polymer concentration for hydrogel fabrication is on the order of 100 
mg/mL. In this study, when the direct contact assay was performed, cell culture 
medium was added on top of the hydrogel layer after its solidification. In the 
course of the 24-h incubation, the hydrogel was phase-separated, which means 
that the addition of medium diluted down the supernatant solution. This step was 
however required to ensure nutrient delivery to the cells. Solutions of lower 
concentrations did not show significant gel formation. Since the solutions were 
made in cell culture medium, no further addition for nutrient supply was deemed 
necessary. The cytotoxicity of the macromers also showed a time-dependent 
behavior (Figure C.8). Acrylated macromers all showed statistically significant 
higher cytotoxicity at the 24 h time interval compared to 2 and 6-h exposure. The 
same correlation was observed for the methacrylated macromers with lower 
(10%) modification. Macromers with a higher degree of methacrylation (29%) 
showed significantly higher toxicity already after 6-h incubation compared to 2 h. 
This study seems to be a good indicator for determining the kinetics of the 
crosslinking reaction by establishing the tolerable time of exposure of cells to the 
(meth)acrylated macromers. It represents the worst-case scenario, since within 
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the time frame examined, chains would have already started to crosslink with the 
addition of an initiator system. If the toxicity of the macromers is low for up to 6 
hours, cells can be exposed to them for that time interval, during which 
crosslinking will be completed and the detrimental effects of the (meth)acrylate 
end groups should be eliminated. The presence of reactive end groups, such as 
the (meth)acrylate groups, contributes to the toxicity of materials. Increasing 
degrees of modification drastically reduce cell viability, as can be seen in Figure 
C.9. 
To the best of our knowledge, there are only a few studies that investigate 
the cytocompatibility of (meth)acrylated, uncrosslinked macromers. De Groot et 
al22 showed that methacrylate- and hydroxyethyl methacrylate-derivatized 
dextran had comparably low toxicity with unmodified dextran over an incubation 
period of 72 h at a 100 mg/mL concentration. Poly(ethylene glycol) diacrylate 
(PEG-DA) (molecular weight 3.4 kDa) showed similar cytotoxicity patterns at 24 h 
as the higher modified (meth)acrylated thermogelling macromers in our study, 
whereas PEG-DA of lower molecular weight (575 Da) showed high toxicity 
already after 2-h incubation.13 Extracts of the crosslinker propylene fumarate 
diacrylate, a low molecular weight and comparably hydrophobic macromer, were 
found to be very toxic on cells.23 Many studies have been carried out to elucidate 
the cytotoxic effects of acrylic and methacrylic monomers as these materials are 
extensively used in dentistry. In general, acrylic monomers have been reported to 
be more toxic than corresponding methacrylic analogues.24,25 Some researchers 
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suggested that toxicity correlates with monomer lipophilicity, and that cytotoxic 
effects of (meth)acrylates are exerted through reacting with and disrupting the 
lipid bilayer in cell membranes.26,27 Other researchers did not find toxicity related 
to hydrophobicity and identified a mechanism involving the covalent binding of 
electrophilic reactive (meth)acrylates to cellular targets such as thiol groups on 
proteins through a Michael-type reaction.28, 29 In the present case, we found 
acrylated macromers to be more cytotoxic than methacrylated ones after 2-h 
incubation, which is in agreement with the statements presented above. 
However, after 24 hours, this phenomenon seemed to have reversed. Figure 
C.10 shows the fraction of live cells at 2 and 24 hours as a function of transition 
temperature of the macromer solutions. Our previous studies11 showed that the 
hydrogel stability at 37 °C is proportional to the LCST of the macromer solutions. 
Hydrogels fabricated of macromers with low transition temperatures tend to 
phase-separate and precipitate faster. This offers an explanation for the higher 
toxicity observed for methacrylates as compared to acrylates with the same 
degree of modification after 24-h incubation. At 2 hours, the gels are still stable, 
but the precipitation over the 24-h time interval happens sooner for macromers 
with lower transition temperatures, as in the case of methacrylates. A lower 
transition temperature and faster precipitation prolongs the period in which non-
gelled, (meth)acrylated, reactive macromer chains interact directly with structures 
of the cells, such as membranes, as opposed to chains that are fully assembled 
into a gei. This increased contact enhances the toxic action of the methacrylated 
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macromers after 24 hours. The results suggest that when (meth)acrylates form a 
gel, their cytotoxic effects are diminished. Macromer toxicity seems to be 
associated with their soluble form, or in this specific case, precipitated, and not 
when the macromolecular chains are assembled in a physical network. These 
findings may have important implications with regard to hydrogel use for cell 
encapsulation. 
C.5 Conclusions 
This study demonstrated the good cytocompatibility properties of a novel 
type of thermally responsive, chemically crosslinkable macromers. It was found 
that unmodified macromers with number-average molecular weights in the range 
of approximately 1500 to 3000 Da with varying molecular compositions allowed 
for high cell viability over a 24-h time interval. The chemical modification with an 
acrylate or methacrylate group enables the chemical crosslinking of the 
macromers. We investigated the effect of the (meth)acrylate derivatization on the 
toxicity of uncrosslinked macromers and determined that a 6-h time frame for 
crosslinking completion would allow for viable cell encapsulation. Increased 
degrees of modification were shown to decrease the thermal transition 
temperature as well as the cytocompatibility of the macromers. Formulations with 
the parameters established in this study will be used towards the fabrication of 
injectable, thermoresponsive, in situ forming hydrogel systems for cell and drug 
delivery. 
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C.7 Figures 
Table C.1. Molecular composition, molecular weight characteristics and transition 
temperature of unmodified thermogelling macromers3 
Molecular weight group 
Molar Composition 
PEDAS/NiPAAm/AAm/HEA 
1/15.4/2.6/2 
1/15.4/2.6/2 
1/15.4/2.6/2 
1/15.4/2.6/2 
Mn[Da] 
1750±370 
2300±140 
2440±420 
2830±170 
PI 
3.4±0.6 
2.9±0.3 
3.0±0.8 
3.6±0.5 
Tn [°C] 
31.6±0.3 
32.7±0.8 
32.6±0.2 
31.5±1.2 
Composition group 
Molar Composition 
PEDAS/NiPAAm/AAm/HEA 
Acrylic 
Monomer 
Ratios 
(%HEA/%AAm) 
Mn [Da] PI 
1/16/0/4 
1/15.4/1/3.6 
1/15.4/2.6/2 
1/14/3/3 
1/16/4/0 
LCST group 
Molar Composition 
PEDAS/NiPAAm/AAm/HE 
A 
1/20/0/0 
1/18.5/1.5/0 
1/16/4/0 
1/16/4/0 
1/14/6/0 
20/0 
18/5 
10/13 
15/15 
0/20 
Mn[Da] 
2560±250 
2450±280 
1700±80 
1370±100b 
1470±250 
3050±140 
3810±260 
1750±370 
2700±120 
1700±80 
PI 
2.7±0.1 
2.6±0.2 
2.7±0.1 
2.9±0.1 b 
6.9±2.1 
2.9±0.2 I 
3.0±0.3 : 
3.4±0.6 ! 
2.7±0.1 I 
2.7±0.1 I 
Tn [°C] 
27.2±0.2 
30.6±0.4 
38.7±3.0 
40.8±1.4 
43.5±2.3 
Tn [°C] 
23.2±0.1 
26.5±0.1 
31.6±0.3 
33.7±0.2 
38.7±3.0 
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a
 Molecular weight characteristics were obtained by gel permeation chromatography. 
The transition temperature Tn was determined from rheological measurements of 10% 
(w/v) macromer solutions as the inflection point of the temperature-complex viscosity 
curve. Values represent means ± standard deviation for a sample size of n=3. Table is 
adapted from [11]. 
bThe average and range for this formulation were determined for n=2. 
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Table C.2. Acrylated or methacrylated thermogelling macromers with varying 
degrees of modification and their transition temperaturesc 
Molar Composition: PEDAS/NiPAAm/AAm/HEA 
Modification 
No modification 
Acrylation 
Acrylation 
Acrylation 
Methacrylation 
Methacrylation 
% of hydroxyls 
0 
8 
32 
49 
10 
29 
modified 
: 1/15/3.5/1.5 
TDSC 
[°C] 
35.6 ±0.5 
31.2 ±0.2 
24.6 ±0.3 
20.8 ±0.9 
24.1 ±0.6 
15.2 ±0.9 
c
 The degree of hydroxy! group conversion was determined by 1H-NMR. The transition 
temperature TDSC was obtained by differential scanning calorimetry (DSC) for 10% (w/v) 
macromer solutions. Values represent means ± standard deviation for a sample size of 
n=3. Table is adapted from [11]. 
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H 3 C _ C H ? 
{/k)
^r°^p~~°^r—^^^s^f~h-
(B) 
CH 
Figure C.1. Structure of thermogelling macromers (A) before and (B) after 
modification with the addition of a (meth)acrylate group. The asterisk indicates 
possible branching sites. The indices m,n,o could equal zero in some 
formulations. The sum of the modified (z) and unmodified (x) hydroxyl groups 
equals the initial hydroxyl group number prior to (meth)acrylation (x+z=o). 
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(A) 
• 10-fold dilution 
• no dilution 
1750 2300 2440 2830 
Polymer Molecular Weight (Mn) 
(B) 
1750 2300 2440 
Polymer Molecular Weight (Mn) 
2830 
Figure C.2. Cell viability after 24-h incubation with macromers of different number-
average molecular weights and polydispersity indices (PI). A) Leachables assay: 
incubation with hydrogel supernatant B) Direct contact assay: incubation with 
hydrogel. Error bars represent standard deviation; n= 3-5. 
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(A) 
• 10-fold dilution 
• no dilution 
20/0 18/5 10/13 15/15 0/20 
Molar Composition 
(% HEA / % AAm) 
20/0 18/5 10/13 15/15 
Molar Composition (% HEA / % AAm) 
0/20 
Figure C.3. Cell viability after 24-h incubation with macromers of different 
molecular ratios of 2-hydroxyethyl acrylate (HEA) and acrylamide (AAm) in their 
compositions. A) Leachables assay: incubation with hydrogel supernatant B) 
Direct contact assay: incubation with hydrogel. Error bars represent standard 
deviation; n= 3-5. Characters on experimental groups indicate statistically 
significant differences when groups are not marked with the same letter (p<0.05). 
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For clarity purposes, in figure (A) differences are marked for undiluted group 
only. 
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(A) 
a 10-fold dilution 
• no dilution 
27.2 30.6 38.7 40.8 43.5 
Transition Temperature (°C) 
27.2 30.6 38.7 40.8 
Transition Temperature (°C) 
43.5 
Figure C.4. Cell viability after 24-h incubation with macromers of different 
transition temperatures (Tn). A) Leachables assay: incubation with hydrogel 
supernatant B) Direct contact assay: incubation with hydrogel. Error bars 
represent standard deviation; n= 5. Experimental groups denoted by different 
420 
letters show statistically significant differences (p<0.05). For clarity purposes, in 
figure (A) differences are marked for undiluted group only. 
421 
Figure C.5. Fluorescence microscopy images of fibroblasts after 24-h exposure to 
hydrogel leachables or in direct contact with hydrogel and treatment with 
Live/Dead reagent. Letters denote the positive control (A), negative control (B), 
treatment with a formulation composed of PEDASiNiPAAm2o in leachables assay 
(C) and direct contact (D), treatment with a formulation composed of 
PEDAS1NiPAAm16AAm4 in polymer-conditioned media (E) and direct contact (F). 
Scale bar indicates 100 Mm. 
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osmolality 
cell viability 
Figure C.6. Osmolality of dextran solutions of different concentrations and cell 
viability values after 24-h incubation with these solutions. Differences in 
cytocompatibility are not statistically significant (p<0.05). 
Fr
ac
tio
n
 
o
f L
iv
e 
Ce
lls
 
o
 
Fr
ac
tio
n
 
o
f L
iv
e 
Ce
lls
 
o 
o 
o 
o 
o 
M
 
ji 
b) 
bo
 
-
»
 
w
 
Fr
ac
tio
n
 
o
f L
iv
e 
Ce
lls
 
N>
 
•&
.
 
b>
 
2 acrom "1 O o 3 centrati o 3 3 g/m £ 
-
*
 
o o
 
-
o o 
1- 
H 
W
Uf
t 
2 lacrom (V O o 3 icentrat o 3 "3
 g/m C 
u
 
_
»
 
o o
 o o
 
o o 
co
 
Q)
 
0) 
q 
q 
=
3 
o
 
o
 
o
 
•
? 11)
 H -b. CD 
•
? ro
 H <o ro 
•
? n>
 H 00 ss 
^
 
m
 
ry Li) 
•2
 
u>
 
o 
o 
o 
o 
-
»
•
 
O
 
M
 
'
^
 
O)
 
00
 
-
»
 
M
 
•
&.
 
o
>
 
tH
 
+1
 
m
 
m
 
£B
 
q 
q 
9 
5 
q 
CD
 
CD
 
•<
 
^
 
-
d 
g=
 
3 
0) 
0) 
0) 
CD
 
Q3
 
o 3 o 
n
 
n
 
o
.
 
•
5
-2
 
3 
^
 
*
s.
 
*
s.
 
o o 
3 01 o -i UI0 CH
 
-
t o
 
o
 
3 O
 
f»
 
3 «-
*
 
^
 
0) i-»
 
o
 
3 *-^
 
3 (Q 3
 
r 
-
*
 
-
*
 
-
—
*
 
o 
.
 
o 
-
o o
 
h  
'
^
 
1 
ftr
 
| 
^
 
' 
(T 
H
*#
«h
 
lit
 
+
 
H 
H 
-
b.
 
CO
 
00
 
CO
 
K
) 
s
°
 
a
 
a
 
Q>
 
0) o ryl Si- -I -fc.
 
CO
 
CO
 
^
 
0^
 
-
1 CJ
O 
ro
 
s ^ a H
 
00
 
s«
 
meth 8 ^ » 
meth 8 •*!
 
Si
 Z
3 O
 ^
 
o
 
2£
 
S?
 
.&.
 
424 
Figure C.7. Cell viability after (A) 2-h, (B) 6-h and (C) 24-h incubation with various 
concentrations of (meth)acrylated macromers with a theoretical composition of 
PEDAS1 NiPAAm^iAAmssHEAT 5. Error bars represent standard deviation for n=3-
5. 
(A) 
425 
6 
Time (h) 
24 
• no modification 
• acrylation 8% 
• acrylation 32% 
• acrylation 49% 
(B) 
• no modification 
• methacrylation 10% 
• methacrylation 29% 
24 
Time (h) 
Figure C.8. Cell viability over time after exposure to 100 mg/mL solutions of (A) 
acrylated and (B) methacrylated macromers, with an unmodified composition as a 
control. Error bars represent standard deviation for n=3-5. Statistically significant 
426 
differences over time within one composition group are marked with an asterisk 
(p<0.05). 
427 
"35 
O 
> 
-acrylation 
methacrylation 
0.1 0.2 0.3 0.4 0.5 
Degree of Modification 
0.6 
Figure C.9. Cell viability after 24-h incubation with 100 mg/mL solutions of 
acrylated and methacrylated macromers with different degrees of modification. 
Modification is expressed as the fraction of hydroxyl moieties substituted by 
(meth)acrylate groups. Error bars represent standard deviation for n=3-5. 
428 
40 35 30 25 20 15 
Transition Temperature (°C) 
10 
•acrylates at2h 
• methacrylates at2h 
•acrylates at 24h 
•methacrylates at24h 
Figure C.10. Cell viability after 2 and 24-h incubation with 100 mg/mL solutions of 
acrylated and methacrylated macromers as a function of their thermal transition 
temperature. Error bars represent standard deviation for n=3-5. 
